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1. NK cell functions  
 
Natural killer cells (NK) are members of the Innate Lymphoid Cells (ILCs) family and represent 
approximately 5-15 % of circulating lymphocytes in healthy adults 1. At first, they have been defined 
as large granular lymphocytes (LGL) for their size, larger than that of T and B lymphocytes, and 
Natural Killers for the presence, in their cytoplasm, of a cytolytic machinery composed by small 
granules containing perforin and granzymes, and for their ability to kill given targets in the absence 
of prior stimulation 2. However, it is now evident that they require different stimuli to exert an optimal 
effector function 3, are involved in shaping adaptive immune responses and, although belonging to 
the innate immunity, they are capable of mounting a peculiar antigen-specific immunological 
memory, thus overcoming the original view of NK cells 4,5. Along this line, a crucial regulatory role 
of NK cells has been demonstrated in both pathological and para-physiological events such as 
pregnancy (see 1.2 paragraph).  
 
1.1 Cytolytic activity 
Most studied function of NK cells is certainly represented by their cytotoxic activity against 
transformed cells such as tumor or virus-infected cells. However, they also contribute to the resolution 
of innate responses or to DC cells editing by exerting killing capability against autologous non-
transformed cells such as neutrophils, macrophages and immature Dendritic Cells (DCs) 6,7. 
The NK cytolytic activity is regulated by activating and inhibitory surface receptors whose integrated 























Figure 1. Protection or susceptibility to NK-mediated killing is the results of a balance between inhibitory and 
stimulatory signals in NK cells. 
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In a simplify view, normal autologous cells are spared since they express high levels of ligands of 
inhibitory receptors that control the activating signals 12. Conversely, tumor transformation or 
infections lead to the downregulation/loss of inhibitory ligands and upregulation of ligands of the 
activating receptors (“danger signals”) causing killing of target cells 8,9. 
In human, the principal activating NK receptors are represented by NKp46 (CD335), NKp30 (CD337) 
and NKp44 (CD336) (collectively termed natural cytotoxicity receptors, NCR). Their expression is 
mainly restricted to NK cells and characterizes both CD56dim and CD56bright. NK cells, which 
represent the two most abundant circulating NK cell subsets in healthy donors. However, more 
recently studies have showed that other cell types express NCR, including innate lymphoid cells 1 
(ILC1) (NKp46+) 10, plasmacytoid dendritic cells (NKp44+) 11 and a peculiar subtype of CD8+ T 
lymphocytes (NKp30+) 12. 
NKp30 and NKp46 are expressed by not-stimulated (resting) and activated NK cells, whereas NKp44 
represents an activation marker 13. NCR are transmembrane proteins of type I with a short cytoplasmic 
tail lacking functional motifs capable of triggering intracellular signaling cascade. NKp46 is 
characterized by two Ig-like extracellular domains and a transmembrane portion with a positively 
charged residue (Arg), allowing its association with the ITAM (Immunoreceptor Tyrosine- based 
Activator Motif)-containing FcϵRIγ and CD3ζ signal transduction molecules. These are also 
associated with NKp30, whereas NKp44 transduces activating signals thanks to the ITAM-bearing 
KARAP/DAP12 molecules. Both NKp30 and NKp44 are characterized by one Ig-like domain in their 
extracellular regions. In the last decade, several groups dedicated many efforts to discover the nature 
of the ligands expressed at the cell surface of transformed cells and specific for the activating 
receptors (Fig.2). NKp46 still remains an “orphan receptor”, while NKp44 has been shown to 
recognize a novel isoform of the mixed-lineage leukemia (MLL5) protein14. NKp30 has been shown 
to bind B7-H6 molecule 15, although different experimental evidences suggest that NKp30 could 
recognize other, still unknown, tumor-associated ligand/s. Importantly, a functional cross talk occurs 
between the different NCRs, possibly resulting in the amplification of the activating signals 16. 
Another receptor participating in the cytolytic activity of NK cells is NKG2D (CD314), which 
belongs to type C-lectin family and is also expressed by CD8+ TCR γ/δ e α/β T lymphocytes. In 
humans, NKG2D associates with DAP-10, an adaptive molecule containing in the cytoplasmic tail 
an YxxM sequence that, after phosphorylation, recruits the PI3K. NKG2D recognizes MICA/B and 
ULBPs, stress inducible molecules de-novo expressed after tumor transformation or virus infection17. 
Another crucial activating receptor is DNAM-1 (CD226), a transmembrane protein belonging to the 
immunoglobulin family 18.  PVR (CD155) and Nectin-2, two members of the Nectin family, have 
been identified as two ligands specific for DNAM-1 19. PVR plays a crucial role in determining the 
NK-related susceptibility of ex-vivo derived tumors and has also been shown to have a key role in 
cell motility during tumor cell invasion and migration 20. More recently, PVR has been shown to be 
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Figure 2. Principal non HLA-I specific activating receptors 
 
 
Natural Killer cells express other triggering surface molecules that support the activity of the main 
activating receptors. These molecules, indicated as co-receptors, include 2B4 (CD244), NTB-A, 
NKp80 and CD59.  
The activating function of NK cells is under the control of signals mediated by receptors that 
recognize self-HLA (Human Leukocyte Antigen) class I (HLA-I), molecules whose expression is 
high in normal healthy cells and decreases upon viral infections and tumor transformation 21. These 
inhibitory NK receptors (iNKR) are represented by the inhibitory killer Ig-like receptors (CD158, 
iKIRs), which recognize HLA-A, HLA-B or HLA-C allotypes, the heterodimeric CD94/NKG2A 
complex, which recognizes non-classic HLA-I molecules (HLA-E), and LILRB1 with a broad HLA- 
I specificity. The iKIRs are clonally distributed and, together with CD94/NKG2A and LILRB1, create 
stochastic but tolerant repertoires of NK cells. In healthy individuals, the NK cells repertoire is 
selected during maturation in such a way that each NK cell expresses at least one iNKR for self-HLA 
class I molecules (self-iNKR). This phenomenon is termed classical “licensing” or “education” and 
provides the basis of self-tolerance. In developing NK cells, iNKRs are engaged, possibly in trans, 
by surrounding self-HLA-I expressing cells and transduce permissive signals that allow their 
phenotypic/functional maturation. Educated NK cells are self-tolerant but “armed”, becoming fully 
responsive to the engagement of activating receptors, exerting strong cytotoxicity against abnormal 
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targets and releasing large amounts of immunostimulatory cytokines. Lack of expression of self-
iNKR results in the generation of “uneducated” NK cells that are detectable in small percentages in 
healthy individuals but functionally anergic. 
Inhibitory KIRs (iKIRs) are type I transmembrane glycoproteins, with two or three extracellular Ig-
like domains (KIR2D and KIR3D respectively) and a long intracytoplasmic tail containing Immune 
Tyrosine-based Inhibitory Motifs (ITIM). KIR2DL recognizes HLA-C and KIR3DL HLA-A/B 
allotypes, respectively (Fig.3). Regarding HLA-C allotype, the group 1 or group 2 alleles differ for 
the amino acid present in position 80 in the extracellular domain of the heavy chain and are recognized 
by different KIRs. 
The engagement of iKIRs by their HLA-I ligands determines the phosphorylation of ITIM thus 
leading to the recruitment of Src homology 2 containing phosphatase 1 e 2 (SHP- 1 and SHP-2) 22, 
that inhibits NK cells activation. 
CD94/NKG2A is an heterodimeric complex belonging to the C-type Lectin superfamily that, in the 
NKG2A intracellular portion, contains two ITIMs recruiting SHP-1 and SHP-2 after phosphorylation 
of tyrosine residues 23.  
Activating counterparts of both iKIRs and CD94/NKG2A have been identified. The activating KIRs 
(aKIRs) (KIR2DS, KIR3DS) are highly homologous to the inhibitory ones in the extracellular portion 
whereas they present short cytoplasmic tails lacking ITIM and a charged transmembrane domain. 
They associate with the DAP12 signaling molecule that contains an Immunoreceptor Tyrosine-based 
Activation Motif (ITAM). The cross-linking of aKIR-DAP12 leads to NK cells activation through 
the recruitment of SYK and ZAP-70 protein tyrosine kinases. 
The HLA-E specific heterodimeric CD94/NKG2C represents the activating counterpart of the 
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Figure 3. Principal MHC class-I specific inhibitory receptors 
 
 
Natural killer cells are also capable of mediating Antibody Dependent Cellular-Cytotoxicity (ADCC) 
24 (Fig.4). Antibodies (IgG), specifically reacting with surface antigens highly expressed by virus-
infected or tumor cells, bind to CD16 (or FcγRIIIa), the low affinity Fc receptor expressed by Natural 
killer cells, unleashing cytotoxicity and target cells death. Importantly, ADCC seems to be more or 
less efficient depending on the CD16 isoform expressed by NK cells 25, an aspect that may deeply 





































CD16 is highly expressed by around 90% of circulating NK cells, whereas a minor fraction of 
circulating NK cells (and tissue-resident NK cells such as decidual NK cells) expresses very low 
levels or lack its expression. CD16low/neg NK cells  are unable to mediate ADCC but, due to the 
constitutive expression of receptor for cytokines, produce large number of cytokines such as IFN-γ 



















Figure 5. CD56bright (red) and CD56dim (blue) NK cells 
 
 
CD16 low/neg and CD16high NK cells express high or low levels of CD56 molecule (CD16bright or 
CD16dim, respectively) and differ for their migratory properties, since are equipped with a different 
repertoire of chemokine receptors 27. 
CD16bright CD16 low/neg express high levels of CC chemokine receptor 7 (CCR7) specific for 
CCL19/21 chemokines, involved in the migration to the secondary lymphoid organs, and L-selectin 
(CD62L), an adhesion molecule crucial for the interaction with high endothelial venules (HEVs) 
present in secondary and tertiary lymphoid organs. Moreover, they express high levels of CXCR3 
and CCR5, that regulate the traffic of natural killer (NK) cells into peripheral tissues. On the contrary, 
CD56dim CD16high NK cells lack CCR7 and CD62L expression but express good levels of CXCR1 
(receptor for CXCL1 or IL-8), S1P15 (receptor for S1P), CX3CR1 (receptor for CX3CL1 or 
fractalkine) and CHEMR23 (receptor for chemerin), essential for their migration to inflamed 


















Figure 6. Chemokine receptor repertoire of CD56dim and CD56bright NK cells 
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1.2 NK cell Regulatory activity  
Another important function of NK cells is represented by their ability to produce and release 
chemokines and cytokines, in particular IFN-γ, TNF-α and GM-CSF that regulate immune responses. 
An example of the importance of the regulatory activity of NK cells is their capacity to influence the 
activity of other effectors of innate immunity such as Dendritic Cells and Macrophages, which NK 
cells may meet in inflamed tissues 28. After tissue damage or inflammation, as occurs upon virus 
infection or tumor invasion, NK cells are recruited in “perturbed” tissues by chemokines such as 
CXCL8, chemerin and CX3CL1, produced by different cell types present in the damaged sites 29. The 
crosstalk between NK cells, macrophages and DCs, which release immunostimulatory cytokines such 
as IL-12, IL-15 and IL-18, induces NK cells activation with increased cytotoxicity and the release of 
IFN-γ and TNF-α 30,31. These cytokines contribute to maturation of DCs, a process involving the 
engagement of NKp30 32 , that recognizes a still undefined ligand. The DCs’ maturation includes the 
upregulation of HLA-I, protecting DC from NK-mediated attack. DCs with defective maturation are 
efficiently killed by NK cells, which therefore contribute to the selection of the best APCs priming T 
lymphocytes toward Th1 polarized immune responses in secondary lymphoid tissues 33. NK cells can 
also regulate the activity of mature DCs (mDCs) in secondary lymphoid tissues (SLT). Indeed, during 
DCs and macrophages crosstalk, NK cells can acquire CCR7 expression driving their migration to 
SLT. Despite this “late crosstalk”  in humans needs further studied, in mice Fontecha et al 
demonstrated that, during immune responses, NK cells can be recruited in SLT via CXCR3, in a 
CCR7 independent way 34. The recruitment of NK cells in lymph nodes was correlated with the 
induction of Th1 responses in vivo, since they act as an initial source of IFN-γ, fundamental for Th1 
polarization. In vivo experiments with IFN-γ deficient NK cells unequivocally confirmed the relevant 
NK-mediated regulatory role in T cell polarization. 
It is now established that IFN-γ and TNF-α, although optimizing Th1 responses, can also exert 
negative effects on anti-tumor activity by modifying tumor cells toward a phenotype that favors their 
escape from the immune surveillance, a process called “adaptive immune resistance” 35. This can be 
based on the de-novo surface expression on cancer cells of protective ligands. These include different 
immune checkpoints molecules such as PD-L1 and PD-L2, recognized by the inhibitory PD-1 
receptor expressed by NK (and T cells) (see for more details chapter 3,1 Factor dampening NK cell 
activity). Importantly, IFN-γ also upregulate PD-Ls on APCs 36. In particular, IFN-γ released by NK 
cells induces in different hematopoietic cell lines and primary tumor cells (Multiple Myeloma, Acute 
Myeloid Leukemia and Acute Lymphoblastic Leukemia) a strong upregulation of PD-L1 (through 
the phosphorylation of JAK-1, JAK-2 and STAT-1) 37which leads an increased resistance of tumor 
cells to the NK cell lysis. Killing can be restored by blocking the PD1-PD-L1 axis, using inhibitors 
blocking IFN-γ or of one or more transcription factors involved. Another relevant IFN-γ-mediated 
regulatory role for NK cells is represented by the upregulation of HLA-I expression on different kind 
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of tumor cells 38, which acquire resistance to NK cells killing, ac aspect that will be further discussed 
below. 
A peculiar interesting regulatory role is that exerted by NK cells colonizing human decidua. Decidual 
NK cells (dNK) are low cytotoxic cells that show strong pro-angiogenic and tissue remodeling 
properties 39. They are also involved in the induction of T regulatory lymphocytes (Treg), necessary 
to maintain the maternal tolerance towards the fetal allografts. dNK cells, representing the majority 
of lymphoid cells present in decidua in the first trimester of pregnancy, are characterized by a 
CD56bright CD16neg KIRspos phenotype, but despite this their KIR repertoire is skewed toward 
recognition of HLA-C, the only classical MHC class I molecules expressed by trophoblastic cells 40. 
dNK cells present a particular repertoire of other inhibitory receptors specific for HLA-E, G and C 
and express the inhibitory form of 2B4 receptor. These cells have low capability of forming 
immunological synapses and, despite the perforin and granzymes content, are poorly cytotoxic 
against classical targets. dNK cells, that could derive from CD34+ hematopoietic precursors present 
in human decidua, 41 produce angiogenic factors such as VEGF, release cytokines such as IL-8, SDF-
1 and IP-10, and are involved in trophoblast growth, invasion and differentiation, as well as in the 
formation of new blood vessels . The proangiogenic properties of dNK have been confirmed in vivo 
in mouse models. After injection of human JEG-3 trophoblast choriocarcinoma cells and dNK cells, 
the mean size and weight of tumors were significantly greater, as compared to the tumors from mice 
inoculated with JEG-3 cells alone or with JEG-3 cells together with Peripheral Blood NK subsets 42. 
Importantly, in pleural effusions of patients affected by inflammatory diseases or primary or 
metastatic tumors of different origin, NK cells can acquire a decidua like phenotype 43 , with the 
specific expression of surface markers like CD49a (an integrin alpha subunit that binds collagen and 
laminin) and CD9 (a tetraspanin protein family that plays a role in cell adhesion and cell motility), 
and a reduce expression of CD57, a marker of terminal differentiated and cytotoxic mature NK cells. 
Moreover, these NK cells derived from pleural effusions present less perforin content and a reduced 





2. NK cells activity against cancer and cancer-associated tumor cells 
Tumors are composed of a heterogeneous combination of cells, with different phenotypic 
characteristics and proliferative potential. The cytolytic activity of Natural killer cells is not limited 
to parenchymal tumor cells but they have the capability of recognizing and killing other cells present 
in the tumor microenvironment, In this context, chronic inflammation plays a critical role in cancer 
progression and some immune cell type types contribute in the growth and survival of tumor. 
 
 
2.1 Cancer Stem Cells 
 
In many type of tumors, two different subpopulation of cells have been described: CSC (cancer stem 
cells) characterized by stem cell properties, slow and asymmetrical growth, and more differentiated 
fast proliferating cancer cells 44. CSC would be responsible of tumor generation/maintenance (they 
are also called tumor-initiating cells, TIC) and exert a crucial role in tumor recurrence, due to their 
resistance to irradiation and chemotherapy (Fig.7). 
CSC represent an optimal therapeutic target to achieve complete eradication of the tumor, so many 
efforts focus on the discovery of strategies to identify and kill these cells. These include adoptive NK 
cells-based immunotherapeutic approaches. Indeed, it has been shown that NK cells efficiently kill 
tumor cells with stem cell like properties of tumors such as melanoma 45, glioblastoma (GBM) 46, 
breast 47 and colon carcinoma 48. Preliminary reports considered NK cells inappropriate for adoptive 
immunotherapy, because GBM cells were shown to be resistant to lysis mediated by freshly isolated 
NK cells and NKL, a commonly used NK cell line 49,50. These results were challenged by a study that, 
although confirming resistance of GBM cells to killing mediated by resting NK cells, showed that 
appropriate cytokine stimulation (IL-2 or IL-15) rendered NK cells highly cytolytic against both 
autologous or allogeneic GBM cells. Importantly, NK cells exerted a strong cytolytic activity against 
autologous GBM CSC cells expressing typical neural stem cells markers such as CD133 and c-KIT. 
Lysis was mainly due to the activity of DNAM-1 and NKp46 (although also NKG2D and NKp30 
were involved) that prevailed on HLA-I-specific iNKR receptors. The high expression of PVR and 
Nectin-2 on the surface of GBM cells explained the main involvement of DNAM-1 in the killing. 
These data support the idea that NK cells could play an important role in the restraint of tumor 
recurrence and metastatization. 
Regarding melanoma, a study revealed that primary CD133+ cells resulted more resistant to 
radiations than the CD133- counterpart, but both cell types expressed PVR, Nectin-2, ULBP-2 and 
MICA surface ligands specific for NK activating receptors, resulting equally susceptible to lysis 
mediated by IL-2 stimulated NK cells. 
Interestingly, in colorectal carcinoma, CSC and non-CSC cells, derived from two cancer 
compartments, were differently susceptible to the action of fresh purified NK cells . CSC were more 
susceptible to lysis by NK cells than the relative differentiated cells, both in allogeneic and autologous 
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context. This peculiar behavior correlated with a higher surface expression, on CSC, of NKp30L and 
NKp44L and a lower expression of MHC-I, as compared to the differentiate tumor population. The 
same group has also demonstrated that NK cells were also able to recognize and kill breast CSCs, 
derived from human (and murine) breast cancer cell lines, in vitro and in vivo. In particular, CSCs 
enriched tumor spheres from the murine breast tumor cell line were more susceptible to the cytotoxic 
activity of NK cells than the parental cells. This correlated with a reduced surface frequency of 
inhibitory ligand H2-K and the high expression of PVR on the tumor spheres, confirming previous 
data on the crucial role of DNAM-1 in the recognition of CSCs. Tumor spheres were selectively killed 
even when freshly explanted murine NK cells were used as effectors. 
Collectively, these results suggest that NK cells could be considered a potential weapon in therapeutic 





















Figure 7. Cancer stem cells hypothesis from: “Stem cells, cancer, and cancer stem cells” 
 
 
2.2 M2 macrophages 
 
During inflammation NK cells can be interact with resident or recruited immune cells, including 
Dendritic Cells or Macrophages, influencing early innate and adaptive immune responses 51. 
Monocytes can be recruited in tissues during inflammation and under the action of different soluble 
factors can differentiate in macrophages (M0 type)52 and polarize toward M1 or M2, two different 
functional phenotypes. Macrophages polarizing towards M1 are characterized by an 
immunostimulatory behavior, release high amount of proinflammatory/immunostimulatory cytokines 
such as IL-1, IL-6, TNF-α, IL-12 and IL-23, and exert optimal antigen presenting activity. On the 
contrary, M2 show immunosuppressive and therefore pro-tumoral properties via different 
mechanisms. Although contributing to ECM deposition and tissues remodeling, M2 release/activate 
TGF-β (and IL-10) that inhibits the functions of NK cells and CD8+ lymphocytes, and produce factors 
promoting tumor vasculature and metastatization (VEGF or MMPs). Whereas M1 are protected 
thanks to the high expression of HLA-I, activated NK cells efficiently kill autologous M0 and M2 
13 
 
macrophages  and  NKp46 and DNAM-1 resulted to be the main activating receptors involved in 
killing .53 
Importantly, in the context of pathogen-derived stimuli (e.s. LPS and BCG), a mutual fruitful 
crosstalk occurs between NK cells and M0 and M2 (but not M1-polarized macrophages). In 
particular, upon TLR stimulation macrophages polarize toward M1 and induce NK cells activation as 
demonstrated by the expression of CD25 and CD6, increasing the cytotoxicity against tumor cells 
and iDCs. Moreover, NK cells release IFN-γ, a process that requires the interaction of DNAM-1 and 
2B4 with their ligands expressed on macrophage, as well as the action of macrophages-derived 
cytokines. A pivotal role is played by IL-18 that it is expressed as a membrane form by M0 and M2 
and it is released as soluble form during M1-polarization. IL-18 is also responsible for the acquisition 
of CCR7 by NK cells 54. On the other side, IFN-γ released by macrophage-activated NK cells supports 
polarization toward M1 and by increasing HLA-I expression protects M1 from NK-mediated attack. 
Importantly, a similar crosstalk occurs between NK cells and tumor associated macrophages (TAMs) 
isolated from ascites of patients with ovarian cancer 55. Indeed, TAMs present a M2 like surface 
phenotype and show expression levels of PVR, Nectin 2 and HLA-I similar to in vitro IL-4 polarized 
M2 macrophages, derived from healthy donors. Accordingly, autologous IL-15 activated NK cells, 
derived from both ascites and peripheral blood and activated during NK/TAM crosstalk, were able to 
kill TAMs via DNAM-1 and NKp46. 
 
 
2.3 Cancer-associated fibroblasts 
 
Cancer associated fibroblasts (CAFs) are the dominant stromal components in the tumor 
microenvironment. These cells can have different origins: the majority of them derive from resident 
fibroblasts as a result of activation and genetic alterations 56, but their heterogeneity suggests that 
other cell types like adipocytes 57 , bone marrow derived stem cells 58, epithelial cells 59 (through 
epithelial mesenchymal transition) and endothelial cells (though End MT (endothelial-mesenchymal 
transition) could represent their source. 
Their interaction with cancer cells is fundamental for the growth and the immune surveillance of 
tumor. In fact, CAFs are able to produce different growth factors and cytokines supporting the 
proliferation and the invasiveness of the primary tumor and the metastasis 60. Among these, CAFs 
produce different pro-angiogenic factors, including vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF)-2 and interleukin (IL)-8/CXCL8 61. Moreover, CAFs modify the ECM 
architecture through deposition of collagen and enhancement of cross-linking of collagen fibers, 
favoring the presence of fibrotic ECM, often correlated with a poor prognosis. Thanks to the 
Hyaluronan synthesis and the production of different Damage-associated molecular patterns 
(DAMPs), CSFs recruit macrophages into the stroma, where they are polarized toward M2. For 
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example, CAFs-mediated macrophages’ recruitment into mammary carcinoma 62 and prostate cancer 
has been show to be dependent to secretion of CCL2 or CXCL14, respectively 63. 
CAFs also modulate the activity of other immune cells present in tumor microenvironment, including 
T cells, thanks to the production of immune-suppressive cytokines such as TGF-β1, that impairs the 
acquisition of different T-cell effector functions, including anti-tumor cytotoxic 64. 
TGF-β1 production is a hallmark of a subset of fibroblasts associated to non-small cell lung cancer 
(NSCLC)65, which constitutively express PD-L1 and PD-L2, immune checkpoint ligands further 
upregulated by IFNγ. In three out of eight tumors analyzed, TGF-β1-producing CAFs (in the article 
indicate as TAF=tumor-associated fibroblast) co-cultured with autologous tumor associated T cells 
(TATs), suppressed their activation. However, in the other tumors analyzed, TAFs showed an 
opposite effect, stimulating TATs activation in a contact-dependent way, highly supporting the 
concept of phenotypic and functional heterogeneity of these cells. 
Importantly, TGF-β1 has been described to represent a crucial autocrine mediator. Kojima and 
colleagues reported that resident human mammary fibroblasts, during the course of tumor 
progression, progressively shift toward a myofibroblast phenotype and acquire a TGF-β1 autocrine 
signal loop, necessary to maintain their tumor-promoting phenotype. This autocrine loop also 
involves stromal cell derived factor 1 (SDF-1, CXCL12) that mediates myofibroblasts differentiation. 
TGF-β1 and SDF-1 have also been found to be secreted by human prostatic CAFs 66. In this tumor, 
TGF-β1 was able to increase the surface expression on tumor cells of CXCR4, the CXCL12 receptor, 
supporting the TGF-β1-mediated autocrine loop. Thanks to production of TGF-β1 and CCL5 
(RANTES), CAFs have also been shown to contribute to the differentiation and recruitment of Treg 
cells into primary mammary tumors, stimulating cancer progression 67. Moreover, several evidences 
suggest that CAFs, thanks to the production of TGF-β1, IL-6, IL-1β and CCL5, key cytokines for 
human Th17 differentiation, can also stimulate the generation and expansion of Th17 cells in different 
kind of tumors68,69, thus promoting inflammation in the tumor microenvironment. 
Shaping of the tumor microenvironment by the CAFs includes their influence on NK cells’ phenotype 
and functions. It has been showed that, differently from normal fibroblasts, CAFs affect the cytolytic 
activity of NK cells against primary metastatic melanoma cells 70. The phenomenon was paralleled 
by a significant dowregulation of NKp44, NKp30 and DNAM-1 expression, whereas the expression 
of NKG2D and NKp46 was only partially affected. The inhibition of DNAM-1 was contact-
dependent, while Prostaglandin E2 (PGE-2), released by CAFs, was involved in the modulation of 
NKp30 and NKp44. Similar results were obtained in colorectal cancer 71. In this experimental setting, 
NK cells co-cultured with purified CAFs presented a low surface expression of NKG2D, DNAM-1, 
NKp30 and NKp44, low expression of the CD69 activation marker and downregulation of cytolytic 
proteins such as perforins and granzymes. CAFs were also able to reduce the proliferation of NK cells 
and their capacity to release TNF-α and IFN-γ after activation. Also in this case, the high release of 
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PGE-2 by CAFs, as compared to normal fibroblasts, suggests its role in the modulation of main 
activities of NK cells. 
 
2.4 Tumor-associated endothelial cells (TECs) 
 
Tumor cells, in order to survive, proliferate and disseminate in the body, need adequate supply of 
oxygen and nutrients. Thus, an important hallmark of tumors is represented by neo angiogenesis 135. 
Physiologically angiogenesis is a strongly controlled phenomenon that depends on chemical signals 
either stimulating or inhibiting angiogenesis. The prevalence of stimulating factors such as Vascular 
Endothelial Growth Factor (VEGF) occurs when specific sensors of oxygen relieve a hypoxic status 
inducing a regulated formation of new blood vessels (wounding or menstrual cycle). In tumor 
microenvironment, hypoxia stimulates an uncontrolled angiogenesis that supports the growth of 
tumor 72. It has been demonstrated that  tumor cells and TAMs can overproduce growth factors like 
VEGF, in order to have a constant supply of nutrients, necessary to maintain an accelerate metabolism 
73. Thus, angiogenesis is a critical phenomenon involved in the progression of the tumor, both primary 
and metastasis. This is the reason why, in recently years, different drugs have been developed 
targeting molecules and growth factors involved in the angiogenesis. Different soluble factors present 
in tumor microenvironment, like VEGF, FGF and TGF-β can promote angiogenesis, through the 
proliferation of tumor-associated endothelial cells and/or the recruitment from the BM of endothelial 
cells precursors (EPC). Tumor vessels present an altered anatomy as compared to the normal 
counterparts, an irregular shape and size as well as cytogenetic anomalies and different gene 
expression profile 74.  
Recent studies have evidenced that tumor endothelial cells (TECs) can promote metastasis, producing 
proangiogenic factors 75. In the initial steps of tumor metastasis, the production of biglycan, a small 
leucine-rich-repeat proteoglycan by TECs, facilities the trans endothelial migration of tumor cells, 
thanks to the interaction of tumor’s byglican receptors TLR2 and TLR4. TECs, isolated from highly 
metastatic tumors, produced more byglican than those derived from low metastatic tumors, and the 
byglican levels in plasma was significantly lower in healthy donors than in cancer patients. Moreover, 
mice knockout for byglican expression and injected with highly metastatic TECs presented a low 
number of circulating tumor cells and lung metastases. 
Different evidences suggest that TECs could modulate the activity of immune cells by an efficient 
cross talk with tumor cells 76,77. Tumor cells derived from Lewis lung carcinoma produced soluble 
factors able to stimulate endothelial release of different immune suppressive factors 78. In particular, 
endothelial cells pretreated with tumor-conditioned medium produce increased levels of PGE-2, 
VEGF and IL-6 and decreased levels of IL-12. In line with the hypothesis that VEGF is the main 
responsible of the modulation of endothelial cells functions, the block of VEGF through a selective 
inhibitor of the VEGF receptor tyrosine kinase prevented the increased secretion by lung endothelial 
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cells of PGE2 and IL-6. VEGF produced by endothelial cells was also involved in the downregulation 
of the production of IFN-γ by T cells. Again, blockade of the interaction between VEGF with its 
receptor restored the control levels of IFN-γ release. 
To expand the scenario of immunomodulatory role of TECs, it has been showed in mouse models 
that recombinant VEGF, used at concentrations similar to those observed in advanced stage cancer 
patients, can shape T cell development 79. In particular, VEGF can lead to a thymic atrophy and 
reduction of the number progenitors T cells in the thymus, contributing to the immune deficiencies 
observed in tumor. The same group also reported that a continuous infusion of VEGF in non-tumor 
bearing mice caused a decreased percentage of T cells in the spleen and lymph nodes 80. 
The ability of VEGF to alter mature immune cells in a tumor context has been described for CD8+ T 
cells 81 and Dendritic Cells 82. Analyses of human breast cancer showed inverse correlations between 
VEGF-A expression and CD8+ T cell infiltration. Moreover, in many type of tumors, dendritic cells 
are defective in their capacity to present antigens. Indeed, the presence of high amount of tumor-
derived VEGF in tumor microenvironment, which associates with a poor prognosis, contributes to 
inhibition of the DCs functions by inhibiting the DCs maturation and consequently their capacity to 
stimulate T cells.  
A study carried out in mice showed that TECs can also modulate the activity of Natural Killer cells 
83. TECs express high levels of RAE, a mouse ligand of NKG2D. Engagement of NKG2D by the 
corresponding ligand causes its internalization leading to its disappearance from NK cell surface and 
to reduction of the NK cells–mediated antitumor activity. Moreover, normal endothelial cells treated 
with tumor-conditioned media were able to downregulate IFN-γ and TNF-α production by NK cells 
and to upregulate the release of the immunosuppressive cytokine IL-10. This strengthens the concept 
of the occurrence of a relevant crosstalk between tumor cells, TECs and NK cells 84 and 





3. Factors Dampening NK Cells Activity 
 
The capacity of NK to recognize and kill tumor cells and different tumor-associated cells that favor 
tumor progression (CAFs, M2-macrophages, and TECs) renders these immune cells promising 
effectors for immunotherapy. However, there is a growing evidence that NK-based therapeutic 
approaches must also consider that, in tumor microenvironment, different mechanisms could favor 
tumor escape from NK-mediated surveillance. 
 
 
3.1 Membrane-Bound Molecules 
 
The strongest NK-to-tumor contact inhibitory mechanism is represented by KIRs/HLA-I interactions 
(Fig.8). Indeed, it has been shown that in some instances the neoplastic cells (i.e. acute lymphoblastic 
leukemia (ALL) can retain high levels of HLA-I expression. Moreover, IFN-γ can increase the surface 
expression of HLA-I both further reducing their susceptibility to NK-mediated killing 85. This 
scenario might easily occur in vivo and depend on effector cells number and/or cytokines’ level. 
Indeed, it has been demonstrated that, when exposed to low numbers of NK cells, compatible with 
those infiltrating tumors, melanoma cells acquire resistance to NK-mediated aggression cells, mainly 
due to their high levels of HLA-I, resulting from IFN-γ activity 162. Moreover, Propper et al showed 
that low doses of IFN-γ induced the expression of MHC-I in patients affected by metastatic melanoma 
86. Therefore, in certain tumors the inhibitory action of KIRs might prevail on the activating signals, 
leading to their protection from NK-mediated immune surveillance. In particular, therapeutic 
approaches in hematological and non-hematological malignancies, that include stem cell 
transplantation, select KIR/KIR ligand mismatched donors vs recipient combinations in order to 
ensure the onset in the recipient of NK cells donor endowed with “graft versus tumor” activity. 
PD-1 is a receptor that has been described to be expressed and inhibited T cell activity 87. It recognizes 
PD-L1 and PD-L2, expressed by Antigen Presenting Cells, and physiologically limits the immune 
response avoiding autoimmunity reactions. However, ligands can be expressed also by tumor cells. 
PD-1 has been detected also in NK cells and high percentages of PD-1+ NK cells have been described 
in cancer patients and in some healthy donors sero-positive for cytomegalovirus CMV 164. In the last 
donors, representing about the 25% of all donors analyzed (200), PD1+ NK cells belong to CD56dim, 
NKg2A neg, KIRpos, CD57pos NK cells population. The functional analysis showed a reduce activity 
of PD-1+ NK cells, as compared to PD-1- cells, in terms of degranulation, capacity of performing 
ADCC and capacity to proliferate after exposure of rIL-2 and rIL-15. NK cell-mediated killing against 
PDLs+ tumors could be partially restored by PD1-specific mAbs and a complete recovering of killing 
was observed only by the combined masking of PD-1 and KIRs. The inhibitory PD-1/PDLs axis plays 
a pivotal role in recognition of tumors such as neuroblastoma that do not express detectable amounts 
of HLA-I. In this context, it has been shown that neuroblasts derived from bone marrow metastasis 
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significantly upregulate PD-L1 expression upon IFN-γ conditioning, with a more rapid kinetic as 
compared to HLA-I molecules. Importantly, PD-L1 has been shown to be constitutively expressed 
by different tumor histotypes and the evaluation of PD-L+ tumor cells in terms of percentage is a 
parameter predicting responsiveness to anti-PD1 therapies 88,89. 
Another important inhibitory immune checkpoint is represented by the interaction between the B7-
H3 ligand, an orphan ligand expressed by tumor, and its still unknown receptor(s). It has been shown 
that high expression of B7-H3 protects target cells from the NK-mediated cytotoxicity 90. Indeed, the 
NK-mediated killing of metastasizing neuroblastoma (NB) highly expressing B7-H3 was deeply 
affected and significantly recovered by the use of a B7-H3 specific monoclonal antibody. The 
inhibitory role for B7-H3 has also be highlighted in the context of glioblastoma using a 
methodological approach based on B7-H3 specific siRNA 91 . Thus, B7-H3 has been recently 
included in the growing list of immune-checkpoints. B7-H3 is mostly tumor specific, is not 
significantly expressed by normal tissues and is highly expressed by tumor-associated endothelial 
cells. Importantly, B7-H3 has also been shown to promote tumor cells invasion and metastasis of 
different tumor hystotypes 92. 
TIM-3, a member of the T cell immunoglobulin and mucin domain (Tim) family, represents an 
additional inhibitory receptor expressed by mature NK cells. It is also expressed by other immune 
cells, including CD4+ and CD8+ T. Once engaged by its ligand, galectin 9, which is expressed by 
different tumor cells, TIM-3 is able to reduce the functional activities of immune cells, including 
those of NK cells.  A recent study in advanced melanoma  93 showed that circulating NK cells present 
a higher expression of TIM-3 and this is correlated with their exhausted phenotype. In patients with 
lung adenocarcinoma, blockade of TIM-3 recovered the capacity of NK cells to kill tumor cells and 
produce cytotoxic cytokines 94. Homita et al. showed that about 75% of NK cells infiltrating GIST 
were positive for this receptor 95. Importantly, all the GIST tissues with TIM-3 + NK cells were also 
positive for galectin 9. It is note that TIM-3 can also interact with the alarmin protein HMGB1 (High-
Mobility Group Box 1), expressed by dendritic cells and different evidences suggest the presence of 
other still unknown ligand(s). 
An additional inhibitory mechanism is represented by LAG-3 (lymphocyte activation gene 3), a 
transmembrane protein found on the surface on NK, T and B cells that belongs to immunoglobulin 
superfamily and recognizes with high affinity MHC class II molecules. Accumulating data suggest 
that, after activation, LAG-3 could negatively regulate different functions of immune cells, like 
activation and proliferation, and it could be involved in T cells exhaustion in cancer and chronic 
infections. Moreover, it seems to have a role in the immune suppressive activity of Treg. In NK cells, 
the data on the activity of LAG-3 are less clear. In LAG-3 deficient mice, NK cells presented reduced 
capacity to kill some tumor cell lines 96, suggesting that it could be crucial for NK function. On the 
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contrary, in human LAG-3 did not appear to be involved in NK cytotoxicity, because antibodies that 
blocked the molecule did not modify NK cells cytotoxicity 97. 
TIGIT (T-cell immunoglobulin and ITIM domain) is an additional inhibitory receptor. It is expressed 
by NK cells, T cells (both effector and memory) and Treg cells. It recognizes CD155 (PVR) and 
CD112 (nectin 2), the same ligands of the activating receptor DNAM-1. It binds ligands  with higher 
affinity, thus competing with DNAM-1 and negatively regulating the antitumor responses. In healthy 
donors, the expression of TIGIT on NK cells is heterogeneous, and TIGIThigh NK cells have reduced 
functional activities 98.  The expression of TIGIT on NK cells has been associated with NK cells 
exhaustion in tumor bearing mice 99. Moreover, in patients affected by colon cancer, TIGIT was 
significantly higher in NK cells present in the intratumoral region as compared to NK cells in 
peritumoral site. TIGIT+ NK cells presented a lower IFN-γ and TNF-α production, as well as a lower 
expression of the lysosomal marker CD107a and of the cytotoxic molecule TRAIL, suggesting a 
reduced anti-tumor activity. Other studies confirmed that TIGIT is expressed by all human NK cells 
and that it can directly inhibit the cytotoxicity of NK cells thanks to its ITIM motifs 100. Moreover, 
TIGIT can compete with DNAM-1 in the binding of PVR1 and Nectin-2 (CD112), but not Nectin- 3 
(CD113). 
All the above mentioned inhibitory axes are currently targeted by mAb-mediated therapies 101,102, 
Therapies are at different stages of clinical development, most of them are clinical trials in Phase I or 
Phase II, as occurs for Lirilumab, a monoclonal antibody specific for KIR2DL1/DL2 receptor. The 
most advanced immune interventions are represented by the use of FDA-approved antibodies 
targeting PD-1 or PD-L1 in different kind of solid and hematological malignancies. However, clinical 
responses are not observed in all treated patients and major efforts are now employed to discover 
biomarkers predicting responses to therapy. In this context, it has been shown a correlation between 


















Figure 8. Principal membrane-bound and soluble factors limiting anti-tumor NK-cell activity 
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3.1 Soluble factors: TGF-β1, the prototypic immune suppressive factor 
 
Tumors can evade the immune-surveillance mediated by NK cells thanks to the production of 
different soluble factors (Fig.8), that are able to modify, in NK cells, the expression levels of some  
receptors or to downregulate the main effector functions. These factors include soluble ligands of 
activating receptors (see section 1.1) that compete with the membrane-bound forms or induce 
downregulation of the counter receptors on NK cells surface. 
Soluble MIC (sMIC) ligands are responsible of the downregulation of NKG2D in NK cells and CD8+ 
T cells infiltrating epithelial tumors 103. Patients with tumors capable of releasing soluble MICA 
showed a strong downregulation of NKG2D on TILs, whereas NK cells of patients with sMIC 
negative tumors did not show this altered phenotype. The altered expression level of NKG2D was 
neutralized using a specific antibody binding sMIC or inhibitors of lysosomal pathway, confirming 
downregulation of NKG2D by endocytosis/degradation. sMIC, present in the serum of patients, had 
different sources deriving from tumor cell death, tumor-derived exosomes, proteases mediated 
shedding. A study analyzed the presence of NKG2D soluble ligands in serum of patients with 
melanoma metastasis. The authors found a strong correlation between the presence of sULBP2, but 
not sMICA, and disease progression. Both soluble ligands were more elevated as compared to healthy 
donors and high concentrations in the serum were associated with a reduced overall survival 104. 
Soluble PVR (CD155), the main ligand of DNAM-1 activating receptor, has been detected in the 
serum of patients affected by a large variety of tumors (gastrointestinal, lung, breast and gynecologic) 
105. In patients, sPVR was present in higher concentrations as compared to healthy donors, and was 
significantly higher in those with advanced stages. In mouse model, the concentration of sCD155 was 
directly dependent of the weight of tumor, and, after the surgery, the concentration significantly 
decreased. Therefore, sCD155 may be considered a possible biomarker for cancer progression. 
Another mechanism of immune escape, in particular from NK cells, is represented by soluble B7-H6. 
Elevated concentration of sB7-H6, the ligand of the activating receptor NKp30 106, have been detected 
in blood serum of patients affected by melanoma, as compared to healthy donors. Importantly, the 
amounts of sB7-H6 in serum of patients correlated with the levels of expression of B7-H6 by patients’ 
tumor cells. sB7-H6 has been detected in culture supernatants derived from different tumor cell lines 
(pancreatic carcinoma, liver carcinoma and melanoma). However, the downregulation of NKp30 was 
evident also after co-culture with tumor cells in which the presence of sB7-H6 was undetectable, 
suggesting that other factors, such as TGF-β1, might be responsible to the regulation of the expression 
of NKp30 (see below). ADAM-10 and ADAM-17 has been identified as the metalloproteases 
responsible for the sheading of B7-H6, and their inhibition increased the expression of B7-H6 on the 
surface of tumor cells, with increase activation of NK cells. It has been shown that the release of 
soluble B7-H6 by activated monocytes and neutrophils can be induced, in inflammatory conditions, 




Galectin 9 has been identified as the main ligand of TIM-3, being TIM-3/galectin 9 an immune 
checkpoint axis involved in the downregulation of the response of T cells and NK cells. Galectin 9 is 
a member of a family of carbohydrate-binding protein and can be released in soluble form by a large 
array of tumors 107. In humans and mice, galectin-9 upon TIM-3 engagement can impair the main NK 
cells functions, including cytotoxicity and cytokines production 108. 
Recent studies showed that an important role in the regulation of the immune activity of NK cells is 
played by catabolic molecules derived from the amino acid Tryptophan (Trp),109, in particular by the 
enzyme indoleamine 2,3-dioxygenase (IDO). IDO is produced by different kind of tumors, and 
upregulation of its activity has been correlated with tumor progression 110. Among the catabolites 
generated by IDO and endowed with immunomodulatory activity against Natural Killer Cells, it 
should be mentioned L-kynurenine, which has been demonstrated to prevent the IL-2-induced 
upregulation of NKp46 and NKG2D activating receptors in NK cells, both at protein and mRNA 
levels 111. This negative regulation significantly affected the activating receptor-mediated capability 
of killing of tumor cells and of releasing cytokines. IDO-derived catabolites are effective molecules 
also used by Dendritic Cells, Mesenchymal stem cells (MSC), and tumor associated fibroblasts to 
shape NK cells proliferation and functions 112 . Other soluble factors showing an inhibitory activity 
against NK cells are prostaglandin E2 (PGE2), macrophage migration-inhibitory factor (MIF) and 
adenosine. The first is a small lipid molecule, produced by different kind of tumors cells and engaging 
the Prostaglandin E2 receptor 4 (EP4), whose targeting in mouse model was shown to prevent the 
inhibition of the main activities of NK cells leading to a better control of breast cancer.  MIF, a factor 
involved normally in the survival of macrophages is constitutively produced by different tumor 
histotype, like ovarian cancer 113, melanoma 114  and uveal melanoma, and exert an inhibitory effect 
on NK cells that could be efficiently contrasted by a specific monoclonal antibody. In ovarian cancer, 
one of the MIF-mediated mechanisms leading to NK suppression is represented by the 
downregulation of NKG2D expression at transcriptional level. Adenosine, another soluble molecule 
present in tumor microenvironment, is an endogenous purine nucleoside that mediates various 
biological effects by binding to adenosine receptors (AdoRs), present in 4 different isoforms (A1, 
A2a, A2b, A3),. Concentrations of adenosine similar to those produced in tumor microenvironment 
by Sarcoma cells and Lewis lung carcinoma cells in hypoxic conditions, inhibited main functions of 
murine NK cells 115. These effects have been confirmed in human, in which it has been demonstrated 
to be due to the adenosine-mediated engagement of Adenosine Receptor 2A (AdoR2A) 116. 
Among the plethora of soluble factors negatively regulating the NK cells mediated activity, 
Transforming Growth Factor beta (TGF-β) plays a strong and pleiotropic pivotal role. 
TGF-β1, the most studied isoform, is released by a large array of cell types including immune cells. 
It is a physiologic regulator controlling the activation and the proliferation of different cell types, 
including macrophages and T lymphocytes, regulating the amplitude of immune responses and 
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maintaining peripheral tolerance 117. According to its functions, TGF-β1 knocked-out mice showed 
multiorgan inflammation and early death 118. TGF-β1 also contributes to the development of 
regulatory FoxP3+ lymphocytes and Th17 lymphocytes in the context of infections by pathogens 119. 
Importantly, the in vivo TGF-β1 activity is finely regulated. TGF-β1 has been called a “sleeping 
giant” 120,  since it is available in large amounts but inactive in the body. Indeed, after intracellular 
synthesis and processing is released in a Small Latent Complex (SLC), non- covalently bound to the 
protein LAP, or in a larger complex called Large Latent Complex (LLC), formed by SLC covalently 
bound to LTBP protein called Latent TGF-β-Binding Protein. Notably, a specific region of LTBP 
shows binding sequences for extracellular matrix (ECM) with important consequences on TGF-β1 
localization within ECM. Different stimuli (heat, acidic PH, Reactive Oxygen species, various 
proteases, shear stress or binding with some integrins) allow the release of TGF-β1 from complexes. 
The free active form is capable of interacting with its receptors TGF-RI and RII, leading to the 
phosphorylation of intracellular SMAD molecules,  regulating NK cells development and functions 
121. NK cells derived from peripheral blood of healthy donors and cultivated in the presence of TGF-
β1 drastically reduced their cytolytic activity against tumor cell lines, in a concentration dependent 
manner122. Moreover, TGF-β1 is capable of modulating in NK cells the constitutive and the IL-2 
driven expression of the activating receptors NKG2D and NKp30 123. A reduction of the 
corresponding transcript was detected for NKp30 but not for NKG2D. Accordingly, TGF-β1 has been 
shown to downregulate DAP10 protein, a signal transducing molecule essential for NKG2D 
expression in human 124. The reduced levels of NKG2D and NKp30 resulting from TGF-β1 
conditioning significantly affected the NK-mediated killing of different tumor cell lines and/or of 
autologous immature myeloid DCs, likely impacting on the selection of iDC undergoing successful 
maturation. Importantly, NKG2D downregulation has been documented by in NK (and CD8) cells 
isolated from patients affected by glioblastoma multiform 125. NKG2D expression was recovered after 
tumor resection, an observation that correlated with an increased killing of NKG2D-positive tumor 
targets. In this study, blockade of TGF-β1, differently from blocking of soluble ligands for NKG2D, 
was sufficient to restore the NKG2D levels. Accordingly, high levels of TGF-β1 were detected in the 
patients’ serum that could be produced not only by tumor cells but also by regulatory T cells, present 
in high percentage in these patients. An in a vitro model showed that a chronic interaction between 
IL-15 stimulated human NK cells and colorectal tumor cell lines led to an exhaustion of NK cells 
characterized by a strong reduction of NKp30, NKG2D and DNAM-1 and a reduced production of 
IFN-γ. This chronic inhibition was mediated by TGF-β1, and the use of TGF-β1 antibody restored 
the main NK functions. NK cells with exhausted phenotype were detected in ascites of patients 
affected by ovarian cancer but not in their peripheral blood 126. 
The same exhausted phenotype could be induced in blood-NK cells after coculture with autologous 
tumor cells, and the correct levels of activating receptors could be restored using a specific TGF-β1 
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antibody, confirming its important role in affecting NK cells functions in tumor microenvironment in 
vivo. Along this line, TGF-β1, in concentrations similar to that observed in tumor microenvironment 
of AML patients, was able to progressively impaired the killing capability against myeloid leukemia 
cells of ex vivo expanded NK cells, which showed a progressive decline in the expression of NKG2D 
and CD16 127. 
TGF-β1 can also be expressed as a membrane form as occurs in Myeloid derived suppressor cells 
(MDSC), a myeloid population strongly expanded during tumor progression and able to inhibit 
different immune cells including T cells, DCs and NK cells. The inhibition mediated by the 
Membrane-bound form of TGF-β1 is the main responsible for the suppression of the NK cells 
functions in liver cancer 128. 
It is well known that TGF-β1, activating STAT transducing molecules, also reduces the production 
of IFN-γ and TNF-α induced by the synergistic effect of different proinflammatory cytokines such as 
IL-12, IL-15 and IL-18. Moreover, recently a new regulatory function for TGF-β1 has been 
demonstrated. Both rTGF-β1 and TGF-β1 released by neuroblastoma cell lines were capable of 
modulating the chemokine receptor repertoire of NK cells 129. In particular, it upregulated the 
expression of CXCR4 and CXCR3, while downregulating that of CX3CR1. On the contrary, the 
expression of CCR7 and CXCR1 was unaffected. The decreased expression of CX3CR1, that plays 
a role in NK cell adhesion to endothelium and extravasation, may hamper their recruitment to 
peripheral tissues, including tumor sites. 
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AIMS OF THE STUDY 
 
 
During my PhD program at University of Genova my research activity has been focused on the 
analysis of the anti-tumor activity of human NK cells and of the mechanisms that may limit or 
enhance their function.  
The topics have been summarized and critically discussed in reviews (publication n°1, 2, 3) and 
new data published in research articles.  In particular, I have analyzed the activity of cytokine-
stimulated NK cells against tumor-associated endothelial cells, isolated from bone marrow 
aspirates of MM patients with active disease (MMECs) (publication n°4); investigated the 
immunological off-target effects of imatinib and nilotinib, tyrosine kinase inhibitors (TKIs) used 
in the clinical management of hematological neoplasms that have also showed benefits in solid 
tumors such as stage 4 neuroblastoma (NB) (publication n°5); analyzed the miRNA involved in 
the TGF-1-mediated modulation in NK cells of CX3CR1, a chemokine receptor that drives these 
effectors toward peripheral tissues, including tumor sites. (publication n°6)    
 
More recently, my efforts have been dedicated to the following aims: 
AIM 1. Identification of the mechanisms strengthening or contrasting TGF-β1-mediated 
modulation of NK cells activity. 
AIM 2.  Analysis of the impact of gut microbiome on immunotherapy. Experiments  have been 
carried out during my stay at the Institute Gustave Roussy (Villejuif, France) (January 2018-
October 2018) under the supervision of Prof. Laurence Zitvogel.  








IL-18 boosts the immunomodulatory effects of TGF-β1 in NK cells 
As previously shown 123,129, optimal concentrations of TGF-β1 induced down-regulation of the 
NKp30 and NKG2D activating receptors and modified the chemokine receptor repertoire of 
peripheral blood (PB) NK cells. In particular, it significantly increased the expression of CXCR4 
and CXCR3 and decreased that of CX3CR1 (Fig.1). In search for cytokine(s) that could modify 
the TGF-β1-mediated immunomodulatory effects on human NK cells, we cultured PB NK cells in 
the presence of TGF-β1 alone or in combination with different cytokines known to exert 
immunostimulatory functions (Fig.1). 
IL-2 and IL-15 significantly contrasted the TGF-β1-mediated down regulation  of the activating 
receptors, which recovered expression levels comparable (or even higher) to untreated NK cells. 
On the contrary, IL-21, IL-12, IL-27 and IL-32 had no effects. IL-18 was unable to restore NKG2D 
expression (Fig.1), despite its ability to upregulate its expression when used alone (Fig.2). Notably, 
IL-18 showed an unexpected immunomodulatory role, significantly strengthening the TGF-β1-
mediated downregulation of NKp30 surface expression (Fig.1). 
Regarding the chemokine receptor repertoire, none of the cytokines analyzed influenced the effect 
of TGF-β1 on CXCR3 expression. IL-2 and IL-15 did not alter the effect of TGF-β1 on CX3CR1 
while strongly contrasted the CXCR4 up-regulation (Fig.1), leading to chemokine receptor’s 
surface levels even lower than those present in untreated NK cells. Again, IL-18 showed a very 
peculiar behavior. Indeed, it significantly potentiated the activity of TGF-β1 further reducing the 
expression of CX3CR1 and increasing that of CXCR4 (Fig.1). The latter effect was evident in both 
CD56dim and CD56bright NK cells. Notably, a significant decrease of CX3CR1 surface levels was 
detected also when IL-18 was used alone (Fig.2). Morever, IL-18 also decreased the expression of 
CXCR1, both when used alone or in the presence of TGF-β1 (Fig.1 and Fig.2).  
Among the other cytokines analyzed, IL-21 significantly counteracted the TGF-β1-mediated up-
regulation of CXCR4, although to a lower extent as compared to IL-2 and IL-15 (Fig.1). On the 
other hand, IL-21 shared with IL-18 the property of further reducing the CX3CR1 surface levels 
resulting from TGF-β1 conditioning. IL-12, IL-27 and IL-32 did not modify the TGF-β1-mediated 
modulatory effect on the chemokine receptor repertoire (Fig. 1 and Fig.2).  
It is of note that IL-18 significantly potentiated the activity of TGF-β1 on NKp30 and CXCR4 
expression but had no effect on these molecules when used alone (Fig.1).  Moreover, IL-18 alone 
shared with IL-15 classical immunostimulatory functions such as upregulation of NKG2D, CD69 
and CD25 surface levels (Fig. 2). The additive effect of IL-18 on TGF-β1-mediated up-regulation 
of CXCR4 was preserved using TGF-β1 concentrations ≥1 ng/ml (Fig.3).  
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On the contrary, that on NKp30 surface levels was lost using suboptimal concentrations of TGF-



















Figure 1. Effect of pro-inflammatory cytokines on the main TGF-1-mediated immunomodulatory effects 
NK cells purified from peripheral blood of healthy donors (PB NK) were cultured for 48 hours either in the absence 
(control, CTR, white bars) or in the presence of TGF-β1 used alone or in combination with the indicated cytokines.  
Cells were analyzed by flow cytometry for the expression of activating and chemokine receptors. Average of 6 
independent experiments (6 unrelated healthy donors). Mean fluorescence intensity (MFI) and 95% confidence 
intervals are shown. **p<0.01 *p<0.05; ns means p not significant. If not indicated, statistical significance is referred 
















Figure 2. Effect of IL-18 or IL-15 on the expression of activating and chemokine receptors 
 
PB NK cells, cultured for 48 hours either in the absence (CTR) or in the presence of IL18 or IL-15, were analyzed by 
flow cytometry for the expression of the indicated molecules. Average of 6 independent experiments (6 donors). Mean 
























Figure 3. Analysis of the effects of IL-18 in combination with sub-optimal doses of TGF-β1  
 
A) Cytofluorimetric analysis of the expression of CXCR4 and NKp30 in PB NK cells cultured for 48 hours in the 
absence (CTR, white bars) or in the presence of suboptimal doses of TGF-β1 alone or in combination with IL-18 or 
IL-15. Average of 5 independent experiments (5 donors). Mean of MFI and 95% confidence intervals are shown. 
*p<0.05; ns means p not significant. Statistical significance is referred to results obtained with TGF-β1 alone. 
B) Representative experiment of the cytofluorimetric analyses shown in panel A. White profiles refer to cells 
incubated with isotype-matched mAbs. Values inside each histogram indicate the MFI. 
 
 
TGF-1 plus IL-18 affect NKp30-mediated triggering 
We analyzed whether the very low NKp30 surface densities resulting from TGF-β1 plus IL-18 
conditioning impacted on the killing capability of NK cells.  To this end, PB NK cells were treated 
with the cytokines combination and analyzed in ADCC against the FcγR+ P815 target cells. As 
shown in fig. 4A, differently from untreated cells, the mAb-mediated engagement of NKp30 in 
TGF-β1 plus IL-18 conditioned NK cells was virtually unable to induce target’s lysis. On the 
contrary, the engagement of CD16 still induced optimal cytotoxicity. This result suggested that 
the combined action of these cytokines selectively affected the triggering capability of NKp30 
rather than significantly impacting on the overall cytolytic potential of NK cells (i.e. 
granzyme/perforin cellular content).  
Next, we analyzed whether classical immunostimulatory cytokines could counteract the TGF-β1 
plus IL-18 immunomodulatory effects. To this end, PB-NK cells were treated with TGF-β1 plus 
IL-18 in combination with either IL-2 or IL-15 (Fig.4). Both cytokines induced in NK cells the 
recovery of the NKp30 surface expression (Fig.4B). This was paralleled by restoration of 
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receptor’s function. Indeed, mAb-mediated engagement of NKp30 resulted in  a strong cytolytic 
activity against target cells, significantly higher as compared to untreated PB-NK cells (fig.4A).  
Finally, IL-2 and IL-15 abrogated the CXCR4 up-regulation induced by TGF-β1 plus IL18 
(Fig.4B). 
 
Figure 4. IL-2 or IL-15 strongly contrast TGF-β1 plus IL-18-mediated modulatory effects  
 
A) PB NK in the indicated culture conditions were analyzed for cytolytic activity (51Cr release) against the FcγR+ 
P815 target cell in the presence of mAb specific for NKp30 or CD16.  
B) Cytofluorimetric analysis of NKp30 and CXCR4 expression in PB NK cells treated with the indicated cytokines 
combinations. Average of 4 independent experiments (4 donors). Mean of MFI and 95% confidence intervals are 





Molecular mechanisms involved in the IL-18-mediated additive effect on TGF-β1 activity 
To analyze whether transcriptional regulation was involved in the IL-18-mediated additive effect 
on TGF-β1 activity, PB NK cells were treated with different concentrations of TGF-β1 in the 
absence or in the presence of IL-18 or IL-15 and analyzed by quantitative PCR for CXCR4 and 
NKp30 mRNA expression. qPCR for CD25 mRNA was also performed as control. As shown in 
Figure 5, treatment with optimal doses of TGF-β1 resulted in an increase of CXCR4 mRNA and 
reduction of NKp30 mRNA, effects that were significantly potentiated by IL-18. The addition of 
IL-18 to suboptimal doses of TGF-β1 (2,5 ng/ml) did not cause any significant change in NKp30 
mRNA levels, according to results on receptor expression depicted in Fig.3. On the contrary, 
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although significant up-regulation of CXCR4 at protein level was detect upon addition of IL-18 to 
suboptimal doses of TGF-β1 (both at 2,5 and 1 ng/ml) (Fig.3), this effect did not seem to correlate 
with increased CXCR4 mRNA levels, suggesting the release to the cell surface of preformed 
cytoplasmic CXCR4 (Fig.5) 
As expected, IL-18 alone caused a significant up-regulation of CD25 mRNA, an effect shared by 
IL-15. Moreover, IL-15 contrasted the effect of TGF-β1, significantly increasing NKp30 and 







Figure 5. CXCR4, NKp30 and CD25 mRNA expression in NK cells treated with TGF-β1 plus IL-18 or IL-15 
 
PB NK cells were treated for 48h with the indicated amounts of TGF-β1, in the absence or in the presence of IL-18 or 
IL-15, and analyzed by qPCR for CXCR4, NKp30 and CD25 mRNA expression. Average of 5 independent 
experiments (5 donors, each analyzed in triplicate). GAPDH has been used as reference control. 
 
p38 MAPK and MEK/ERKs are kinases involved in the transduction pathway of IL-18 and TGF-
β1 . To analyze their possible involvement in the additive effect of IL-18 on TGF-β1 activity, PB 
NK cells were conditioned with these cytokines, in the absence or in the presence of specific kinase 
inhibitors (Fig.9), and analyzed by flow cytometry for NKp30 and CXCR4 expression (Fig.6 and 
Fig.7). The capability of TGF-β1 alone to modulate NKp30 and CXCR4 expression was not 
significantly affected either by p38 MAPK or MEK/ERKs inhibitors, suggesting a predominant 
intervention of the SMAD signaling pathway. Differently, p38 MAPK and MEK/ERKs were 
involved in the additive effect of IL-18 on TGF-β1. In particular, the p38 MAPK inhibitor 
abolished  (NKp30) or significantly reduced (CXCR4) the additive effect of IL-18 (Fig.6 and 
Fig.7). That on NKp30 down-regulation was also significantly affected by inhibition of 
MEK/ERKs . On the contrary, MEK/ERKs inhibition did not cause significant variation in up-
regulation of CXCR4 (Fig.6 and Fig.7).  






Figure 6. Effect of p38MAPK or MEK/ERK inhibitors on the additive effects mediated by IL-18 on TGF-β1 
activity  
 
Cytofluorimetric analysis of CXCR4 and NKp30 surface expression in PB NK cells treated with TGF-β1 or TGF-β1 
+ IL-18, in the absence (CTR) or presence of p38MAPK inhibitor (panel A) or MEK/ERK inhibitor (panel B).  
Average of 4 independent experiments (4 donors). Mean of MFI and 95% confidence intervals are shown. *p<0.05, 




























Figure 7. Effect of p38MAPK or MEK/ERK inhibitors on the additive effects mediated by IL-18 on TGF-β1 
activity  
 
A, B Representative experiment of the cytofluorimetric analyses shown in Fig.9. White profiles refer to cells incubated 




Effect of IL-18 plus TGF-β1 on NK cell proteome  
To gain insight on the effects of TGF-β1 and IL-18 on NK cell phenotype and function we used a 
proteomic approach. PB-NK cells untreated (CTR) or conditioned for 48 hours with TGF-β1, alone 
or in combination with IL-18, were lysed and analyzed by high-resolution mass spectrometry. As 
control, NK cells were analyzed for receptors expression by flow cytometry (data not shown). Data 
processing through the MaxQuant software allowed the identification of a total of 4331 proteins 
(of which 3971 were quantified using a Label-Free Quantitation approach).  
In order to analyze the statistically significant regulated proteins, two volcano plots were generated 
from TGF-β1 vs CTR and TGF-β1 plus IL-18 vs TGF-β1 data sets, and representative proteins 
selected on the basis of a two-sample t-test (FDR = 0.05 and s0 = 0.1 log10 of P value, y-axis) 
(Fig.8). By this selection, several proteins have been identified, involved in different cellular 
processes including innate and adaptive immune responses, cell-to-cell adhesion, responses to 
external stimuli, exocytosis (SANKEY) (Fig. 9). Among these, 40 proteins were regulated by both 
TGF-β1 and IL-18 with student’s t test difference or –log student’s T test ˂ or ˃ 1. We focused on 
proteins expressed at the cell surface membrane. Few of these molecules were identified and, 
differently from cytofluorimetric results, in no cases an additive effect of IL-18 was detected. In 
particular, the protein level of CXCR4 was significantly increased by TGF-β1, but the additive 
effect of IL-18 was not appreciated. Moreover, no decrements in the protein levels of NKp30 (and 
NKG2D) were detected in the presence of TGF-β1 used alone or in combination with IL-18. These 
results showed that sensitivity of the proteomic approach was considerably lower as compared to 
the flow cytometry. 
Nonetheless, we detected a strong, opposite modulatory effect of TGF-β1 and IL-18 on the C-Type 
Lectin Domain Containing protein 14A (CLEC14A). a molecule involved in cell-to-cell contact 
and angiogenesis. As shown in Fig 8, its protein level strongly decreased in the presence of TGF-
β1, an effect that was completely abrogated by IL-18. Interestingly CLEC14A has been never 
described in NK cells and no data on its expression and function are available so far.  
This and other proteins, that among the 40 selected showed co-regulation by IL-18 and TGF-β1,  

















Figure 8. Proteomic analysis of NK cells unconditioned or conditioned with TGF-β1 (TGF-β1 vs CTR data set)  
 
Volcano plot representation of differentially expressed proteins. Plots represent stimulated (TGF-β1) vs. not 
stimulated (CTR) NK cells (A) ot TGF-1 plus IL-18 vs. TGF-1 data sets (B). Black dots represent proteins that 
display both large magnitude fold-changes (x-axis, proteins up-regulated after treatment are shown on the right) as 
well as high statistical significance (FDR = 0.05 and s0 = 0.1 log10 of P value, y-axis). Colored plots represent protein 
more significantly downregulated (blue) or upregulated by TGF-β1 treatment Gray squares represent  proteins not 





















































Figure 9. Profile plot of 1D annotation enrichment results. 
Enrichment is done by GOBP downloaded from Uniprot with a significance threshold of p<0.0001. The output file is 
converted into a Sankey plot where different colors are associated with different data sets and the width of flow line 




COMMENT TO THE STUDY AND FUTURE PERSPECTIVE 
 
NK cells play a fundamental role in the immune surveillance of virus infected and tumor cells. 
However, especially in advanced tumors, the NK cell function is dampened by different escape 
mechanisms set up by tumor cells or by the other cell types colonizing tumor microenvironment. 
Mechanisms include the release of soluble factors such as TGF-β1, which in NK cells negatively 
modulates the expression of crucial activating receptors, reduces IFN-γ production and regulates 
the migratory properties. TGF-β1 is also fundamental to sustain the expansion of ILCreg, a 
subpopulation of cells colonizing both mouse and human intestines, which, via IL-10, contribute 
to the resolution of inflammatory processes 130. TGF-β1 shapes the differentiation process of ILCs 
and modulate their effector functions 117. In particular, it negatively impacts on NK cell 
differentiation 131 leading to peripheral NK cells with a decidual NK-like phenotype 132 and 
represents a key mediator regulating both tolerant and regulatory NK cells residing in the liver and 
in the uterus, respectively 133. In mouse salivary gland, TGF-β1 is required for the generation of a 
peculiar ILC subpopulation endowed with both, NK and ILC1 features 132. In accordance with data 
showing that TGF-β1 selectively and quickly represses the mTOR pathway 134, a crucial integrator 
of pro-inflammatory signals, it deeply affects, both in vitro and in vivo, the NK cell functions.  
Due to the pleiotropic effect of TGF-β1 on phenotype and functions of NK cells and ILCs, we 
considered particularly relevant to compare different cytokines for their capability of contrasting 
TGF-β1 activity. Our study highlighted an unpredictable behavior of IL-18, a cytokine that is listed 
among the immunostimulatory cytokines. Indeed, we showed that, different from other typical 
cytokines such as IL-2 or IL-15, IL-18 strengthened rather than weakening some TGF-β1-mediated 
effects.  
IL-18 is produced by macrophages and its role could change depending on the inflammatory 
context. In acute inflammation such as in response to pathogen-related stimuli, IL-18 produced by 
M1-polarizing macrophages may synergize with IL-12 and IL-15, thus exerting an 
immunostimulatory rather that immunoregulatory role. In chronic inflammation processes such as 
those occurring in tumor tissues, it could support the function of TGF-β1 that is produced/activated 
by M2-polarized tumor-associated macrophages (TAM). In this context, a membrane-bound form 
of IL-18 has been described (see Introduction: 2.2 M2 macrophages section) that is expressed by 
a subset (30-40%) of un-polarized (M0) and M2-polarized macrophages and by the majority of 
TAM. The mechanisms responsible for its membrane retention and release still remain enigmatic. 
Interestingly, IL-18 shows many predictable cleavage sites of MMP-2 and -9 (Protease specificity 
prediction server, PROSPER), extracellular proteases produced by different cell types including 
M2/TAM that are also involved in TGF-β1 activation. Considering that also tumor cells may 
represent a source of MMPs, TGF-β1 and IL-18, the synergistic effect of TGF-β1 and IL18 might 
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be supported by the proteases intervention and play a pivotal role during M2- (and TH2-) polarized 
immune responses occurring in the tumor microenvironment. According to the IL-18 capability of 
strengthening the negative regulatory effect of TGF-β1 on tumor immune-surveillance, in several 
tumor types high concentrations of IL-18 correlated with advanced tumor stages and were 
significantly, and independently, associated with shorter overall survival 135.  
It should also be mentioned that urticaria, asthma, dermatitis, rhinitis, and eosinophilic disorders 
all have shown a correlation with increased IL-18 levels either in the tissue or in systemically 
136.TGF-β1 and IL-18 might also synergize in inducing collagen deposition highly affecting 
organs’ structure and functionality as occurs in tumor-associated fibrogenesis related to radiation 
therapy, which contributes to morbidity in cancer patients. This synergistic effect might be also 
crucial in the immune responses against parasites where fibrosis limits their spread through 
encapsulation. In line with this hypothesis, in mouse model IL-18 has been shown to play a role 
in the pathogenesis of chronic obstructive pulmonary disease (COPD), the fourth leading 
cause of death, where tissue fibrosis and collagen deposition represent key pathological features 
137.  
To conclude, our study highlights an additive effect of IL-18 on some crucial regulatory functions 
of TGF-β1, strongly supporting the concept that IL-18 can be considered “more than a Th1 
cytokine” 138. First identified as interferon (IFN)-γ inducing factor due to its capability of inducing 
Type 1 helper T (Th1) cells, IL-18 might cooperate with cytokines exerting opposite, immune-
stimulatory (with IL-12, IL-15 or IL-2) or -inhibitory effects (with TGF-β1). The different IL-18 
behavior might depend on the relative amount of the various soluble factors characterizing the 
cytokine milieu, which results from both the type of stress/infectious signal and the different 
cytokine timing release.  
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MATERIALS AND METHODS  
Cells used in the study 
NK cells were purified with “Human NK Cell Isolation kit” (Miltenyi Biotec, GmbH, Bergisch 
Gladbach, Germany) from PBMC of healthy volunteer blood donors admitted at the blood 
transfusion center of IRCCS S. Martino-IST after obtaining informed consent and the study was 
approved by the Ethics committee of IRCCS S. Martino-IST (39/2012). The degree of purity of 
the isolated NK cells (CD3-, CD56+, NKp46+) was > 98%.  
Monoclonal antibodies and cytokines 
The following mAbs were produced in our laboratory: AZ20 (IgG1) (anti-NKp30), BAT221 
(IgG1) (anti-NKG2D), MAR93 (IgG1) (anti CD25) and C227 (IgG1) (anti CD69). Anti-human 
CXCR4 (IgG2b) and anti-human CXCR3 (IgG1) were purchased from R&D Systems 
(Minneapolis, MN). Anti-human CXCR1 (IgG1) mAb was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Anti-human CX3CR1 PE (rat IgG2b) and the isotype control (rat 
IgG2b-PE) were purchased from MBL international (Woburn, MA). 
Human recombinant cytokines were purchased from PeproTech (rTGF-β1, rIL-15, rIL-12, and 
rIL-21), Novus Biologicals (rIL-32), Proleukin (rIL-2), MBL International (rIL-18) and R&D 
Systems (rIL-27). NK cells were cultured for 48 hours in the presence of RPMI 1640 completed 
medium (supplemented with 2 mM glutamine, 50 mg/ml penicillin, 50mg/ml streptomycin and 
5% heat-inactivated FCS) supplemented with the different cytokines used at the following 
published working concentrations: rIL-12: 1 ng/ml; rIL-15: 20 ng/ml; rIL-18: 100 ng/ml; rIL-21: 
20ng/ml; rIL-27: 100 ng/ml; rIL-32  (Dondero et al.) 
Flow cytometry  
For cytofluorimetric analysis (FACSCalibur Becton Dickinson & Co, Mountain View, CA) cells 
were stained with the appropriate PE conjugated mAbs or with unconjugated mAbs followed by 
PE-conjugated isotype-specific goat anti-mouse second reagent (Southern Biotechnology 
Associated, Birmingham, AL). Isotype-matched irrelevant mAbs were used as control. On every 
experimental session, the flow cytometer performances were monitored, and the reproducibility of 
the fluorescence intensity was aligned by calibrated microsphere (Becton Dickinson & Co, 
Mountain View, CA).  
Real-time PCR 
Total RNA was extracted from NK cells using the miRCURY RNA Isolation Kit - Cell and Plant 
(Exiqon), according to the manufacturer guidelines. 250 ng RNA were reverse transcribed using 
the SuperScript VILO cDNA Synthesis Kit (Invitrogen). Real-time PCR was performed using 
specific TaqMan Gene Expression Assays (Applied Biosystems). CXCR4, NKp30 and CD25 gene 
expression was normalized to GAPDH gene expression. Experiments were performed in triplicate.  
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p38MAPK and MEK/ERK inhibitors 
Inhibitor SB203580 (p38MAPK) and PD98059 (MEK/ERK) were purchased from Selleckchem. 
Following recommended procedures both inhibitors were diluted in DMSO (0,1%) and in 
complete RPMI medium in order to obtain the desired concentrations (20 μM for SB203580 and 
80 μM for PD98059). 2x 105 resting NK cells were then incubated with p38MAPK inhibitor or 
MEK/ERK for 1 hour or 72 hours respectively or with DMSO (0,1%) as control. After two washing 
in complete RPMI medium NK cells were seeded in 96 round bottom wells and conditioned by 
cytokines for 2 days  
Statistical analysis 
Statistical analysis with level of significance (p) and graphic representation were performed using 
Wilcoxon-Mann-Whitney p-value test (non-parametric significance test) and GraphPad Prism 6 







In recent years great importance has been assumed by immunotherapy as a new strategy to fight 
cancer, in particular in combination with standard therapies such as chemotherapy and 
radiotherapy. Along this side the Nobel Prize has been recently assigned to Prof. J.P. Allison and 
T. Honjo for their discovery on Immune checkpoints limiting anti-tumor immune surveillance. 
These studies have been fundamental for the development of new combined immunotherapeutic 
approaches, including the targeting of the PD1/PD-L1 axis. In particular, in metastatic renal cell 
carcinoma (RCC) the standard therapy, which involved the use of Tyrosine Kinase Inhibitors 
(TKIs) 139 was strengthened by the use of immune checkpoint blockade (ICB). However, only 20-
30% of patients were responders, i.e. showed clinical benefits from ICB (stable disease, partial or 
complete response). These and other studies highlighted the impact of biological variables on the 
patients’ response to immunotherapy. 
Along this line, in recent years several evidences have suggested that microbiome could play a 
fundamental role in predicting the response to immunotherapy as ICB can affect the integrity of 
the intestinal barrier 140–142. Two recent studies by the Zitvogel’s group (Routy et al, Gut 
microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science 
2018; Derosa et al., Negative association of antibiotics on clinical activity of immune checkpoint 
inhibitors in patients with advanced renal cell and non small cell lung cancer, Annals oncology 
2018) highlighted that 1) dysregulation of the intestinal microbiome due to antibiotics treatment 
(ATB) reduced overall survival (Fig.1, left), progression-free survival, and response to 
immunotherapy of patients with non–small-cell-lung-carcinoma (NSCLC) (Fig.1 left), renal cell 
carcinoma (RCC), and urothelial carcinoma (UC) (retrospective analysis). Indeed, patients who 
better responded to immunotherapy (responders) did not receive antibiotics. These observations 
were confirmed in several cohorts of patients, and validated using a sarcoma mouse model (MCA-
205 cell line) (Fig.1 right) showing that tumor-bearing mice treated with antibiotics were 





Figure 1. Antibiotics compromise the efficacy of CTLA-4 and PD-1 blockade in cancer patients and in mouse 
tumor models (Routy et al, Science 2018) 
 
2) feces from NSCLC and RCC patients, responders or non-responders to ICB therapy, showed a 
different bacterial composition. It has been shown by the use of fecal microbiota transplantation 
(FMT) using patients’ feces to recolonize germ-free or ATB-treated mice in two tumor models 
(MCA-205 and RENCA). Feces from responder patients conferred to tumor-bearing mice a 
stronger ICB response as compared to feces from non-responders. Metagenomics analysis of the 
fecal microbiome showed that the percentage of NSCLC patients (Fig.2) presenting Akkermansia 
muciniphila was significantly higher in responders (PR and SD) as compared to patients with 














Figure 2. Frequency of patients with detectable Akkermansia muciniphila in their feces according to PR (partial 




3) Akkermansia muciniphila was a predictive factor of response to ICB and it was able to contrast 
resistance to immunotherapy. In particular, in MCA-205 non-responders FMT mice , the oral 
supplementation with A. muciniphila restored the efficacy of anti-PD-1 Ab. A more in-depth 
analysis suggested some mechanisms responsible for this effect. Indeed, mice recovering response 
to ICB had dendritic cells capable of producing larger amount of IL-12. Accordingly, mice 
supplemented by A. muciniphila showed a significant increase in the recruitment of CCR9pos, 
CXCR3pos CD4pos T Central Memory (TCM) lymphocytes from the mesenteric lymph nodes to 
the tumor site (Fig.3 left). Moreover, an increase in the CD4pos/FoxP3 ratio in tumor site was 
















Figure 3. Biological importance of A. muciniphila during anticancer PD-1 blockade treatment 
 
Left: flow cytometry analysis of CCR9 and CXCR3 expression in mLN-residing CD4+ TCM among the tumor-
infiltrating lymphocytes (TILs) at D+17 after the first injection of PD-1 mAb in ATB-treated animals 
Right: Immunohistochemically determination of CD4 and FoxP3 infiltrates in treated tumor sites (Routy et al. Science 
2018) 
 
In RCC, a retrospective analysis of responder patients together with a mouse model (RENCA-
renal cell carcinoma orthotopically transplanted) showed that responsiveness to ICB therapy was 
linked to the enrichment of microbiome with A. muciniphila and some Bacteroides spp. In 
particular, Bacteroides salyearsiae, but not Bacteroides xylanosolvens, was significantly enriched 
in responder patients (fold ratio of 27.09, p=0.05). Accordingly, the resistance to ICB therapy 
(anti-PD1 + anti-CTLA-4) of mice treated with feces of non-responder patients could be bypassed 
after the gavage, and consequent intestinal re-colonization, with A. muciniphila or B. salyearsiae 
but not with B. xylanosolvens (Unpublished Data).  
 
We studied the correlation of the responsiveness to ICB therapy, following microbiome 
replacement, and changes in the immune compartment in the RENCA mouse model. In particular, 
we analyzed blood, spleen, mesenteric lymph nodes and tumor site immune cells landscape in non-






Figure 4: Experimental design 
 
The experimental design is shown in Fig.4 and Table 1.  
1) At day -21, BALB/c mice (6 mice/group) were treated with an antibiotic solution (ATB) 
containing ampicillin (1 mg/ml), streptomycin (5 mg/ml), and colistin (1 mg/ml) (Sigma-Aldrich) 
added to the sterile drinking water of mice. 
2) After 48 hours (day -19), the treatment with antibiotics was stopped and the mice received the 
FMT with non-responder patients’ feces. Frozen fecal samples were thawed and thoroughly 
vortexed. Large particulate material was allowed to settle by gravity. 200 μl of supernatant was 
administered in a single dose by oral gavage. An additional 100 µl was topically applied onto the 
fur of each animal. 
3) After 14 days (day -5), mice were anesthetized with isoflurane and 104 Luciferase-transfected 
Renca cell lines, syngeneic for BALB/c mice (kindly provided by Transgene, Illkirch, France) in 
30μL PBS were injected into the sub capsular space of the right kidney. Tumor growth was 
monitored after 5 days using IVIS Imaging System 50 Series (Analytic Jenap) or through the 
analysis of the weight of kidney. 
4) At day -1, the mice received Akkermansia muciniphila, Bacteroides salyearsiae or 
Bacteroirodaes xylanosolvens. Re-colonization was performed by oral gavage with 100 μl of 
suspension containing 1 × 108 bacteria (AKK, SALY, XYLA groups). 
5) At day 0 and at day 4, mice were treated (intraperitoneal injection) with combined 
immunotherapy, anti-PD-1 (250µg/mouse; clone RMP1-14,) and anti-CTLA-4 (100µg of anti-
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CTLA-4 mAb (clone 9D9) (groups Combo and Combo + bacteria). Control mice received isotype 
matched Abs (clone 2A3 and MCP11) (group Iso). Moreover, the mice received the oral gavage 
with bacteria as in day -1. All antibodies were purchased from BioXcell, NH, USA. 
 
 
Table 1: mice groups, treatments and sample analyzed 
 
 
Samples collection and flow cytometry analysis 
Tumors, mesenteric lymph nodes (mLN), blood and spleens were harvested at day 6 (i.e 7 days 
after the first bacterial gavage and 6 days after the first injection of anti-PD-1 and anti-CTLA-4 
mAb).  
During blood sample collection, animal will be in terminal anesthesia. 0.3 - 1 ml of blood can be 
obtained depending on the size of the mouse from the heart, preferably the ventricle, which can be 
accessed either via the left side of the chest, through the diaphragm, from the top of the sternum 
or by performing a thoracotomy. Blood should be withdrawn slowly to prevent the heart 
collapsing. Excised tumors were cut into small pieces and digested in RPMI medium containing 
Liberase (25 μg/mL) and DNase1 (50 UI/mL) for 30 minutes at 37°C, crushed and filtered twice 
using 100 and 70 μm cell strainers.  Lymph nodes and spleen were crushed in RPMI medium and 
subsequently filtered through a 100-μm cell strainer.  
The cells obtained were counted with Vi-CELL Cell Viability Analyzer (Beckman Coulter),  
stained with direct fluorescent antibodies (BD) and analyzed by flow cytometry. To detect 
NKp46+ cells, including NK cell population, an anti-mouse antibody specific for NKp46 molecule 

















Table 2: Comparison of the different conditions regarding the % of NKp46+ cells and of PD-L1+ NKp46+ cells 
 
 
In peripheral blood, the percentage of CD3- NKp46+ cells was significantly lower in Combo mice 
as compared to Iso (Fig5A and Table 2). On the contrary no significant variations in NKp46+ cells 
were observed in COMBO + bacteria mice groups as compared to Combo mice group.   
In COMBO mice NKp46+ cells also show a clear tendency to increase the percentage of PD-L1 
molecules (Fig-5B).This effect was influenced by the recolonization with Akkermansia 
muciniphila but not with other bacteria. Indeed, mice group recolonized with “the good bacteria” 
did not show significant increase in the percentage of NKp46+ PD-L1+ cells.   
In spleen and secondary lymphoid organs (Fig.6), the percentage of CD3- NKp46+ cells was not 
altered by the treatment with ICB, as compared to ISO. However, in the spleen the percentage of 
CD3-NKp46+ was significantly higher in Combo mice re-colonized with Akkermansia 
muciniphila and even more evident in those that received Bacteroides salyearsiae. The treatment 
Figure 5: Analysys of % of NKp46+ cells (A) and PD-L1+NKp46+ cells (B) in peripheral blood 
44 
 
with Bacteroirodaes xylanosolvens didn’t affect the percentage of CD3- NKp46+ in spleen, 
whereas it was associated with a strong increase of their number in mesenteric lymph nodes.  
 
 
Figure 6: Analysys of % of NKp46+ cells in spleen (A) and in mesentheric lymphnodes (B) 
 
Finally, we analyzed CD3-NKp46+ cells in tumor site (Fig.7). Although a statistic significance 
was not reached, the analysis showed that the % CD3-NKp46+ cells tends to decrease in ICB 
treated mice that have received FMT from NR patient (not to be expected to be responsive to 
therapy). Combo mice receiving “good” bacteria showed a trend in restoring the percentage of 





















COMMENT TO THE STUDY AND FUTURE PERSPECTIVE 
 
Our preliminary results indicate that the combined ICB treatment in mice FMT from non-
responder patients results in a significant reduction of circulating NKp46+ cells. This appears to 
involve other immune cells including CD8+ T cell population (data not shown). Two hypotheses 
may explain the results: a) ICB treatment may affect the viability of NKp46+ cells; b) ICB 
treatment might influence the exit of NK cells from the blood and their recruitment into peripheral 
tissues. CD3- NKp46+ cells also show enrichment in PD-L1+ cells, a phenomenon that seems to 
be counteracted by re-colonization with Akkermansia muciniphila, “the good bacteria”. Further 
analyses are necessary to confirm these data and to evaluate in additional tumor model, if this 
phenomenon is tumor-specific. The decreased number of PD-L1+ NKp46+ cells observed in a 
favorable background (i.e. in the presence of Akkermansia muciniphila) might positively influence 
the responses to ICB. Indeed, PD-L1 on NK cells may negatively regulate the function of  immune 
cells types expressing the specific receptor (PD-1 or CD80) such as NK cells themselves, T cells 
and macrophages. Along this line, ICB treatment in a favorable background led to a higher 
percentage of NKp46+ cells in the spleen, but not in mesenteric lymph nodes. Future analysis will 
analyze PD-L1 expression in both spleen and mLN. An interesting hypothesis may be that spleen, 
rather than mLN, represents crucial site for the orchestration of ICB-based anti-tumor responses. 
Regarding the tumor site, the percentage of NKp46+ cells seems to decrease in COMBO mice and 
to increase upon re-colonization with good bacteria. In order to confirm and to strength these data, 
further analysis will be done at later time points. Moreover, in-vivo depletion of NKp46+ cells 
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Abstract
Many evidences suggest that NK cells are effective in patrolling for and eliminating tumors in their onset phase,
but hardly limit the progression of large established solid tumors. Beside the transition of tumor cells towards a more
aggressive phenotype, the NK cell efficacy might be limited by a complex immunosuppressive milieu present in the
tumor microenvironment. Indeed, different mechanisms damping NK cell function have been shown in these last
years. These include a plethora of tumor-derived immunomodulatory soluble factors (TGF-β, MIF, adenosine, L-
Kynurenin, PGE2) as well as soluble ligands (MICA, ULBP-2, PVR, B7-H6) that compete with membrane-bound
tumor ligands for binding to activating NK receptors. During NK-tumor cell contact the NK cell function can also be
inhibited by the engagement on NK cells of different inhibitory receptors. The specific ligands might be either
constitutively expressed at the tumor cell surface (HLA-I, B7-H3, PVR) or de novo induced/up-regulated (PD-Ls) by
immunostimulatory factors (IFN-γ, TNF-α). These are largely released during the active phases of the immune
responses and exert an unwanted side effect called “tumor adaptive immune resistance”. This review aims to
summarize the best-known molecular mechanisms that, at various times and in different ways, can limit the efficacy
of the NK-mediated immune surveillance of tumors.
Keywords: NK cells; Tumor microenvironment; Soluble factors;
TGF-β1; HLA-I; Immune-checkpoints; PD-1/PD-L1; B7-H3
INTRODUCTION
Natural killer cells (NK) are crucial cytolytic effectors belonging to
the family of innate lymphoid cell (ILC) [1,2]. Originally described as
cells exerting a “natural” cytolytic activity due to their capability to kill
the highly susceptible K562 eritroleukemia cell line, it is now well
established that they require activation to exert optimal effector
functions. Moreover, the susceptibility to NK-mediated killing of
established tumor cell lines is superior to that of tumors ex-vivo
isolated from patients, as occurs in bone marrow metastases that are
much more resistant to NK-mediated aggression [3]. This supports the
concept that an effective NK-mediated anti-cancer activity can’t
dispense with an optimal activation of endogenous or adoptively
transferred NK cells. It is also crucial to understand which NK cell
subset, once activated, can exert the most effective anti-cancer activity
in a particular immunotherapeutic setting. Indeed, it has been recently
stressed that a great heterogeneity in NK cell phenotype and functions
exists that goes beyond the classical CD56dim CD16high and CD56bright
CD16low/neg NK cell dichotomy [4]. Beside the identification and
description of CD56neg NK cells [5] that are particularly abundant in
peripheral blood of virus-infected donors, several studies highlighted
the great heterogeneity of peripheral blood CD56dim NK cells, which
include subpopulations characterized by different capabilities of being
activated by cytokines, antibodies or tumor contact [6,7]. Thus,
adoptive transferred NK cell-based therapeutic protocols should
combine optimal activation strategies, the selection of the best NK cell
subpopulation, consider the in vivo persistence of the in vitro activated
NK cells, and, last but not least, their chemokine receptor repertoire.
Indeed, the scarce attitude of cytotoxic CD56dim NK cells to reach and
invade the tumor parenchyma represents a major obstacle for the
effectiveness of NK cells, especially in the therapy of solid tumors [8,9].
This might occur also in a chemokine-rich tumor milieu, due to a
defective expression in NK cells of the chemokine receptors involved in
their migration toward peripheral tissues. This hypothesis matches
with the scenario described in neuroblastoma patients whose
peripheral blood CD56dim NK cells are characterized by an unusual
reduced expression of CX3CR1, the fractalkine (CX3CL1) receptor
[10]. Interestingly, CX3CR1 has been shown to be deeply down-
regulated by transforming growth factor beta 1 (TGF-β1), a pleiotropic
soluble factor released by most cell types including tumors that is
capable of modulating pivotal effector functions of different immune
cells [11,12]. TGF-β1 is one among the several soluble factors present
in the tumor microenvironment that recently emerged as potent
immune-modulators. Moreover, beside the classical HLA class I-
mediated inhibition of the NK cell activity, several additional
inhibitory signals have been recently described that, during NK-to-
tumor contacts, limit the NK-mediated immune-surveillance. Thus,
the choice of the most effective, activated NK cell subsets should not
disregard their profile in terms of the cognate inhibitory receptor-
ligand interactions. This review summarizes the best-known tumor-
derived soluble factors and tumor-associated surface molecules
exerting an immunomodulatory role in NK cells.
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Soluble Immunomodulatory Mediators
MIF, adenosine, L-Kynurenin, PGE2
In the past few years, many different tumor-associated regulatory/
suppressive mechanisms have been widely studied (Figure 1). Among
these, molecules shed from the tumor cell surface, such as the soluble
ligands of NKG2D [13-15], DNAM-1 [16] and NKp30 [17], activating
receptors crucial for T- and/or NK cell-mediated immune-surveillance
[18]. sMICA, sULBP-2, sPVR and sB7-H6 compete for binding with
the ligands expressed on the tumor cell surface, thus hindering the
efficient target recognition. Moreover, different tumor-secreted soluble
mediators have been shown to clearly suppress the efficacy of the
immune system. Among these, the macrophage migration inhibitory
factor (MIF, also known as Glycosylation-Inhibiting Factor) [19-21]
and adenosine, an endogenous purine nucleoside highly produced by
tumors expressing CD39 and CD73, ectonucleotidases converting ATP
to adenosine. Both MIF and adenosine have been demonstrated to
inhibit cytotoxicity and cytokine production in human NK cells, the
second mainly through the engagement of the adenosine receptor 2A
(AdoR2A), which is coupled to adenylyl cyclase via Gs protein [22,23].
In the mouse model the use of AdoR2A antagonist reduced the
metastatic potential of CD73+ tumors [24] that was further reduced by
blockade of AdoR2B. Since in vitro AdoR2B blockade had no
significant effects on NK cell cytotoxicity, the benefit observed in
tumor-injected mice treated with AdoR2 antagonist might depend on
both NK cell-dependent and -independent mechanisms. Along this
line, in mice selectively lacking AdoR2 expression in myeloid
compartment it has been shown that adenosine can indirectly
suppresses T and NK cell-mediated antitumor activity by shaping the
functions of different myeloid cells. In particular, in this mouse model,
a reduced melanoma growth was associated with a significant increase
in MHC class II expression and IL-12 release in tumor-associated
macrophages (TAM), features fitting with an M1-like pro-
inflammatory macrophage polarization. Moreover, AdoR2neg TAM,
dendritic cells (DC), and myeloid-derived suppressor cells (MDSC)
showed a clear reduction in IL-10 expression, a cytokine originally
described as a negative regulator of IL-12 production in LPS-
stimulated peripheral blood mononuclear cells [25]. To date IL-10
cannot be definitively included among the tumor-derived cytokines
limiting NK cell activity since both stimulatory and inhibitory effects
on NK cell functions have been described. On the contrary, a huge
number of data have demonstrated the immunomodulatory function
of L-kynurenine, the tryptophan catabolite derived from indoleamine
2,3-dioxigenase 1 (IDO1) pathway [26], and of Prostaglandin E2
(PGE2). Both factors deeply affect the cytokine-mediated upregulation
of the expression and function of different activating NK receptors
such as NKp46, NKp44 and NKG2D [27-29] a mechanism that seems
to involve the c-Jun N-terminal Kinase (JNK) pathway [29]. The extent
of in vivo suppression mediated by L-kynurenine and PGE2 might be
considerable since these factors are released by several cell types
colonizing tumor microenvironment, including the cancer-associated
fibroblasts (CAF) [30,31], MDSC and DC [32]. In particular, IDO-
expressing DC exert a deep immune-suppressive effect by affecting not
only proliferation and effector function of NK cells, but also by
inducing the conversion of CD4+ T cells into CD4+ CD25+ Foxp3+
regulatory T cell (Treg) [33]. Tumor-derived PGE2, via the EPA4
receptor [34,35] decreases human NK cells proliferation, granzyme B/
perforin content [36] and drives NK cells towards apoptosis [37].
Moreover, via the EPA2 and EPA4 receptors, PGE2 induces the release
of TGF-β1 by MDSC [38] that further inhibit NK cell activity. TGF-β1
represents a secretory immune-suppressive hallmark of several other
cells in tumor microenvironment including Treg and TAM [39].
TGF-β1
TGF-β1 is the prototypic tumor-derived immunomodulatory
soluble mediator, although many additional functions have been
described over the years, highlighting its pleiotropic activity. Different
studies reported a significant contribution of TGF-β1 in the epithelial
to mesenchymal transition (EMT), a process that allows tumors of
epithelial origin to acquire a less differentiated, invasive and pro-
metastatic phenotype [40,41]. TGF-β1 has been shown to suppress the
differentiation process and the effector functions of several immune
cells [12]. In particular, it represses the development of human NK
cells from CD34+ progenitors and inhibits differentiation of CD16pos
NK cells [42], TGF-β1 promotes the conversion of peripheral NK cells
to a decidual NK-like phenotype [43] and, as shown in mouse salivary
gland, it drives the differentiation of a particular ILC subpopulation
sharing NK and ILC1 features [43]. Released as a large latent complex,
TGF-β1 remains biologically unavailable until its activation in
inflammatory sites such as the tumor microenvironment by signals
including low pH, heat, proteases and members of the integrin
receptor family [11]. Once activated, TGF-β1 shows a potent inhibitory
effect on NK cells, both in vitro and in vivo, limiting the main NK cell
effector functions including IFN-γ production and cytotoxicity
[44-48]. In this context, in vitro conditioning of NK cells with
recombinant TGF-β1 (rTGF-β1) caused severe downregulation of the
surface expression of NKp30 and NKG2D, activating NK receptors
cooperating in recognition and killing of several tumor histotypes [44].
The same occurred with rTGF-β2 [10], although knockout mice
lacking TGF-β1 or TGF-β2 showed distinct phenotypic features
suggesting that the two isoforms could also have specific, non-
overlapping functions [49]. Interestingly, while the TGF-β1-mediated
downregulation of NKp30 occurred at the transcriptional levels no
significant changes in NKG2D transcript was observed in TGF-β1-
treated NK cells [44]. Accordingly, it has been shown that the reduced
NKG2D surface expression observed in the presence of TGF-β1 both
in vitro and in vivo, is due to its capability of downregulating at
transcriptional and translational level DAP10, the signaling subunit
associated with NKG2D [50-52]. Very recently it has been shown that
TGF-β1 also inhibits the IL-15-induced NK cell activation, particularly
by selectively and quickly repressing the mTOR pathway [53], a crucial
integrator of both pro- and anti-inflammatory signals. Recent data also
suggest that the tumor-derived TGF-β1 might modify the migratory
capability of NK cells. Indeed, it has been shown that neuroblastoma
(NB) cell lines spontaneously release amounts of TGF-β1 capable of
modulating the chemokine receptor repertoire of NK cells [10]. In
particular NB-derived TGF-β1 increases CXCR4 and CXCR3 surface
expression in all NK cells whereas it decreases that of CX3CR1 in the
CD56dim NK cell subset. Notably, unusual CX3CR1low CD56dim and
CXCR3high CD56bright NK cell populations were observed in peripheral
blood of patients with high risk NB (stage 4 or M) [10]. Thus, tumor-
derived TGF-β1 can affect the expression of chemokine receptors that
play a key role in the bone marrow homing, egress, interaction with
endothelium and recruitment into peripheral tissues of NK cells.
Recently, in a mouse model of pulmonary allergic responses, it has
been shown that TGF-β1 is crucial for the generation of allergic
response acting as chemotactic factor recruiting ILC2 and eosinophils
[54]. Importantly, it has been demonstrated that TGF-β1 modulates in
tumor cells, the expression of specific microRNAs and up-regulates B7-
H3 (CD276) [55], a molecule belonging to the family of immune
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checkpoint proteins, which acts as co-inhibitory factor and limits the
function of NK cells. Overall data suggest that TGF-β1 antagonists,
capable of overcoming or blocking its immunomodulatory effect might
represent a valuable adjuvant therapy in the cure of different tumors.
In this context, it has been recently shown that blocking of TGF-β1R in
combination with antibodies targeting the NB-associated antigen GD2,
potentiates the NK-mediated anti-NB activity leading to a reduced
tumor growth and increased survival of mice injected with NB cell
lines or patient-derived neuroblasts [56]. Moreover, ongoing clinical
trials will evaluate the benefit of TGF-β or TGF-βR blockade in
neoplastic patients (ClinicalTrials.gov NCT02452008; NCT02581787).
It is of note however that, due to the wide homeostatic regulatory role
of TGF-β, in order to obtain specific and restrained therapeutic effects,
light should be made on the signaling pathways mediated by the
different TGF-β isoforms and on the mechanisms regulating the
immunomodulatory effects.
NK-To-Tumor Contact Immunomodulatory Signals
KIRs/HLA-I and NKG2A/HLA-E
The most powerful inhibitory pathway affecting the NK cell activity
is represented by the interaction between HLA class I molecules (HLA-
I) on target and specific inhibitory receptors on NK cells (Figure 1).
These inhibitory receptors include Killer Ig-like Receptors (iKIRs),
clonally distributed receptors distinguishing among allotypic
determinants of the classical HLA-A, -B and - C, and the CD94/
NKG2A heterodimer specific for HLA-E [57-59]. Mature NK cells can
also express the activating counterpart of these HLA-I specific
inhibitory receptors, i.e. activating KIRs (aKIRs) and CD94/NKG2C
[60,61]. During NK cell maturation the engagement of inhibitory
receptors by their self HLA-I ligands confers functional competence to
NK cells, through a process referred to as “licensing” or “education”
that has been explained by different models [62-64]. Based on the
“rheostat” model, during NK cell education NK cell reactivity is tuned
by the strength of the inhibitory signal induced by self-HLA-I
molecules [65]. The inhibitory receptor repertoire acquired by NK cells
during maturation guarantees that in normal conditions inhibitory
signals prevail on the activating ones safeguarding HLA-I+ autologous
healthy cells from NK cell-mediated killing. The NK cytolytic activity
is unleashed in pathologic conditions such as virus infection or tumors
where transformed cells increase the expression of ligands for
activating NK receptors while downregulating that of HLA-I [66]. NK
cell reactivity can be limited when tumor cells retain high levels of
HLA-I expression, as occur in hematological malignancies such as
acute lymphoblastic leukemia (ALL). However, it has been shown that
in allogeneic settings such as in the context of haploidentical
hematopoietic stem cell transplantation (haplo-HSCT), the
differentiation of alloreactive NK cells from the donor, i.e cells
expressing KIRs specific for HLA-I molecules absent in the recipient,
strongly improve anti-leukemic surveillance [67,68].
The studies describing the beneficial graft versus leukemia (GvL)
effect of alloreactive NK cells in haplo-HSCT has inspired the design of
new immunotherapies aimed to enhance anti-tumor NK cell reactivity
by blocking the interactions between HLA-I and iKIR or CD94/
NKG2A. A fully human anti-KIR mAb (1-7F9, Lirilumab, IPH2101)
that recognizes iKIRs (KIR2DL1, KIRDL2 and KIR2DL3) has been
generated [69], which favors the NK cell-mediated killing of HLA-
matched tumor cells as documented in vitro and in vivo in phase I/II
clinical trials involving Acute Myeloid Leukemia (AML) and multiple
myeloma (MM) patients, [69,70]. Interestingly, Lirilumab has been
successfully combined with the anti-CD20 rituximab to augment NK-
mediated cytotoxicity against lymphoma cells in vitro [71]. Based on
the broad expression of HLA-E on both solid and hematological
malignances, a novel therapeutic approach has been designed to block
the CD94/NKG2A-HLA-E interaction, by using the humanized anti-
NKG2A Monalizumab, which is currently in a phase I/II clinical trial
[72].
Figure 1: Soluble and membrane-bound factors dampening NK-
mediated anti-tumor activity.
This novel approach was developed upon the observation that
NKG2A+ NK cells predominate in the early period of immune
reconstitution after HSCT, thus representing optimal targets to
potentiate NK cell-mediated anti-leukemic activity [73]. In addition,
NKG2A+ NK cells express higher levels of activating receptors such as
NCRs as compared to more differentiated KIR+ NKG2A- NK cells [6].
The high expression level could compensate the low cytotoxic potential
displayed by these less differentiated NK cells. KIRs, CD57 and LIR
represent phenotypic hallmarks of terminally differentiated NK cells,
which show a good cytolytic potential but poor responsiveness to
cytokines [74]. Interestingly, in individuals exposed to pathogens such
as cytomegalovirus (CMV), the mature NK cell population is
characterized by a very high percentage of cells expressing CD94/
NKG2C or aKIR [75-78], which show features similar to cells of
adaptive immunity including clonal expansion capability, strong
effector functions and longevity. This “memory-like” population
represents a powerful candidate for adoptive NK cell transfer therapy
in cancer patients [79]. Along this line it is crucial to define whether its
efficacy might be limited during NK-to-tumor contacts by additional
inhibitory or co-inhibitory signals, whose activity might be particularly
relevant in the context of HLA-Ilow or negative tumors.
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PD-1/PD-Ls, LAG-3/HLA-II and TIGIT/PVR
The PD-1/PD-Ls axis is a well-known immune
checkpoint, i.e. inhibitory pathways that physiologically
maintain self-tolerance and limit the duration and amplitude of T cell
immune responses, thus minimizing tissue damage [80-82]. The PD-1
receptor (CD279) has been demonstrated to limit T proliferation and
switch off the T cell functions mostly in peripheral tissues. More recent
reports show the presence of PD-1pos NK cells in both cancer patients
and in a relevant proportion of healthy donors who were serologically
positive for human CMV [83-86]. PD-1 expression is confined to
terminally differentiated NKG2AnegKIRposCD57pos NK cells and their
antitumor activity can be partially restored in vitro by antibodies
disrupting the interaction between PD-1 and its cellular ligands PD-L1
and PD-L2 [86,87]. PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC,
CD273) belong to the B7 family that consists of several members
including B7-H3 (see below) (Figure 1). PD-L1 is expressed in several
normal tissues, whereas PD-L2 is mainly restricted to antigen
presenting cells (APC) [80,81]. Importantly, both inhibitory ligands
can be expressed by tumor cells in response to immunostimulatory
factors such as IFN-γ and TNFα that are released by activated T and
NK cells [80,85,88]. This phenomenon called “adaptive immune
resistance” [88] is a mechanism of escape by which cancer cells adapt
their phenotype to the pressure of immune responses. Interestingly, it
has recently been shown that PD-L1neg metastatic cells purified from
bone marrow aspirates of high risk NB patients have different
capabilities of up-regulating PD-L1 in response to IFN-γ [85]. The lack
of PD-Ls upregulation in some patient might contribute to a reduced
clinical response to therapy with anti-PD-1. However, it should not be
disregarded that the therapeutic efficacy of anti-PD1 antibodies has
been observed also in patients who at the time of therapeutic decision
carried PD-L1neg tumors. Indeed, the clinical benefit might also
depend on the strengthening of the crosstalk between PD-Ls+ APC
and PD-1+ immune effectors including T or NK cells. IFN-γ is also a
potent inducer of HLA class II molecules that can be recognized by
LAG-3, an additional inhibitory mechanism that recently emerged in
human NK cells together with TIGIT/PVR and TIM-3/galectin-9
interactions (Figure 1) [89-92]. Interestingly, the heterogeneous
expression of the TIGIT inhibitory receptor observed in NK cells from
healthy individuals inversely correlates with their capability of
performing degranulation and IFN-γ release in response to IL-12
stimulation [91]. Moreover, low TIGIT expression has been described
in CMV-induced terminally differentiated NK cells that appear more
resistant to the inhibitory effect mediated by PVRpos MDSC. Since
studies explored the cytokine-induced expression of these co-
inhibitory receptors mainly in long term-cultured NK cell lines such as
NK92 [93], data on primary NK cells are required to better understand
the relative contribution of these inhibitory pathways and the kinetic
that regulates their emergence.
B7-H3R/B7-H3
Another interesting NK-to-tumor contact inhibitory pathway is
mediated by the B7-H3 ligand, a tumor-associated surface molecule,
also present in tumor-derived exosomes [94], which is endowed with
both immune-regulatory and pro-tumoral functions. B7-H3 is capable
of inhibiting the cytolytic activity of human NK cells against
neuroblasts purified from bone marrow aspirates of high risk NB
patients, which are characterized by reduced levels of HLA-I [18] and
adhesion molecules (unpublished observation). The B7-H3-mediated
inhibitory effect, which depends on its interaction with a still unknown
inhibitory receptor, is particularly evident when using xenogenic B7-
H3high transfectants [95]. This suggests that this inhibitory pathway
might require peculiar conditions to be unleashed, which could be
represented by poor engagement of potent inhibitory NK receptors
and/or by the presence of weak activating signals. It should be
mentioned that in mouse B7-H3 has been described as a “friend” in
tumor immunology [96]. In particular, intratumoral injection of an
expression plasmid encoding mouse B7-H3 led to a complete NK-
(and T-) mediated regression in approximately half of tumor-bearing
mice [97]. Interestingly, the mouse B7-H3 gene codes for a molecule
characterized by two Ig-like domains while human cell tissues
predominantly express a four Ig-like domains isoform resulting from
exon duplication [98]. While in human B7-H3 is still an orphan ligand,
an activating receptor has been identified in mice that is represented by
TREM-like transcript 2 (TREML2, TLT-2), expressed by activated T
cells and myeloid cells [99]. Importantly however, Leitner and co-
workers who extensively faced this issue did not find evidence for B7-
H3/TREML2 interaction in human [100]. Considering that B7-H3
belongs to the B7 family that includes members interacting with both
activating and inhibitory receptors, it can’t be excluded the existence of
a complex scenario resulting from the capability of B7-H3 to engage
receptors with opposite signal. However, to date most in vitro and in
vivo data lean toward a B7-H3 inhibitory role in human and the B7-
H3R/B7-H3 axis has been included among the immune checkpoints
[81,101,102]. An adjuvant therapeutic strategy in cancer might be
represented by antibodies disrupting the interaction between B7-H3
and its receptor/s. Different phase I Clinical trials are ongoing with
humanized anti-B7-H3 mAbs (NCT02628535; NCT02982941;
NCT02475213) [81] and encouraging results have been obtained in the
first in-human intrathecal injection of radioiodinated anti-B7-H3 Ab
(following standard therapy) in 21 neuroblastoma patients with
recurrent Central nervous system (CNS) metastasis [103]. It is of note
that the therapeutic efficacy of anti-B7-H3 mAbs might depend not
only by the strengthening of the NK- (and T-) mediated anti-tumor
responses, but also by the weakening of the direct pro-tumoral activity
of B7-H3. Indeed, studies in tumor of different histotype showed that
high B7-H3 expression drives tumor cell progression through different
molecular mechanisms. These include promotion of migration and
invasiveness [104] and reduction of sensibility to chemotherapy-
induced apoptosis, as demonstrated in breast [105] and pancreatic
carcinoma [106]. Accordingly, high expression of B7-H3 is a negative
prognostic factor in several tumors including neuroblastoma
[18,107-111]. In particular, in primary neuroblastoma high B7-H3
surface expression, in terms of both intensity and percentage of
positive cells, has been correlated with poor event-free survival also in
patients with localized disease (stage 1–3), suggesting that high B7-H3
expression might discriminate between low- and high-risk patients
who need a more careful follow-up.
Conclusions and Future Perspective
NK cell-based immunotherapy is becoming a promising approach
for the treatment of both hematological malignances and solid tumors.
However, recent published data show that the complexity of the
immune-suppressive milieu characterizing the tumor
microenvironment can’t be neglected. Indeed, different inhibitory
mechanisms represented by soluble factors or by tumor-associated
surface ligands could deeply reduce the NK cell activity against tumors.
Importantly, malignant cells can constitutively express some of these
ligands (HLA-I, B7-H3) or increase/de novo induce their expression
(PD-Ls) as an adaptive defense mechanism promoted by
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immunostimulatory factors (IFN-γ) that are released during effective
NK and TH1 cell-mediated immune responses. Thus, future
immunotherapeutic interventions should consider the possible onset
in patients of multiple, different immunosuppressive mechanisms
affecting the function of endogenous or adoptively transferred NK
cells. Also the chemokine receptor repertoire acquired by NK cells
during their in vitro-expansion needed for the adoptive transfer in
patients should not be neglected. Along this line, it might be relevant
to hinder the effects of factors (TGF-β1) capable of modifying, in
endogenous or infused NK cells, the expression of chemokine
receptors crucial for their extravasation and recruitment at the tumor
sites.
Executive summary
NK cells and cancer immunotherapy
NK cells are crucial cytolytic effectors in anti-tumor immune
responses.
NK cell-based immunotherapy is becoming a promising approach
for the treatment of both hematological malignances and solid tumors.
Ready to kill or killers who require to be armed?
Originally described as cells exerting a “natural” cytolytic activity it
is now well established that, to exert optimal effector functions, NK
cells require activation via immunostimulatory cytokines and tumor
contact.
NK cell population is heterogeneous and includes subsets
characterized by different capabilities of being activated and different
effector functions.
Once activated, NK cells need a chemokine receptor repertoire ideal
to their recruitment in inflamed tissues such as tumors.
How tumors may dump NK cell function in vivo?
Tumor cells purified from patients are less susceptible to NK-
mediated killing than established tumor cell lines commonly used in
vitro.
A complex immunosuppressive milieu is present in the tumor
microenvironment.
A plethora of tumor-derived immunomodulatory factors exists,
either soluble or membrane bound, that might limit the NK-mediated
immune-surveillance in vivo.
Soluble immunomodulatory mediators
Tumor cells may release soluble ligands (sMICA, sULBP-2, sPVR
and sB7-H6) that compete with membrane-bound tumor isoforms for
binding to activating NK receptors.
Different tumor-secreted soluble mediators (MIF, adenosine, L-
kynurenine, PGE2, TGF-β1) have been demonstrated to inhibit NK
cell function including proliferation, cytotoxicity and cytokine
production. These factors can be released by tumor cells as well as by
other cell types colonizing the tumor microenvironment (TAM, DC,
MDSC, CAF).
TGF-β1 is the prototypic tumor-derived immunomodulatory
soluble mediator. In NK cells, it represses development from CD34+
progenitors and differentiation, limits the main effector functions
(IFN-γ production and cytotoxicity), reduces the expression level of
activating receptors (NKp30, NKG2D) and alters the chemokine
receptor repertoire.
NK-to-tumor contact immunomodulatory signals
NK cell reactivity can be limited when tumor cells retain high levels
of HLA-I expression, as occur in hematological malignancies.
Tumor cells may express ligands (PD-L1, PD-L2, B7-H3) belonging
to the immune checkpoint family, i.e. inhibitory pathways that limit
the duration and amplitude of anti-tumor responses.
B7-H3 not only weakens the strengthening of the NK- (and T-)
mediated anti-tumor responses, but also exerts a direct pro-tumoral
activity.
Tumor cells can constitutively express inhibitory ligands or increase
their expression in response to immunostimulatory cytokines (IFN-γ,
TNF-α) that are released by activated NK (and T) cells, a phenomenon
called “tumor adaptive immune resistance”.
IFN-γ, besides inducing PD-Ls expression, is also a potent inducer
of HLA- II that can be recognized by LAG-3, an additional inhibitory
mechanism that recently emerged together with TIGIT/PVR and
TIM-3/galectin-9 interactions.
Future directions
When designing immunotherapies, we can’t neglect the complexity
of the immune-suppressive milieu characterizing the tumor
microenvironment. Thus, NK cell-based therapeutic protocols should
combine optimal activation strategies, the selection of the best NK cell
subpopulation, consider the in vivo persistence of NK cells, and their
chemokine receptor repertoire. Valuable adjuvants may include the use
of humanized mAb to disrupt immune checkpoints pathways and/or
to hinder the effects of soluble factors that in vivo may dampen the NK
cell activity against tumors.
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Abstract: The NK cells functions are finely tuned by several kinds of inhibitory and activating 
receptors, whose pattern of expression characterizes different NK subpopulations and varies with the 
cell activation status. MicroRNAs have an important role in tightly regulating the expression of NK 
receptors and, analogously, the expression of their ligands in target cells. The relevance of the 
microRNA-mediated control is highlighted by the dysregulation of these pathways observed in 
cancer and virus-infected cells. Here we review our current knowledge of the microRNAs involved 
in the regulation of NK receptors, as well as that of the corresponding cellular ligands. 
Keywords: NK cells; microRNAs; NK receptors; NK receptor ligands; TGF-β1 
 
1. Introduction  
Natural Killer (NK) cells are innate lymphoid cells endowed with several effector and 
regulatory functions, including cytotoxic activity against virus infected and tumor-transformed cells. 
Although there is a growing knowledge of the phenotypic heterogeneity of the NK cell population [1], 









 cells, which have different function and tissue distribution. CD56
bright
 NK cells, which 
release large amount of soluble factors in response to pro-inflammatory cytokines, are poorly 
represented in peripheral blood, while largely populating secondary lymphoid organs. Conversely, 
CD56
dim
 cells, which are highly cytotoxic effectors, represent the largest percentage of circulating 
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NK cells.  
The NK cell functions are finely regulated by a variety of germline-encoded inhibitory and 
activating receptors and by different cytokines, produced in the early or in the late phase of immune 
responses. All these cytokines other than potentiate NK cell responsiveness towards transformed 
cellular targets, stimulate the production of chemokines and cytokines (IFN-γ, TNF-α) crucial for 
shaping both innate and adaptive immunity [1,2]. 
The main inhibitory NK receptors include: Killer-cell immunoglobulin-like receptors (KIRs), 
CD94/NKG2A and LILRB1, MHC class I-specific receptors that physiologically maintain 
self-tolerance; PD-1, TIM-3 and LAG-3 that belong to the immune checkpoint family, inhibitory 
pathways that are induced/up-regulated during immune responses and limit the duration and 
amplitude of the immune responses, thus minimizing tissue damage. Activating signals are mediated 
by a plethora of activating receptors and co-receptor including NKp46, NKp30 and NKp44 
(collectively termed Natural Cytotoxicity Receptors, NCR), NKG2D and DNAM-1. The activating 
receptors recognize non-MHC ligands up-regulated or de novo expressed by cells upon cellular stress, 
tumor transformation or viral infection. The modality of NK cell activation, well depicted by the 
rheostat model [3,4], depends on the cytokine milieu as well as on the presence/absence and surface 
densities of the different ligands on neighboring healthy or altered cells.  
Different mechanisms regulate the expression of receptors, on effector NK cells, or ligands on 
potential targets. Among these, microRNA-mediated mechanisms that regulate gene expression at 
the post-transcriptional level. MicroRNA (miRNAs) are small RNAs, processed from stem-loop 
regions of longer RNA transcripts, which can interact with the 3’-Untranslated Region (3’-UTR) of 
target mRNAs via sequence complementarity, thus down-regulating gene expression through 
translation repression and/or mRNA degradation [5]. The importance of this kind of regulation is 
underlined by the fact that tumors and viruses evolved mechanisms to negatively affect NK activity 
acting through these pathways.  
This review synthetically describes the current knowledge of miRNAs targeting molecules 
fundamental for the NK cell effector functions and trafficking. 
2. NK cell receptors and miRNAs 
Several miRNAs have been described that target different NK receptor pathways. These include 
activating receptors (NKG2D), the DAP12 signaling molecule, inhibitory receptors (KLRG1), 
immune checkpoint receptors (TIM-3, PD-1 and CTLA-4), chemokine and cytokine receptors 
(CX3CR1, IL-2Rγ). Interestingly, TGF-β1, an immune-modulatory cytokine highly produced and 
activated in the tumor microenvironment [6], has been shown to hamper NK cells activity 
down-regulating different receptors via distinct miRNA pathways (Figure 1). 
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Figure 1. TGF-β1 modifies the receptors expression in human NK cells. The TGF-β1 
contained in the tumor microenvironment reduces the expression of NKG2D, 
DAP12/NKp44 and CX3CR1 in NK cells via different miRNA-mediated pathways. The 
involvement of miRNAs in the TGF-β1-mediated up-regulation of CXCR4 and CXCR3 [9] 
or down-regulation of NKp30 [8] and DNAM-1 [91] remains to be determined. 
2.1. NKG2D 
NKG2D (CD314) is a C-type lectin-like receptor expressed on NK and CD8
+
 T cells. It is an 
activating receptor able to detect and promote the elimination of damaged, transformed, and 
pathogen-infected cells by recognizing stress-inducible ligands belonging to the MIC (MICA and 
MICB) and ULBP (ULBP1–6) families in humans [7]. In vitro studies showed that the surface 
expression of NKp30 and NKG2D is significantly down-regulated by conditioning NK cells with 
TGF-β1 or TGF-β2 [8,9]. Moreover, subsequent studies highlighted the presence in vivo of 
NKG2D
low
 NK cells in cancer patients, ascribable to TGF-βactivity. One mechanism responsible for 
the TGF-β-mediated NKG2D down-regulation has been associated to the impairment of 
transcriptional and translational level of DAP10, the signaling subunit associated with human 
NKG2D [10]. Another mechanism has been showed by Espinoza et al. [11] who reported that 
TGF-β1 causes an increase of miR-1245 in NK cells. Overexpression of miR-1245 induced a 
down-regulation of NKG2D at the cell surface level, but had no effect on other activating receptors 
such as NKp30, NKp44 and NKp46. Moreover, NK cells overexpressing miR-1245 had lower 
cytotoxicity against target cells expressing NKG2D ligands. MiR-1245 was shown to directly target 
and down-regulate the NKG2D mRNA. 
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2.2. DAP12 
DAP12 (DNAX activating protein of 12 kDa) (also termed killer cell activating 
receptor-associated protein, KARAP) is a transmembrane protein containing an immune 
tyrosine-based activation motif (ITAM) in its cytoplasmic domain [12]. DAP12 is a fundamental 
signaling molecule that mediates a broad array of biological functions by associating with different 
activating receptors expressed in cells of lymphoid and myeloid lineage [12]. These receptors include 
the activating isoform of KIRs, CD94/NKG2C, and NKp44, the latter being expressed by NK cells 
upon activation. Donatelli et al. [13] reported that TGF-1 down-regulates the DAP12 level in NK 
cells. MiR-183, which was up-regulated by TGF-1, was shown to directly target DAP12 mRNA. 
NK cells overexpressing miR-183 had reduced DAP12 (both mRNA and protein) as well as 
decreased NKp44 surface levels. NK92 cells transduced with miR-183 were less efficient in killing 
Raji cells (which do not express NKG2D ligands) with respect to control lentiviral transduced cells. 
Interestingly, NK cells infiltrating lung cancers were shown to have a diminished DAP12 expression. 
2.3. KLRG1 
KLRG1 is a C-type lectin-like inhibitory receptor, containing an immune tyrosine-based 
inhibitory motif (ITIM), which binds to members of the cadherin family leading to inhibition of NK 
and T cell function. It is predominantly expressed by NK cells with a mature phenotype [14] and it is 
strongly induced by viral and other infections [15]. Cipolla et al. [16] reported that miR-584-5p 
targets KLRG1 and that overexpression of miR-584-5p in peripheral blood mononuclear cells 
(PBMC) causes a decrease of KLRG1 mRNA expression. Interestingly, a 3’-UTR KLRG1 
polymorphism, rs1805672, associated to the autoimmune disease Pemphigus foliaceus, abolishes the 
binding of the miRNA, thus causing the loss of the miRNA-mediated control of KLRG1 expression. 
Authors suggested a link between the loss of the miRNA-target interaction and predisposition to the 
autoimmune disease. 
2.4. TIM-3 
TIM-3 belongs to the T cell immunoglobulin and mucin domain (TIM) family. It is expressed 
on the surface of several immune cells, including NK cells. Upon activation by the C-type lectin 
galectin-9 ligand, TIM-3 functions as an inhibitory receptor on NK cells by reducing their 
cytotoxicity and cytokine production [17]. Cheng et al. [18] reported that TIM-3 and T-bet 
expression in NK cells from chronically HCV-infected patients is up-regulated compared to NK from 
healthy controls, while miR-155 is down-regulated. The opposite regulation of TIM-3/T-bet and 
miR-155 was recapitulated in vitro by incubating primary NK cells or the NK92 cell line with Huh-7 
hepatocytes expressing HCV. MiR-155 transfected in NK92 cells reduced TIM-3 and T-bet and 
enhanced IFN-γ expression. Authors suggest that TIM-3 expression is indirectly regulated by 
miR-155. 
2.5. PD-1 
PD-1 is an immune checkpoint receptor evolutionary related to the CD28 family. It recognizes 
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two cellular ligands, PD-L1 and PD-L2, and can be expressed on several cell types including T, B, 







 NK cells, whose antitumor activity can be partially restored 
in vitro by antibodies disrupting the PD-1/PD-Ls interactions [19]. Timing in the expression of PD-1 
is in line with the PD-1-dependent regulatory activity, which occurs in the later phases of the 
immune response [20]. To date, no miRNAs modulating PD-1 have been described in NK cells. 
Nevertheless, miR-4717, regulating only PD-1 variants containing a specific polymorphism in the 
3’-UTR, has been described in total lymphocytes [21]. Moreover, miR-138 has been reported to 
modulate CTLA-4 and PD-1 expression in mouse and human CD4
+
 T cells [22], and miR-28 has 
been described to regulate PD-1 in mouse CD4
+
 T cells [23]. 
2.6. CTLA-4 
CTLA-4 (CD152) is an immune checkpoint receptor binding the CD80 and CD86 ligands with 
higher affinity than CD28. It is expressed in Treg and activated T cells, while its expression in NK 
cells has been detected in mouse, but not in human [24]. CTLA-4 is targeted by miR-155, and in 
stimulated naive TH cells transfection with the miR-155 precursor down-regulates CTLA-4 
expression [25]. Moreover, as for PD-1, CTLA-4 is regulated by miR-138 in mouse and human 
CD4
+
 T cells [22]. 
2.7. CX3CR1 
CX3CR1 is a chemokine receptor expressed by different immune cell types, including 
monocytes, dendritic cells (DCs), T, and NK lymphocytes, which binds CX3CL1 (also known as 
fractalkine). CX3CR1, with other chemokine receptors, drives, at steady state, NK cell localization in 
peripheral tissues, and promotes their migration under inflammatory conditions [26]. Moreover, it 
has been shown that CX3CR1, CXCR4 and S1P5 regulate NK cells homing and migration from the 
bone marrow (BM) [27,28]. It has been demonstrated that the surface expression of CX3CR1 was 
down-regulated in NK cells co-cultured with SH-SY5Y neuroblastoma (NB) cells under trans-well 
conditions. Notably, CX3CR1 expression was reduced in NK cells from NB patients compared with 
healthy controls [9]. TGF-β1 released by NB cells has been shown to be responsible for the observed 
CX3CR1 down-regulation, as also confirmed in vitro using recombinant TGF-β1. Looking for the 
mechanisms involved, TGF-β1 was found to determine a significant increase of miR-27a-5p, which 
targeted the CX3CR1 mRNA in NK cells [29]. Up-regulation of miR-27a-5p was due to the 
TGF-β1-dependent up-regulation of miR-23a-27a-24-2 cluster, which encodes, among others, 
miR-27a-5p. As expected, inhibition of miR-27a-5p expression in NK cells caused an up-regulation 
of the CX3CR1 mRNA. Conversely, a reduction of CX3CR1 surface expression was observed in 
CX3CR1-expressing HEK293T cells following their treatment with miR-27a-5p mimic. In agreement 
with the original findings [9], NK cells cultured in the presence of SH-SY5Y NB cells exhibited a 
significant up-regulation of miR-27a-5p and down-regulation of CX3CR1 mRNA [29].  
2.8. IL-2Rγ 
IL-2Rγ is a transmembrane protein belonging to the cytokine receptor gene superfamily. It is the 
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γ component of multiple cytokine receptors, including those for IL-2, -4, -7, -9, -15, and -21, which 
are expressed on the surface of lymphocytes and other hematopoietic cells. Lack of IL2Rγ due to 
mutations of the encoding gene is responsible for X-linked severe combined immunodeficiency 
(X-SCID), a cellular and humoral immunodeficiency with a near-complete absence of NK and T 
cells and nonfunctional B cells [30]. Yun et al. [31] reported that miR-583 targets IL-2Rγ. 
Differentiating NK cells transfected with miR-583 mimics showed a decreased surface expression of 
IL-2Rγ and defective differentiation. In particular, the miR-583 overexpressing NK cells showed 
decreased NKG2D, NKp30 and NKp46 expression and reduced capacity to kill target cells and to 
produce IFN-γ [31]. 
3. NK receptor ligands and miRNAs 
A number of miRNAs have been identified as regulators of ligands of NK cell receptors. 
Targeted molecules include ligands for MHC class I-specific (HLA-G, HLA-C, HLA-E) and non- 
specific (MICA, MICB, ULBPs) receptors, as well as the immune checkpoint ligands PD-L1, B7-H3, 
CD80 and CD86. In cancer cells modification of miRNA expression may represent a common 
mechanism of escape from the NK-mediated immune surveillance (Figure 2). 
 
Figure 2. Altered ligands expression in tumor cells. Cancer cells can hamper NK 
cytotoxicity by up- or down-regulating a number of miRNAs, which reduce the 
expression of ligands of activating receptors or increase that of inhibitory ones, 
respectively. The latter includes the immune checkpoint ligands PD-L1 and B7-H3. 
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3.1. NKG2D ligands 
NKG2D ligands MICA, MICB, and ULBPs can be regulated by several miRNAs, of cellular or 
viral origin [32] that are potentially able to protect cancer cells and virus infected cells from NK cell 
cytotoxicity [7,32,33]. Stern-Ginossar et al. [34] reported 7 miRNAs regulating MICA and MICB 
expression (miRNAs miR-17-5p, miR-20a-5p, miR-93-5p, miR106b-5p, miR-372, miR373-3p, 
miR-520d-3p). Overexpression of these miRNAs in vitro and in vivo resulted in down-regulation of 
MICA and MICB expression and in lower susceptibility to NKG2D-dependent killing by human NK 
cells. On the other hand, three different viral miRNAs (miR-UL112, miR-BART2.5p and 
miR-K12-7), all derived from herpesviridae, targeted MICB, while a miRNA from polyoma viruses 
JCV and BKV targeted ULBP3 [32,33]. Two miRNAs (miR-376a and miR-433) were shown to 
regulate MICB and to decrease NK-mediated cytotoxicity against colon carcinoma cells [35]. 
MiR-34a and miR-34c were reported to target ULBP2 and, when overexpressed in a melanoma cell 
line, down-regulated its expression at the protein level. Moreover, miR-34c transfected melanoma 
cells displayed reduced susceptibility to NK cells cytotoxicity [36]. Other miRNAs (miR-10b, 
miR-519-3p, miR-20a, miR-93, miR-106b, miR302c, miR-520c), which were found overexpressed 
in various tumors, have been shown to down-regulate MICA, MICB and ULBP2, and, consequently, 
to reduce the NK cell-mediated killing of target cells [37–42].  
3.2. HLA-G 
HLA-G is a non-classical HLA class Ib molecule, expressed mainly in the placental trophoblasts, 
where is thought to provide immune protection to the embryo from the decidual NK cells, the major 
lymphocyte population at the fetal-maternal interface. HLA-G is also expressed by tumors and 
virus-infected cells [43]. HLA-G is recognized by LILRB1 and KIR2DL4 inhibitory receptors on 
human NK cells [44] and its soluble form has been described to regulate the chemokine receptor 
repertoire [45]. Several miRNAs down-regulate HLA-G expression: miR-148a, miR-152 (belonging 
to the same miRNA family), miR-133a, miR-548q, miR-628-5p and miR-365 [44,46–48]. An inverse 
correlation was reported between miR-628-5p and HLA-G in primary renal cell carcinoma tumors 
and cell lines [49]. In the case of miR-148a, miR-152 and miR-548q, it has been experimentally 
shown that they induce in target cells HLA-G down-regulation and increased susceptibility to the 
cytolytic activity of LILRB1
+
 NK cells [44,47,49]. The long noncoding RNA HOTAIR has been 
shown to bind miR-148a in cervical cancer [50] and miR-152 in gastric cancer cells [51], thus 
up-regulating HLA-G. TGF-β1 has been reported to cause a down-regulation of miR-152 inducing 
an up-regulation of HLA-G in gastric cancer cell lines [52]. 
3.3. HLA-C 
HLA-C are classical HLA class I molecules recognized by inhibitory KIRs. In particular, 
KIR2DL1 binds C2 allotypes characterized by a lysine in position 80, whereas KIR2DL2 and 
KIR2DL3 recognize C1 allotypes sharing an asparagine in position 80 [53]. Interestingly, miR-148a 
is able to bind not only HLA-G, but also HLA-C. Kulkarni et al. [54] reported that a polymophism in 
the HLA-C 3’-UTR regulates binding capability of miR-148a to its target site, resulting in relatively 
low HLA-C surface expression of alleles that bind this miRNA and high expression of HLA-C 
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alleles that escape post-transcriptional regulation. 
3.4. HLA-E 
The non-classical HLA-E binds a restricted subset of peptides encoded by the leader sequence 
of other class I molecules. It is recognized by the inhibitory CD94/NKG2A and activating 
CD94/NKG2C heterodimeric receptors, both expressed by T cells and NK cells [55]. The human 
cytomegalovirus [HCMV] encodes UL40, a peptide stabilizing HLA-E and driving the proliferation 
of CD94/NKG2C
+
 NK cells [56]. Interestingly, Nachmani et al. [57] showed that the short form of 
the RNA-editing enzyme ADAR1 induced editing of miR-376a in HCMV
+
 cells. Edited miR-376a 
down-regulated HLA-E expression rendering HCMV infected cells susceptible to elimination by NK 
CD94/NKG2A
+
 NK cells. 
3.5. PD-L1 
PD-L1 and PD-L2 are the two ligands of the PD-1 inhibitory receptor, which is expressed by 
activated NK and T cells [58,59]. Under physiological conditions, the PD-1/PD-Ls interactions 
control the duration and amplitude of immune responses, preventing autoimmune reactions. In 
cancer cells the expression of PD-Ls plays a crucial role in immune evasion. Several miRNAs 
regulating PD-L1 have been described, suggesting a tight control of its expression. In cancer cells 
PD-L1 expression is accompanied by miRNAs down-regulation [60–62]. MiR-513 has been the first 
miRNA reported to regulate PD-L1 and its inhibition in cholangiocytes induced PD-L1 protein 
expression [63]. In acute myeloid leukemia samples an inverse correlation was reported between 
miR-34 and PD-L1 expression and miR-34 was found to regulate PD-L1 expression in leukemia cell 
lines [64]. An inverse correlation was also reported between miR-200 and PD-L1 expression in lung 
adenocarcinoma samples. MiR-200 suppressed PD-L1 expression in murine and human 
mesenchymal lung cancer cell lines, while its down-regulation increased PD-L1 expression causing 
CD8
+
 T cells immune suppression [65]. MiR-138-5p was also found to target PD-L1. An inverse 
correlation was reported between miR-138-5p and PD-L1 expression in human colorectal cancer 
(CRC) samples and miR-138-5p overexpression suppressed CRC cell tumorigenicity [66]. Other 
miRNAs have been described as regulators of PD-L1 in various cancer cells, miR-15a, miR-15b and 
miR-16 in malignant pleural mesothelioma cell lines [67], miR-17-5p in metastatic melanoma [68], 
miR-142-5p in a pancreatic cancer cell line [69], miR-140 in non-small cell lung cancer (NSCLC) 
cell lines [70]. MiR-424(322) regulated PD-L1 and CD80 in ovarian cancer and high levels of this 
miRNA correlated with increased progression-free survival of patients [71]. Expression of miR-152 
was low in gastric carcinoma compared to controls, and miR-152 mimics inhibited PD-L1 expression 
in gastric cancer cell lines with increased T cell proliferation and function [72]. MiR-324-5p and 
miR-338-5p targeted PD-L1 and dendritic cells expressing these miRNAs displayed reduced surface 
expression of PD-L1 [73]. 
3.6. B7-H3 
B7-H3, a member of the B7 superfamily [74,75], is the orphan ligand of an inhibitory receptor 
expressed by human NK and CD8
+ 
T cells [74,76]. B7-H3 is considered as a new member of the 
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immune checkpoint family [77]. Indeed, it has been shown to inhibit cytotoxicity and protect 
neuroblastoma (NB) (and other tumor cells) from NK cell-mediated lysis [74,76]. B7-H3 also 
promotes tumor invasiveness [78]. In line with these pro-tumoral properties, high B7-H3 expression 
correlates with poor prognosis in several tumor histotypes [78,79]. B7-H3 expression is regulated by 
several miRNAs. Xu et al. [80] reported that miR-29a, b, c are down-regulated in several B7-H3 
expressing tumor tissues compared to normal tissues. MiR-29a targets B7-H3 in neuroblastoma cell 
lines [80] and down-regulation of miR-29a in central nervous system NB metastasis is associated 
with up-regulation of different molecules, including B7-H3 [81]. MiR-29c expression was inversely 
correlated to B7-H3 expression in melanoma [82] and was reported to target B7-H3 in breast cancer, 
where miR-29c expression correlated with increased survival [83]. Another miRNA targeting B7-H3 
is represented by miR-187. MiR-187 was down-regulated in clear cell renal cell carcinoma [ccRCC] 
compared to normal tissues. Overexpression of miR-187 (as well as silencing of B7-H3) decreased 
cell migration in ccRCC cell lines [84]. Interestingly, in CRC cell lines, miR-143 was 
down-regulated by TGF-β1, thus causing the up-regulation of both its targets B7-H3 and B7-H4 and 
leading to tumor immune evasion [85]. MiR-124 targeted B7-H3 in osteosarcoma [OS] cells and 
inhibited their growth and invasive ability. Moreover, miR-124 was down-regulated in OS clinical 
specimens, with an inverse correlation between miR-124 and B7-H3 protein expression [86].  
3.7. CD80 and CD86 
The expression of CD80 and CD86, CTLA-4 ligands, can be modulated by miRNAs. Besides 
miR-424(322) that regulates both PD-L1 and CD80 (see above) [71], miR-134 has been shown to 
bind CD86 mRNA suppressing its expression. Transfection of miR-134 in a melanoma cell line 
caused reduction of CD86 at the mRNA and protein level [87]. 
4. Conclusion 
What clearly emerges from the recent literature on the regulation of NK receptors and ligands 
expression is a central role of miRNAs in the maintenance of a delicate equilibrium that can be 
heavily perturbed by tumor transformation or viral infection.  
To escape NK cell immunosurveillance, tumor and virus infected cells evolved mechanisms to 
deregulate the expression of genes coding for molecules important for effector/target interactions [88]. 
These mechanisms often use the miRNA machinery. Pathological cells can affect NK-mediated 
recognition by up- or down-regulating miRNA targeting activating or inhibitory receptor ligands, 
respectively. Tumor cells can also act on NK cells by producing immunomodulatory factors, such as 
TGF-β1 that, influencing the expression of different receptors via distinct miRNA-pathways, realizes 
a combined inhibitory action. Other mechanisms can add levels of complexity to the action of the 
miRNA machinery, as the long noncoding RNAs sequestering miRNAs or the polymorphisms in the 
3’-UTR of miRNA target genes. 
The link between miRNA derangement and unpaired NK immunosurveillance makes miRNAs 
potential therapeutic targets [89]. MiRNA mimics or antimiRs can be used to increase or decrease the 
activity of miRNAs with tumor suppressive or oncogenic function. However, susceptibility to 
degradation in biological fluids and poor delivery to target sites might severely hamper the use of 
miRNAs in therapy. Chemical modifications of the miRNA backbone and the use of specific vehicles, 
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as nanoparticles or minicells, have been developed to confer stability to the miRNAs. Moreover, 
specific molecules, such as antibodies, can be conjugated to the miRNAs or to the vehicles to ensure 
an efficient and specific delivery. Avoiding toxicities and off-target effects are additional challenges 
for a miRNA-based therapeutic approach. 
In spite of these difficulties, two different phase I clinical trials treating cancer patients have 
been performed using miRNAs as therapeutic agents. The former study (NCT01829971) used 
miR-34 mimics encapsulated in lipid nanoparticles, without the association with specific targeting 
molecules, to treat patients affected by several solid tumors and hematological malignancies. 
Unfortunately, it was terminated due to immune related serious adverse events. In the latter study 
(NCT02369198), miR-16 mimics encapsulated in minicells targeted to EGFR-positive cancer cells 
by an anti-EGFR antibody have been used to treat patients with malignant pleural mesothelioma and 
non-small cell lung cancer. The study was regularly completed, establishing a dose of miRNA mimic 
which was well tolerated and accompanied by early signs of antitumor activity [90].  
Therefore, combination of targeted miRNA-based therapies with other therapeutic interventions 
represents a possible strategy to reduce tumor aggressiveness and to potentiate NK cell-mediated 
responses against cancer. 
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A large body of data shows that Natural Killer (NK) cells are immune effectors exerting
a potent cytolytic activity against tumors and virus infected cells. The discovery and
characterization of several inhibitory and activating receptors unveiled most of the
mechanisms allowing NK cells to spare healthy cells while selectively attacking abnormal
tissues. Nevertheless, the mechanisms ruling NK cell subset recirculation among the
different compartments of human body have only lately started to be investigated. This
is particularly true for pathological settings such as tumors or infected tissues but also
for para-physiological condition like pregnant human uterine mucosa. It is becoming
evident that the microenvironment associated to a particular clinical condition can deeply
influence the migratory capabilities of NK cells. In this review we describe the main
mechanisms and stimuli known to regulate the expression of chemokine receptors and
other molecules involved in NK cell homing to either normal or pathological/inflamed
tissues, including tumors or organs such as lung and liver. We will also discuss the role
played by the chemokine/chemokine receptor axes in the orchestration of physiological
events such as NK cell differentiation, lymphoid organ retention/egress and recruitment
to decidua during pregnancy.
Keywords: natural killer cells, chemokines and chemokine receptors, migration and residency, tumor and
inflammation, pregnancy
INTRODUCTION
The initial view describing Natural Killer (NK) cells as a quite homogeneous CD3neg CD56+
circulating lymphocyte population has been largely overcome. NK cells have been recently
included in a wider innate lymphoid cell (ILC) family, and circulating cells are just the tip of
an iceberg formed by a conspicuous and heterogeneous lymphoid population colonizing both,
lymphoid and non lymphoid tissues (1–3). Moreover, cytometry by time-of-flight (CyTOF)
highlighted the existence in peripheral blood (PB) of a single individual of at least 30,000
different NK cell phenotypes (4). These findings consolidate the concept that observed phenotypic
and functional NK cell status actually represents a single crystalized picture of a very dynamic
process. Nevertheless, in healthy individuals, two main circulating PB NK cell populations have
been extensively studied, CD56bright and CD56dim NK cells, which represent sequential stages of
maturation and show a dichotomy in phenotypic and functional properties (5). These include the
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expression of MHC class I-specific inhibitory Killer Ig-like
Receptors (KIRs), restricted to CD56dim NK cells that represent
the majority of cells circulating in blood. KIRs are involved in
NK cell “education,” a phenomenon that provides the basis of
self-tolerance and generates “armed” cells, i.e., NK cells fully
responsive to the engagement of activating receptors (i.e., NCR,
NKG2D, and DNAM-1) (6, 7). CD56dim NK cells also express
high levels of CD16, thus exerting strong antibody-dependent
cellular cytotoxicity (ADCC). Moreover, they efficiently respond
to cytokines stimulation and are characterized by a chemokine
receptor repertoire giving them the potential to colonize
lymphoid and non-lymphoid tissues in response to a proper
chemokine milieu.
The composition of the milieu can greatly vary in perturbed
tissues. This justifies the prevalence in some tumors of immature,
poor cytolytic CD56bright NK cells that are undetectable in
matched healthy tissues (8). Tumor parenchyma, as well as
the immune cells participating to the inflammatory processes,
may change the microenvironment providing NK cells with a
plethora of stimuli. These include membrane-bound or soluble
molecules such as chemokines or cytokines (TGF-β, IL-12, IL-
18), which either promote or dampen innate and adaptive
immune responses. Cytokines, in addition to shape the functional
activity of NK cells, modify their chemokine receptor repertoire
altering their native migratory potential (9–13) and at the same
time provide signals essential to generate, expand and recall
memory NK cell populations (14). Interestingly, recent data
showed that non-hematopoietic organs such as liver can be
colonized by peculiar tissue resident NK cell populations that
belong to the memory NK cell reservoir able to mediate "recall”
responses (15).
Here, we will recapitulate studies that analyzed the main
mechanisms regulating NK cell trafficking in lymphoid and
non-lymphoid tissue under either steady state or “perturbed”
conditions, including tumors, inflammation and pregnancy.
DEFINING DYNAMICS OF NK CELLS IN
HEALTHY TISSUES
NK cells are not exclusively found in PB but populate different
tissues and organs. The traditional view of NK cells as “armed”
effector cells, which patrol human body through blood ready to
extravasate to the site of injury, has been partially revisited and a
growing number of studies show that NK cells might also stably
reside in most peripheral tissues, under steady-state conditions.
Until recently, the task of depicting NK cell distribution in
human compartments has suffered from several methodological
shortcomings. Earlier analyses often relied on the use for NK cells
detection of markers poorly specific and/or unable to distinguish
the two main NK cell subsets, i.e., CD56bright CD16low/neg
Perflow and CD56dim CD16pos Perfhigh. The advent of new
OMICS technologies, and the possibility to perform single-cell
analyses have expanded our understanding on the distribution
of NK cells across human body. Indeed, in the recent years, our
knowledge about NK cell diversity has further increased with the
identification of NK cell subsets specifically populating various
peripheral solid organs, such as lung, liver, lymphoid tissues, and
uterus. These findings have challenged the classical view of NK
cells as a lineage comprising a relatively homogeneous population
of cells with similar functions and longevity. Nonetheless, at
variance with B and T cells, we know little about recirculation
and trafficking of NK cells across peripheral tissues. AlthoughNK
cells express an ample array of chemotactic receptors, the role of
the different chemokines in guiding in vivo the distribution of NK
cells through the body compartments still remains unclear. The
distribution of NK cells seems to be subset-specific in mouse, as
different NK cell subsets showed organ-specific localizations (16).
Conversely, this issue has been poorly investigated in the human
system. As the twomajor PB-NK cell subsets display a chemokine
receptors pattern that only partially overlaps, they may have
a peculiar tissue-specific compartmentalization (Figure 1). PB-
CD56bright NK cells are uniquely characterized by the expression
of CCR7, CXCR3, and L-selectin (CD62L), which justify their
abundance in secondary lymphoid tissues (SLTs). Conversely,
PB-CD56dim NK cells, despite sharing the CXCR4 receptor with
CD56bright NK cells, are equipped with receptors specific for
inflammatory chemokines, such as CXCR1, CXCR2, CX3CR1 (8,
16, 17). Additionally, CD56dim NK cells can migrate in response
to factors that do not belong to the chemokine superfamily.
These include the proinflammatory protein chemerin and the
sphingosine 1-phosphate (S1P) molecule that affect trafficking
of NK cells during inflammation or steady-state conditions,
respectively (18, 19). Based on the different expression of
chemotactic receptors, the tissue distribution of human NK cell
subsets observed under steady-state conditions is dependent on
the expression of local tissue-specific environmental signals. In
order to shed light on themechanisms lying behind themigratory
properties of PB NK cells, a wide array of samples derived from
different body compartments was analyzed to investigate the
presence and distribution of functionally different NK cell subsets
(8). The study showed that the relative distribution of CD56bright
and CD56dim NK subsets in the various human districts does not
parallel that in PB. CD56dim NK cells represent the major NK cell
subset in bone marrow (BM), lung, spleen, subcutaneous adipose
tissue and breast tissue, whereas CD56bright NK cells abundantly
outnumber cytotoxic NK cells in gastric and intestinal mucosa
associated lymphoid tissues (MALTs), liver, uterus, visceral
adipose tissue, adrenal gland, and kidney (8, 20, 21). Importantly,
the relative distribution of the two main NK cell subsets matched
with the specific patterns of chemotactic factors expressed in the
tissues (8).
A main question arising from the detection of NK cells
in many organs is whether NK cells stably reside in those
tissues or could eventually exit and recirculate. Studying the
dynamics of NK cells under steady-state conditions is limited
by the difficulty of having access to samples from human body
districts. On this regard, useful hints may be derived from studies
in which human subjects have been treated with monoclonal
antibodies directed against molecules pivotal in lymphocytes
migration, such as integrins. This is the case of natalizumab,
a humanized monoclonal antibody directed against the α4-
chain of VLA-4 (α4β1) and α4β7 integrins, widely expressed
on many different lymphocyte populations including T cells,
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FIGURE 1 | Circulating and tissues resident NK cells. (A) In human two main NK cell subsets, CD56bright and CD56dim, can be detected in peripheral blood (PB NK)
having a different repertoire of chemokine receptors. Tissue resident (tr) NK cells share the expression of certain markers but express molecules typical of the hosting
tissue.(B) large numbers of NK cells populate the decidua, particularly in the first trimester of pregnancy. Decidual NK cells have unique phenotypic and functional
characteristics, which contribute to support nutrition of the fetus, ensure maternal-fetal tolerance and control viral infections. Prf1, perforin; KIRs, killer cell
immunoglobulin-like receptors; SLT, secondary lymphoid tissues.
B cells, and NK cells as well as on a majority of monocytes
and macrophages. Interestingly, it has been reported that 1-
year treatment with natalizumab in multiple sclerosis patients
resulted in a pronounced accumulation (almost 2-fold increase
compared to baseline levels) of NK cells in PB (22), which
then gradually decreased upon treatment interruption (23).
These data are in evident agreement with a dynamic passage of
circulating NK cells across the endothelial barriers for patrolling
peripheral tissues, although it remains to be determined whether
it might occur also in steady-state or just under inflammatory
conditions.
In addition to extravasation from PB to solid tissues, NK
cells may eventually egress from peripheral tissues and trafficking
to SLT. This re-circulation has been suggested by the direct
investigation of afferent lymph draining from normal skin
(24) and analysis of cellular content in seroma fluid upon
axillary lymph nodes (LN) dissection, which represents an
accumulation of bona fide afferent lymph (25, 26). Interestingly,
most seroma NK cells expressed high level of CCR7 and
CD62L, as well as CXCR4, CXCR3, a chemokine receptor
repertoire identifying lymphocyte populations migrating toward
SLTs. These data indicate that high endothelial venules (HEVs)
might not represent the only route for NK cell entrance in
SLTs. Conversely, very little information is available regarding
the egress of NK cells from SLTs. It has been described in the
murine model that changes in responsiveness of sphingosine-1
phosphate receptor 5 (S1P5) to its ligand (S1P) play a key role in
allowing NK cell egress via lymphatics (27). However, whether
this mechanism might also be effective in human has not yet
been confirmed. Notably, NK cells have been detected in efferent
lymph fluid and NK cells exiting from LN have a phenotype
slightly different from that of NK cells found within SLTs. In
particular, a portion of NK cells express significant amounts of
KIR and CD16, implying that CD56bright NK cells might acquire
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these molecules in the LN during inflammation and then egress
through the efferent lymph for recirculating in PB (28).
All these previous studies have so far depicted the distribution
of the twomain “conventional” human NK cell subsets across the
human body (8, 29). Recently, this issue reached a higher level of
complexity because of data showing that various body districts
harbor “unconventional” subsets of NK cells that apparently do
not recirculate in the blood or lymphatics and adopt a unique
phenotype that is distinct from that of circulating NK cells. Tissue
residency has been described for NK cells as well as for other
“helper” innate lymphoid cells (ILCs), T cell subsets (memory
CD8, CD4 and Treg cells) and “innate-like” T cell types, including
subpopulations of γ/δ T cells and natural killer T (NKT) cells
(30). Tissutal NK cells, similarly to other lymphocytes residing
in tissues, may display markers such as CD69, CD103 (also
known as αE integrin) and CD49a (also known as α1 integrin),
which are functionally involved in retaining them in tissues and,
hence, can be useful for the identification and isolation of tissue-
resident (tr) NK cells (Figure 1). As discussed earlier, at least
three-quarters of NK cells in non-reactive lymph nodes display
a CD56bright Perflow phenotype (20, 31). This accumulation is
compatible with the pattern of adhesion molecules (CD62L)
and chemokine receptors (CCR7) expressed on circulating PB-
CD56bright NK cells but not PB-CD56dim NK cells. From recent
data, it is possible to speculate that a fraction of NK cells reaching
the LN could be retained within the structure as trNK cells.
Supporting this hypothesis is the presence of a distinct subset of
NK cells in human SLTs characterized by co-expression of CD69
and CXCR6, high expression of CD54 (ICAM-1) but lacking
CD117 (c-kit) and CD127, the latter specifically expressed by
CD56bright NK cells (32). Because of the high level of CD54,
these SLT-NK cells are also reminiscent of CD56bright NKG2Apos
CD94pos CD54pos CD62Lneg NK cells that accumulate in tonsils
of EBV carriers, which produce high amount of IFNγ, show very
low plasticity even after prolonged cytokine stimulation, and are
able to potently restrict EBV-induced transformation of B cells
(33).
Among solid tissues, liver is abundantly populated by NK
cells, where they represent up to 30–40% of all the lymphocytes
populating this organ (34). At steady-state, NK cells are
preferentially located in the hepatic sinusoids, often adhering
to the endothelial cells (35). Similar proportion of CD56dim
and CD56bright NK cell populations have been reported to
populate this organ (36), but only CD56bright has been described
to own features of trNK cells. Indeed, liver CD56bright NK
cells are characterized by higher level of EOMES transcription
factor, expression of CXCR6 and CD69 as well as CCR5 but
absence of CD62L and CCR7 (37). Interestingly, the expression
of CD49e (also known as α5 integrin or VLA-5 α chain) has
been recently identified has a reliable marker able to distinguish
conventional “circulating” NK cells from bona fide liver-NK cells,
which are otherwise negative for this marker (38). Many reports
have suggested the importance of CCR5 and CXCR6 in their
localization and retention within liver parenchyma, since their
cognate ligands (CCL3, CCL5, and CXCL16) are constitutively
expressed by various parenchymal and non-parenchymal cells in
the liver, including cholangiocytes, sinusoidal endothelial cells,
hepatocytes and Kupffer cells (34). Investigation of human liver
transplants has indicated that EOMEShigh trNK cells can persist
in situ for very long periods (up to 13 years in one human
study), further supporting the idea that subsets of NK cells may
stably reside within liver tissues. At the same time, circulating
CD56bright EOMESlow cells may be recruited to the liver and have
the potential to become CD56bright EOMEShigh NK cells (39).
An exception to the aforementioned tissues is represented
by lungs since: (i) the majority (∼80%) of NK cells populating
these organs belongs to the CD56dim Perfhigh subset (40); (ii)
only a limited fraction of Lung-NK cells is characterized by
expression of markers consistent with tissue-residency (i.e.,
CD69). Interestingly, this fraction is mainly composed of
CD56bright CD16neg and only a small proportion of CD56dim
CD16bright NK cells (41), thus suggesting that “genuine” lung-
resident NK cells may share some commonalities with CD56bright
trNK cells found in the uterus, liver, and lymphoid tissues (37).
Lung-NK cells were detected in the parenchyma only, and were
not found outside of the parenchyma, (i.e., blood vessels or
bronchi) (8, 41). Therefore, overall, these data support a model in
which human lungs mainly contain highly differentiated NK cells
recirculating between lung and blood, rather than a stable pool
of tissue-resident NK cells (41). Consistent with this hypothesis,
using a parabiotic mouse model, it has been recently shown that
parabiont-derived donor NK cells are able to rapidly replenish
the majority of NK cells in the lungs of recipient mouse (42).
Development of tissue-resident lymphocytes seems to involve
a transcription program inducing the expression of genes
involved in tissue-retention while inhibiting that of genes
important for tissue egress and trafficking. In mice, it was
recently described that the transcription factor Hobit (homolog
of Blimp-1 in T cells or ZNF683), a zinc finger protein, acts
in concert with Blimp-1 (B lymphocytes-induced maturation
protein) to serve as a master regulator of tissue-residency for
lymphocytes. Thus, Hobit and Blimp-1 mediate a common
transcriptional program that is shared among tr memory (Trm)
T cells, NKT, trNK cells, and helper-like ILCs. Together with
Blimp-1, Hobit sustain unresponsiveness to signals for SLT re-
circulation from peripheral tissues by suppressing expression
of S1pr1 (which encodes S1P1), Sell (which encodes CD62L)
and Ccr7 (which encodes CCR7) (30). The role of Hobit in
human Trm cells is less clear. Recent reports have shown peculiar
results with regard to the expression of Hobit/ZNF683 in the
two major human PB-NK cell subsets. Indeed, Hobit has been
detected at high levels in circulating CD56dimNK cells (despite
this transcription factor is almost absent in circulating NK cells
in mice) while only poorly expressed by PB-CD56bright NK
cells (43, 44).
However, it has been found that a strong Hobit/ZNF683
expression identifies a subset of intrahepatic CD56bright NK
cells in human liver, which additionally express a distinct set of
adhesion molecules (CD69, CD49a) and chemokine receptors
(CXCR6) consistent with tissue residency (44). These data may
suggest that Hobit expression in humans may instruct unique
migratory properties in the two distinct circulating NK cell
subsets. Whilst low expression of Hobit in circulating CD56bright
NK cells could maintain high levels of CCR7 and CD62L
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necessary for SLT entry, high level of Hobit in CD56dim and
CD56bright trNK cells might down-regulate these markers on
their surface, thus limiting their recirculation to SLT and tissue
egress, respectively.
NK CELLS IN PREGNANCY
Pregnancy is a quite peculiar situation, in which an
immunocompetent individual (the mother) is in contact for a
long period of time with a genetically different immunodeficient
individual (the fetus), and is characterized by a deepmodification
of mother’s tissues. During the first trimester of pregnancy,
extravillous trophoblast cells (EVT) from the fetus invade the
maternal decidua penetrating through the basement membrane
of the uterus epithelium with remodeling of the maternal spiral
arteries. These changes ensure adequate nutrition of the fetus
and are supported by immune cells present at the maternal-fetal
interface (45). In normal pregnancy many different mechanisms
exist to ensure tolerance of the semi-allogeneic fetus by the
maternal immune defense, thus preventing fetus rejection and
allowing the reproductive success.
The decidua is populated by a large variety of leukocytes,
which represent approximately 30–40% of decidual cells. The
most represented leukocyte populations are NK cells, CD14pos
myelomonocytic cells and T lymphocytes (46). Decidual NK
cells (dNK) represent 50–90% of total decidual lymphoid cells
in the first trimester of pregnancy (47) (Figure 1). The number
dwindles by the end of second trimester, and returns to basal
levels at the end of pregnancy. NK cells have also been identified
in non-pregnant endometrium (eNK) and their number changes
throughout the menstrual cycle, reaching the maximal level in
the post-ovulatory phase of the cycle (48). Most uterine NK
cells do not express CD16 and show high levels of CD56.
The dNK cells have been shown to exhibit unique phenotypic
and functional properties. Indeed, relevant differences exist
in the gene expression of the NK cell subsets present in
peripheral blood and early pregnancy decidual tissues. CD9
tetraspanin, galectin, α-1 integrin and other adhesion molecules
are overexpressed in dNK (49). Unlike resting PB NK cells,
dNK cells express the CD69 marker and a large percentage
express the NKp44 activating receptor. The expression levels
of activating receptors/co-receptors (NKp46, NKp30, DNAM-
1, NKG2D, and 2B4) are similar in dNK and PB NK cells
and, regarding to inhibitory MHC class I-specific receptors, the
dNK cells have been shown to express Killer Immunoglobulin
receptor (KIRs), CD94/NKG2A and LILRB1 (also known as
ILT2, LIR1, and CD85j). Interestingly, the KIR repertoire of
dNK cells is skewed toward recognition of HLA-C, the only
classical MHC Class I molecule expressed by trophoblast cells
(46, 50). Although expressing both perforin and granzymes
dNK cells are poorly cytotoxic, a characteristic that has been
linked to the block in the polarization of cytolytic granules
to the immunological synapse (51). Importantly, cytokines,
such as IL-15 can restore the dNK cell cytotoxic function, a
phenomenon that is crucial in normal pregnancy to control viral
infection (52).
Various studies have shown peculiar functional capabilities
of dNK cells. Indeed, they release a wide panel of cytokines,
chemokines, and angiogenic factors that are involved in
the development of placenta, tissue remodeling, trophoblast
invasion and neoangiogenesis (48). Several studies analyzed the
chemokine repertoire in endometrium and decidual tissues of
women undergoing elective pregnancy termination, studying
its involvement in NK recruitment. CXCL9 (Mig), CXCL10
(IP10), CXCL12 (SDF-1), CCL3 (MIP-1α) e CCL4 (MIP-1β)
are constitutively expressed in the endometrium. First-trimester
human trophoblast expressed and released chemokines able
to exert their activity on NK cells, including CXCL12 and
CCL3 (53). In line with these results studies have shown that
chemokines produced by endometrial or trophoblast cells induce
the peripheral blood NK cell chemotactic response. Decidual
endothelial and stromal cells express CCL2 (MCP-1), CXCL8
(IL-8), CXCL10, CX3CL1 (fractalkine), and CXCL12 while only
stromal cells express detectable levels of CCL5 (Rantes) and
CCL4. Noteworthy, CXCL10, CXCL12 and CX3CL1 induce the
migration of PB NK cell across primary cultures of decidual
endothelial and stromal cells (54). Furthermore it has been shown
that also chemerin is expressed in the uterus by EVT and stromal
cells but not by decidual endothelial cells (DEC) (55–58). The
treatment of DECs and stromal cells with progesterone enhanced
CXCL10, CX3CL1, and CCL2 but not CXCL12 levels, while
estrogen treatment of stromal cells resulted in up-regulation
of CXCL10 and CX3CL1 (54–57). Moreover, the treatment
of stromal cell primary cultures from pregnant, fertile non-
pregnant, or menopausal women with progesterone and estrogen
resulted in a significant up-regulation of chemerin secretion.
Although it is unclear how and when the various chemokines
participate in the recruitment of dNK cells, it has been shown
that dNK cells express high levels of CXCR3, low level of CXCR4
and very low levels of CXCR1, CXCR2, CX3CR1 or CCR1, 2, 3,
5, 6, and 7. In this regard, CXCR3 and CXCR4 are involved in
migration of decidual NK cells to CXCL9, CXCL10 and CXCL12
respectively (59). Moreover dNK cells migrate through stromal
cells in response to CXCL10 and CXCL12 but not to CX3CR1
(54). Interestingly, dNK cells from pregnant women express
chemerin receptor (ChemR23 or CMKLR1) that induces their
migration through stromal cells in response to chemerin. The
different chemokine receptor profile between dNK and PB NK
cells suggests that the phenotypic features of leukocytes recruited
from peripheral blood during pregnancy can be influenced by the
decidual microenvironment. In this regard, evidence indicates
that the pregnant uterus is a good source of cytokines acting
on NK cells including IL-15 (60). Interestingly in vitro culturing
of PB NK cell with IL-2 or IL-15 induced a down-regulation
of ChemR23 (18). In line with these observations studies have
shown that co-culture of PB NK cells with stromal cells results
in a chemokine receptor profile similar to that of decidual NK
cells (54).
Nevertheless, it is noteworthy that the precise origin of dNK
cells is not yet clear. It is possible to speculate that a pool of
dNK cells may originate from PB NK cells recruited in decidua
at early stages of pregnancy. On the other hand, studies suggest
that they could also originate from in situ progenitor cells that,
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in response to uterine stromal environment, differentiate into
CD56bright CD16neg NK cells (61).
NK CELLS IN TUMOR TISSUES
A consolidated view considers NK cells as the more effective
lymphocyte subset involved in immune surveillance of
hematological malignancies, initial stages of solid tumors
and blood spreading metastatic cells (62–64). Conversely,
NK cells appear to be poorly efficient in controlling advanced,
consolidated tumors due to different reasons, which comprise the
plethora of immune suppressive factors characterizing the tumor
microenvironment (63, 65). These include the expression by
cancer cells of MHC class I molecules and immune checkpoint-
ligands such as PD-Ls and B7-H3 (63, 66), the lack of expression
or the release of soluble forms of ligands of activating receptors,
and the presence of soluble immunomodulators, the prototypic
one being represented by TGF-β1 (63, 65). Additional aspects
impacting on the NK-mediated tumor immune surveillance
are the low frequency and/or the quality of NK cells attracted
in tumor tissues (Figure 2). Indeed, highly cytolytic CD56dim
CD16pos NK cells are rare and immature CD56bright CD16low/neg
NK cells with low perforin content represent the majority of
tumor-associated NK cells. Although some authors suggested
the possibility of an in situ expansion of CD56bright NK cells
(67), a shared hypothesis considers as primum movens the type
of chemokines/receptors interactions occurring in the tumor
microenvironment.
The tumor orchestrates escape strategies and creates a
chemokine milieu consisting of reduced expression of CXCL2,
CX3CL1, CXCL1, and CXCL8, attracting CD56
dim NK cells,
and increased expression of CXCL9, CXCL10, CXCL19, and
CCL5 that drives migration of CD56bright NK cells. The
dichotomy between high (CD56dim) and low (CD56bright)
cytolytic NK cells has been widely studied and data show that
pro-inflammatory cytokines can increase the killing properties
of CD56bright NK cells (68). However, this cytokine-mediated
rescue mechanism might be deeply affected by TGF-β (69),
which is highly represented in tumor tissues. This is because
the tumor environment is rich in both TGFβ-1 producing cells
and in factors that induce TGFβ activation, such as acidic
pH, reactive oxygen species, proteases and specific members of
integrin family (70). Active TGF-β1 decreases the expression
of activating NK receptors and, by up-regulating mir27a-5p,
of perforin 1 (Prf1) and granzyme B (GzmB), thus hampering
NK cell cytotoxicity. Moreover, TGF-β1 might dampen CD56dim
recruitment and favor that of CD56bright by modifying their
respective chemokine receptor repertoires (13). In particular,
TGF-β1 increases the expression of CXCR3 and CXCR4 in
CD56brigh and CD56dim NK cells, whereas, via mir27a-5p,
down-regulates CX3CR1 expression in CD56
dim cells (13, 71).
CX3CR1, whose cognate ligand is represented by CX3CL1 (also
known as fractalkine), is selectively expressed by CD56dim NK
cells and together with CXCR4 has been demonstrated to regulate
NK cell-egress from bonemarrow andNK cell extravasation (72).
Interestingly, in agreement with this ability of tumors in inducing
a regulatory milieu, an unusual low expression of CX3CR1
has been reported in CD56dim NK cell population of tumor-
infiltrated bone marrow and peripheral blood of Neuroblastoma
(NB) patients (13). Although a more detailed analysis should be
performed to deepen whether this unusual chemokine receptor
repertoire actually defines a peculiar CD56dim population (73)
mirroring the “broad spectrum of human Natural Killer Cell
Diversity” (2), it is conceivable that CX3CR1
low CD56dim cells
show defective migration toward tumor (or inflamed tissues).
Conversely, the recruitment of CD56bright NK cells in a CXCL9
and CXCL10 rich milieu might be favored by their constitutive
expression of high levels of CXCR3 and CXCR4, which further
increase under the influence of TGFβ-1 (8, 16, 17). Along this
line, CD56bright CD16low represented the predominant NK cell
population in the ascitic fluids of ovarian cancer patients (74).
The concomitant up-regulation of CXCR3 and CXCR4 by TGF-
β1 represents an interesting event if considering that these
receptors are subject to cross regulation. Indeed, chemokine
receptors’ function can be modulated by desensitization, which
is a physiological process that prevents overstimulation due to
prolonged agonist exposure by signal attenuation or termination
(27). Desensitization of a receptor can be dependent on
its ligand (homologous desensitization) or by other ligands
present in a complex chemokine gradient, a cross-desensitization
called heterologous desensitization. In this context it has been
shown that pre-stimulation of NK cells with CXCL9 inhibited
NK cell migration not only to CXCR3 ligands but also to
CXCL12, thus indicating that triggering of CXCR3 can promote
both homologous and heterologous (CXCR4) desensitization
(75).
In solid tumors a “fast track entrance” for CD56bright
CX3CR1
neg CXCR3high CXCR4high NK cells might be the ectopic,
neo-generated High Endothelia Venules (HEV) that contribute
to the architecture of Tertiary Lymphoid Structures (TLS)
(76, 77). These transient, un-capsulated lymphoid aggregates
resembling Secondary Lymphoid Organs (SLO) have been
detected in peri- or intra-tumor sites as well as in other chronic
inflamed tissues. TLS share with SLO the presence of distinct
T and B cell compartments, reactive Germinal Center (GC),
Follicular Dendritic Cells (FDC), fibroblastic reticular cells (FRC)
and lymphatic vessels, as well as HEV whose lining endothelial
cells express highly specific addressin molecules, collectively
termed peripheral node addressins (PNAd) (76). These are
known to dictate adhesion and consequent extravasation of
immune cells, including NK cells, within paracortical region
of lymph nodes, an event that might occur also at TLS levels.
In different tumors including lung, breast or gastrointestinal
stromal tumors (GIST) (78), tumor-associated TLS might
contribute to the preferential recruitment of CD56bright NK cells
that constitutively express the homing receptor CD62L and high
levels of CCR7 specific for the lymph node chemoattractants
CCL19 and CCL21. For example, in TLS associated to human
lung cancer intra-tumoral PNAd+ HEV exclusively co-localized
with CD62L+ lymphocytes (76). Notably, while TGF-β negatively
impacts on CD56dim NK cells recruitment in perturbed tumor
tissues, upregulation of CCR7 may promote their migration to
SLO and TLS. Accordingly, enrichment in CD56dim CCR7+
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FIGURE 2 | NK cells in tumor microenvironment. The tumor chemokine milieu presents a reduced expression of chemokines attracting CD56dim NK cells, and an
increased expression of CXCL9/10, CCL5, and CXCL19/21 that drives the migration of CD56bright NK cells toward the stromal compartment and tertiary lymphoid
tissue (TLS). Tumor cells and tumor-associated macrophages (TAM) release/activate TGF-β1 that decreases the capability of NK cells to recognize and kill targets and
modify their chemokine receptor repertoire, hampering the recruitment of CD56dim NK cells and favoring that of poor cytolytic CD56bright. ActR, Activating
receptors; GzmB, Granzyme B.
KIR+ CD57+ highly cytotoxic NK cells has been documented
in tumor-infiltrated lymph nodes of melanoma patients (79).
Several mechanisms involved in the acquisition of CCR7 by
CD56dim NK cells have been identified that include the crucial
role of IL-18, highlighted by Mailliard et al. (80), and the possible
uptake of CCR7 from surrounding cells by trogocytosis (81).
Soluble IL-18 is produced by stimulated antigen presenting cells,
in particular by macrophages that, as M2-polarized cells, might
represent the most abundant immune population in the tumor
microenvironment (82). Interestingly, a variable subset (30–40%)
of unpolarized (M0) and M2 macrophages and most tumors
associated macrophages (TAM) express a membrane form of IL-
18 (mIL-18) (74, 83, 84). Upon TLR stimulation, macrophages
polarize toward M1 and loose mIL-18, an event paralleled by the
release of small amounts of soluble IL-18 (sIL-18) that, acting in
close proximity, induces the expression of CCR7 in CD56dim NK
cells (83). It is of note that, since M1 polarizing macrophages also
acquire CCR7 expression (83), a contribution of trogocytosis-
mediated uptake cannot be ruled out. Although mechanisms
responsible for IL-18 membrane retention and release have
to be clarified, this cytokine shows many predictable cleavage
sites for extracellular proteases such as Matrix metallopeptidase
(MMP) −2 and −9, which characterize the secretory profile of
parenchymal tumor cells and TAM. Thus, also in the absence
of pathogen-derived stimuli, the action of MMPs (or other still
unknown mechanisms), may allow IL-18 shedding from TAM
and the induction of CCR7 expression in CD56dim tumor-
associated NK cells (TA-NK), thus promoting their migration to
SLO and TLS.
In solid tumors CCR7 acquisition by NK cells may depend
on close cell-to-cell contacts with macrophages or dendritic
cells, whereas it is less plausible that tumor cells could
play a relevant role. Indeed, TA-NK cells were found to be
predominantly located in the stromal compartment, whereas
they were rare/absent in the parenchyma in direct contact
with tumor cells (40, 85). Regarding the compartmentalization
of TA-NK cells, in an adenocarcinoma colon model, stromal-
infiltrating NK cells had morphology compatible with actively
migrating cells, and in some instances migrating NK cells
co-localized with degraded matrix (85). In the same model,
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most of the NK-poor tumor nodules were surrounded by a
capsule-like structure with collagen IV and laminin, two major
components of the basement membrane. On the contrary,
tumor nodules lacking these containment structures were more
infiltrated by NK cells. These observations, together with data
showing that poor NK cells infiltration have been equally
detected in both chemokines-rich and -poor tumors, strongly
indicate stromal barriers as a hindrance impacting on possible
NK-to-tumor cell contacts. Along this line, during imatinib
mesylate therapy in GIST patients, the frequency of NK cells
did not change in fibrous trabeculae, whereas significantly
increased in the core of both localized or metastatic tumors,
an observation that correlated with a better prognosis (78).
Interestingly, a recent study analyzing the off-target effect of
imatinib mesylate on immune cells showed that this drug causes
a significant up-regulation of CXCR4 in both T and NK cells
(86). Accordingly, NK cells ex-vivo isolated from peripheral
blood of chronic myeloid leukemia patients receiving imatinib
mesylate showed levels of CXCR4 significantly higher than those
detected in healthy individuals (86). A study by Goda S. and
colleagues (87)may in part explain how increased CXCR4 surface
levels can facilitate NK cells to cross the bridge connecting
the stroma and the tumor parenchyma compartments. In
particular, they showed that human CD56dim CD16pos NK
cell invasion into type I collagen is enhanced by CXCL12,
the CXCR4 ligand, in a matrix metalloproteinases (MMP)-
dependent manner. Notably, CXCL12 has been shown also to
promote the production in monocytes (88) and megakariocytes
(89) of MMP-9, which has protease activity on collagen IV. With
this assumption, it is conceivable that therapies strengthening
the CXCR4/CXCL12 axis could potentiate extracellular matrix
degradation favoring NK (and T) cells migration toward tumor
cells.
In light of these considerations, data on the NK cell phenotype
and density in tumor sites cannot be considered “per se” a
favorable prognostic factor and should be more and more
integrated with data on NK cell localization with respect to
stroma, parenchyma tumor cells and with the analysis of the
whole immune landscape. For instance, high NK cell infiltration
has been associated with improved survival in metastastic
renal cell carcinoma but not in colorectal carcinoma (90).
Contradictory results may depend on the method used to
unequivocally identify NK cells, which still represents a major
challenge as NKp46, the more reliable marker, is also expressed
by other subsets of ILCs (91). Opposite clinical impact of
NK cell infiltration in solid tumors might also depend on the
targeted tissue, the tumor phase and the ratio between NK
and tumor cell numbers. It has been demonstrated that NK
cells can edit tumor cells modifying their immunogenicity. In
particular, in NK and melanoma cell co-cultures performed
at low effector/target ratios, which reflect the level of NK
cell infiltrates observed at the tumor site, an initial tumor
cell lysis is followed by an equilibrium phase characterized
by decreased susceptibility to killing due to up-regulation of
both classical and non-classical MHC class I molecules on
melanoma cells. This effect is mediated by IFN-γ released by
NK cells activated upon melanoma cell recognition. Importantly
IFN-γ and TNF-α are also potent inducers of the expression
of the immune checkpoint ligands PD-L1 and PD-L2 in
macrophages/dendritic cells, tumor cells and tumor-associated
endothelial cells (92, 93). Moreover, TNF-α is known to promote
Epithelial-Mesenchymal Transition (EMT), a process leading
epithelial tumors to acquire a less differentiated, pro-metastatic
phenotype. Along this line, in lung cancer, a recent report
showed an important correlation between PD-L1 expression and
EMT score (93, 94). Thus, low number of NK cells contacting
tumor cells might have more undesirable than beneficial effects,
being unable to efficiently eliminate tumor cells while causing a
gradual accumulation of cytokines that exert a paradoxical tumor
promoting effect by modifying the immunogenicity of tumor
cells.
Whatever the case, when designing NK cell-based
immunotherapeutic approaches for cancer patients, we should
take into account the relevance of the molecular mechanisms
regulating NK cell migration into tumors. For instance, a recent
and promising approach is represented by the infusion of NK
cells engineered to express chimeric antigen receptor (CAR)
specific for tumor-associated antigens (65, 95, 96). The efficacy
of adoptively transferred CAR-NK might be deeply limited
by their inability to cross stromal barriers and to adhere to
parenchymal tumor cells, as recently suggested for T cells by
Caruana and colleagues (97). It was pointed out that in vitro
manipulation aimed to the CAR engineering of T cells leads
to silencing of heparanase (HPSE), an endoglycosidase that
cleave heparan sulfate proteoglycans of ECM, thus reducing
the invasive potential of CAR-T cells in solid tumors. Thus,
cell-based therapy may also include strategies to favor migration
of effector cells through stromal compartment and tumor
parenchyma, a phenomenon unlikely to occur, particularly in
advanced solid tumors.
NK CELLS IN INFLAMED TISSUES
The perturbation mediated by pathogens in peripheral tissues
results in the early activation of resident or recruited cells of
the innate immunity with a consequent boost of chemotactic
factors, which attract different immune cells including peripheral
blood mature conventional CD56dim NK cells. These cells
mainly differentiate in the bone marrow and express CXCR1,
CXCR2, chemR23, S1P5, CXCR4, and CX3CR1 (16, 17, 26).
This chemokine receptor repertoire drives NK cells to inflamed
tissues. Importantly, the relative expression of CXCR4 and S1P5
in developingmouse NK cells has been described to regulate bone
marrow egress into circulation (98). Moreover, in bone marrow,
prevalent CX3CR1 expression by KLRG1
+ NK cells located in
sinusoids suggested its crucial role for NK cell entry into the
vascular compartment (99).
The presence of NK cells in healthy and inflamed peripheral
tissues (18, 26, 29) has been well documented and different
studies demonstrated the existence of a crucial crosstalk between
CD56dim NK cells and DC or macrophages (Figure 3). NK/DC
interactions resulted in a bidirectional activation leading to
killing of immature DC (iDC) by autologous NKG2A+ KIRneg
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FIGURE 3 | NK cells in inflamed tissues. Inflamed tissue produce chemokines (Chemerin, CX3CL1) that drive the migration of circulating CD56dim prf1high NK cells.
Once in tissues they interact with DC and macrophages that, upon pathogen recognition, have begun to mature (mDC) or polarize toward a proinflammatory
functional phenotype (M1). Maturing DC and M1-polarizing macrophages release immunostimulatory cytokines that induce NK cells to produce large amounts of
IFN-γ (which potentiate phagocytes’ functions) and to express IL-2Rα and CCR7, which drive their migration into secondary lymphoid organs (SLO). mDC migrated to
SLO and DC-primed T cells producing IL-2 stimulate CD56dim NK cells and CD56bright NK cells that acquire a CD16pos KIRpos phenotype. ActR-L, Activating
receptors ligands; iNKRs, MHC class I specific inhibitory receptors (KIRs, CD94/NKG2A); Chem, chemerin.
NK cells. NK-mediated DC lysis, due to a pivotal role of NKp30
and DNAM-1 activating receptors (20, 100), is restricted to iDC
undergoing an unfruitful maturation process, characterized by an
inadequate MHC class I up-regulation. This mainly impacts on
the expression of the non-classical HLA-E molecule, the cognate
ligand of the CD94/NKG2A inhibitory receptor. This effect has
been interpreted as a negative selection strategy aimed to avoid
inappropriate antigen presentation by MHC class I low DCs,
which could result in tolerogenic responses. DC that underwent
an appropriate maturation program (mature dendritic cells,
mDC) are spared from NK-cell mediated attack since they
express very high levels of classical MHC class I and significantly
up-regulated HLA-E (101, 102). The principal NK cell-derived
mediators shaping DC immune-phenotype are represented by
TNFα and IFNγ, whose release depends on the synergistic
activity of IL-12 and IL-15 produced by pathogen stimulated
DC. mDC de novo express CCR7, (a phenomenon also occurring
during pathogen-driven macrophage polarization toward M1)
which confers to these cells the competence for migrating to SLO.
In SLO T cell zone, DCs co-localize with NK cells belonging to
the CD56bright CD16low/neg subset, which constitutively express
CCR7 (101).
The complex interactions among NK cells expressing IL-
2Rα (CD25), DC-primed T cells producing IL-2 and mDC
result in a conspicuous IFN-γ production by NK cells shaping
T cell priming, polarization and adaptive immune responses
(101). Whether, in SLO, NK cells may also shape macrophages’
functions remains to be elucidated. CCR7pos. NK cells can
migrate to SLO via HEV since they also express high levels
of CD62L. However, a predominant population of CCR7pos
CD56bright CD16neg NK cells has been described in seroma
fluid, thus depicting afferent lymph as an alternative way
for CD56bright NK cells to colonize SLO (8). Interestingly, it
has been observed, in seroma, the presence of low numbers
of CD56posCD3neg cells expressing CX3CR1, KIRs and CD16
molecules, a phenotype usually characterizing classical CD56dim
NK cells (8). Although a multiparametric analysis providing
information about a possible co-expression of CCR7 was lacking,
these data support the hypothesis that, in vivo, cytolytic CD56dim
NK cells might also migrate to “perturbed” SLO. Along this line,
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the interaction of CD56dim NK cells withM0 orM2macrophages
polarizing toward M1 upon TLR engagement results in the
acquisition of CCR7 and of a fully activated NK cell status
characterized by high CD69 and IL2Rα expression, release of
large amount of IFN-γ and increased cytolytic activity (83). Thus,
in inflammatory conditions, M1-activated CD56dim NK cells,
becoming competent for SLOmigration thanks to the acquisition
of CCR7, might deeply contribute to both immunosurveillance
of tumor metastases and control of infected cells. Migration of
fully functional CD56dim NK cells to SLO, could be particularly
relevant in the context of KIR/KIRL-mismatched haploidentical
stem cell transplantations (haplo-HSCT). Indeed, in SLO, NK-
mediated killing of recipient mDC and residual T cells might
contribute to the low rate of graft vs. host disease (GVHD) and
graft rejection documented in this clinical setting (103).
Nevertheless, is there any in vivo evidence that CD56dim NK
cells might traffic through and leave SLO, thus recirculating
via efferent lymph? A few preliminary reports indicate
this possibility. Non-reactive LNs or LNs characterized
by sinus hyperplasia lack or show low expression of
KIRposCD16pos cells. Interestingly, reactive LNs characterized by
paracortical/follicular hyperplasia harbor a significant percentage
of cells expressing KIR and CD16 and a similar KIRposCD16pos
cells enrichment was observed in the efferent lymph (i.e.,
toracic duct). Several observations, including a difference in the
telomerase length, strongly suggest that CD56bright CD16neg
KIRneg cells can acquire a KIRpos CD16pos phenotype thanks to
the influence of the different pro-inflammatory cytokines present
in LNs (28). However, the hypothesis that CD16pos KIRpos
NK cells might migrate to and expand in LNs before egressing
via efferent lymph cannot be ruled out. In this context, in
pathogen-perturbed tissues, CD56dim NK cells interacting with
macrophages acquire the competence to SLO migration and,
expressing high levels of IL2Rα (83), become highly responsive
to IL-2 produced by T cells in the paracortex area of LN.
Pro-inflammatory cytokines are capable of shaping innate and
adaptive immune responses also acting on the establishment
of the NK cell memory reservoir. Both in mouse and human,
it has been described that the CMV-driven onset of memory
NK cell populations requires the presence of pro-inflammatory
cytokines such as IL-12 and IL-18. Cytokines represent the
third signal essential to generate, expand and recall NK cell
memory. Signal 1 is represented by receptor-mediated antigen
recognition, LY49D in mouse and NKG2C or KIR2DS1 in
humans, and signal 2 by co-stimulatory signals, DNAM-1 and
CD2 in mouse and human, respectively (15, 104). In addition,
cytokines by themselves are capable of generating memory-
like NK cells in an antigen–independent setting (14), as NK
cells, shortly cultured in the presence of IL-12, IL-15 and IL-18,
showed superior IFN-γ and TNF-α production and cytotoxicity
in response to tumor targets and conferred more protection
to leukemia or melanoma in xenograft mouse models. Thus,
full NK cell activation and antigen-dependent or -independent
generation of NK cell memory requires cytokines-mediated
signals. It should be considered that cytokines also strongly
impact on the chemokine receptor repertoire of NK cells.
Beside sIL-18 whose capability of inducing CCR7 expression
has been discussed above, IL-15 has been shown to down-
regulate CX3CR1 expression in mouse bone marrow-derived NK
cells (10) and in human PB NK cells (12), thus reducing the
chemotactic response to CX3CL1 ligand (12). IL-12 in association
with IL-2 significantly decreased the CXCR3 mRNA and their
surface expression in NK cells (9). Additionally, IL-2 alone has
been shown to down-regulate the surface expression of CXCR1
as well as of CXCR4 inhibiting NK cell migration in response
to CXCL12. On the other hand, IL-2 up-regulated the surface
expression of CXCR3 increasing NK cell migration in response
to its ligands CXCL9 and CXCL10 (11).
Regarding the migratory properties of memory NK cells,
different questions remain unanswered. Do cytokines that drive
their onset, impact on their chemokine receptor repertoire
contributing to the generation of tissue-resident memory NK
cells in various anatomical areas? Does the maintenance of
the NK cell memory pool involve tissue-restricted reactivation
of resident memory NK cells or do these cells maintain the
potential to recirculate? Studies focused onmouse recall response
to haptens provided some relevant indications. These studies
showed that memory NK cells responsible for the immune
response were the CD49a+ DX5neg liver resident NK cells, and
that the activity of CD18 and P-selectin, molecules involved
in trafficking of NK cells, was needed (15). In this scenario,
the characterization of human memory NK cells in terms
of chemokine receptor expression, before and after cytokine-
stimulation, could be particularly relevant.
CONCLUDING REMARKS
It has become evident that NK cells are not constituted by a
homogeneous population of innate lymphocytes but rather by
different subtypes with specific abilities as well as distinct homing
properties. Investigating howNK cell subsets distribute in human
body has relevance not only for a better understanding of our
immune defenses but also for exploiting these cytotoxic cells in
therapeutic settings.
It is worth noting that the migratory properties of NK
cell subsets are relevant not only for identifying the region
in which they should exert their activity. Recent reports
indicate that NK cells could acquire specific properties, such as
cytotoxicity, only upon their migration to secondary lymphoid
organs where the cytokine milieu would induce their further
differentiation. At the same time, although the picture of tissue-
resident NK cells is still fuzzy, it is conceivable that these
subsets of NK cells might locally acquire peculiar properties,
such as release of specific soluble factors able to affect
their properties but also influence other cells present in the
microenvironment. As a matter of fact, NK cells (as well as
all other innate lymphoid cells of which they represent the
prototype) are more and more emerging as accessory cells
able to modulate the functions of neighboring cells, including
antigen presenting cells, in the environment in which they are
attracted/hosted.
Despite the relevance of these issues, several open questions
still remain to be addressed regarding the ability of NK cells
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to infiltrate and reside in either healthy or pathological tissues.
Decades after the discovery of NK cells as lymphocytes able
to recognize and kill cancer cells without prior sensitization
to them, we still miss a clear and complete depiction of
the phenotype and properties of tumor-infiltrating NK cells.
Similarly, although a number of studies have now highlighted
the relevance of NK cells in the control of viral infections, how
these cytotoxic lymphocytes recirculate and/or are retained in
infected tissues still remain to be clearly determined, at least in
humans.
On the other hand, novel technologies allowing extensive
multiparametric analyses, either by mass cytometry or classical
flow cytometry, not even conceivable until only a few years ago,
might now open new avenues for a comprehensive mapping of
tissutal NK cells. The path appears already tracked since we have
now, as reported in the present review, a better appreciation of at
least some of the molecules and the signaling ruling the homing
properties of these innate lymphocytes.
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Imatinib and Nilotinib Off-Target Effects on Human NK
Cells, Monocytes, and M2 Macrophages
Francesca Bellora,*,1 Alessandra Dondero,*,1 Maria Valeria Corrias,† Beatrice Casu,*
Stefano Regis,† Fabio Caliendo,* Alessandro Moretta,*,‡ Mario Cazzola,x,{
Chiara Elena,x Luciana Vinti,‖ Franco Locatelli,x,‖ Cristina Bottino,*,†,2 and
Roberta Castriconi*,‡,2
Tyrosine kinase inhibitors (TKIs) are used in the clinical management of hematological neoplasms. Moreover, in solid tumors such
as stage 4 neuroblastomas (NB), imatinib showed benefits that might depend on both on-target and immunological off-target effects.
We investigated the effects of imatinib and nilotinib on human NK cells, monocytes, and macrophages. High numbers of monocytes
died upon exposure to TKI concentrations similar to those achieved in patients. Conversely, NK cells were highly resistant to the TKI
cytotoxic effect, were properly activated by immunostimulatory cytokines, and degranulated in the presence of NB cells. In NB,
neither drug reduced the expression of ligands for activating NK receptors or upregulated that of HLA class I, B7-H3, PD-L1, and
PD-L2, molecules that might limit NK cell function. Interestingly, TKIs modulated the chemokine receptor repertoire of immune
cells. Acting at the transcriptional level, they increased the surface expression of CXCR4, an effect observed also in NK cells and
monocytes of patients receiving imatinib for chronic myeloid leukemia. Moreover, TKIs reduced the expression of CXCR3 (in NK
cells) and CCR1 (in monocytes). Monocytes also decreased the expression of M-CSFR, and low numbers of cells underwent dif-
ferentiation toward macrophages. M0 and M2 macrophages were highly resistant to TKIs and maintained their phenotypic and
functional characteristics. Importantly, also in the presence of TKIs, the M2 immunosuppressive polarization was reverted by TLR
engagement, and M1-oriented macrophages fully activated autologous NK cells. Our results contribute to better interpreting the off-
target efficacy of TKIs in tumors and to envisaging strategies aimed at facilitating antitumor immune responses. The Journal of
Immunology, 2017, 199: 1516–1525.
V
irtually all patients with chronic myeloid leukemia
(CML) and 20% of adult patients with acute lym-
phoblastic leukemia carry the translocation between the
long arms of chromosomes 9 and 22 that generates the Philadelphia
chromosome with a chimeric gene that encodes the fusion protein
BCR-ABL, having constitutively activated tyrosine kinase activity.
Imatinib mesylate (Glivec) was the first designed protein tyrosine
kinase inhibitor (TKI) used in the treatment of CML and BCR-
ABL+ ALL (1–3). This drug binds to the protein in a fashion that
prevents ATP interacting with the ATP-binding site of the ABL
kinase, thereby blocking the tyrosine phosphorylation of proteins
involved in BCR-ABL signal transduction (4). Importantly, in
imatinib-resistant or intolerant BCR-ABL+ patients, an alternative
therapy is based on the administration of nilotinib (Tasigna), a
second-generation TKI that, in vitro, is more potent and selective
than imatinib as a BCR-ABL tyrosine kinase inhibitor (5–7).
Imatinib and nilotinib also target the discoidin domain receptors 1
and 2, the platelet-derived growth factor receptors a and b (8), the
M-CSF receptor (9), and KIT (stem cell growth factor receptor,
CD117) (10, 11). KIT is constitutively active in most human
gastrointestinal stromal tumors (GISTs), a common mesenchymal
neoplasm of the gastrointestinal tract and, in this context, imatinib
is registered for the treatment of GISTs (12, 13). Neuroblastomas
(NB) represent the most common extracranial solid malignancy of
childhood (14); they frequently localize in the abdomen, particularly
in the adrenal gland or at lumbar sympathetic ganglia. Metastatic
disease (stage 4), very often characterized by bone marrow (BM)
infiltration, is diagnosed in at least 50% of NB patients and it is still
associated with a dismal prognosis because of a high risk of tumor
relapse. Children with either refractory or relapsing metastatic NB
have been recently enrolled in a two-stage, phase II clinical trial with
imatinib; the drug was well tolerated and showed benefits in a subset
of patients, particularly those with BM as the only site of metasta-
tization, low tumor infiltration, and low imatinib exposure (15).
It has been suggested that the efficacy of imatinib in GISTs might
depend on both on- and off-target effects, with the latter being
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related to the antiangiogenic effects and strengthening of antitumor
immune responses (16–18). It is conceivable to speculate that also
in NB, the efficacy of imatinib might be at least in part related to
the enhancement of the anti-NB activity of immune cells, such as
NK cells. When properly activated, NK cells exert a potent cy-
tolytic activity and release immunostimulatory cytokines such as
IFN-g that potentiate both innate and adaptive immune responses,
thus representing important effectors against both hematological
and nonhematological malignancies (19, 20).
The NK cell activation depends on the interaction between
activating NK receptors and their cognate ligands on tumor targets.
In humans, the principal activating receptors include NKp46,
NKp30, and NKp44 (collectively termed natural cytotoxicity re-
ceptors), DNAM-1, and NKG2D (21, 22). Different ligands have
been identified that are upregulated or de novo expressed on the
surface of tumor cells. Whereas PVR and nectin-2 are ligands of
DNAM-1 (23, 24), and NKG2D interacts with the stress-inducible
molecules MICA/B and ULBPs (25), the ligands of natural cy-
totoxicity receptors are not yet fully defined. NKp46 is still an
orphan receptor, whereas B7-H6 (26) and a novel isoform of the
mixed-lineage leukemia protein (MLL5) (27) have been identified
as ligands of NKp30 and NKp44, respectively. NK cell activity
unleashed by the interaction between activating receptors and their
ligands is under the control of receptors that recognize optimal
levels of self HLA class I molecules on potential targets and trans-
duce inhibitory signals (21, 28). These NK inhibitory receptors in-
clude the killer Ig-like receptors (CD158) and the CD94/NKG2A
heterodimer.
Either downregulation or loss of HLA class I molecules, which
frequently occur in various types of malignancies, including NB,
allows an efficient NK-mediated killing of tumors (29). However,
it has been shown that several mechanisms might operate in the
tumors to escape from immune-mediated surveillance (14, 30).
The antitumor activity of NK cells depends on their capability of
reaching and infiltrating the tumor tissues. NK cell migration in
pathological tissues must be driven by chemokine gradients that
are sensed through the expression of chemokine receptors that
include CXCR3 (CXCL4, 9, 10, 11 receptor), CXCR1 (CXCL8
receptor), CX3CR1 (CX3CL1 receptor), and CXCR4 (CXCL12
receptor). The latter drives NK cells toward peripheral tissues and
is essential for homing and maintenance of NK cells in stromal
niches within the BM (31). Upon reaching the tumor microen-
vironment, NK cells encounter not only neoplastic cells, but also
other immune effectors such as macrophages, which are the most
represented leukocytes in cancer tissues. Peripheral blood (PB)
monocytes express CCR1, are recruited by CCL1 (MIP-1a), and
differentiate into macrophages (M0) under the influence of M-CSF
(also known CSF1) (32). M0 cells can polarize toward either
the M1 immunostimulatory or the M2 “alternative” immuno-
suppressive functional phenotype, depending on microenvi-
ronmental conditions.
The tumor microenvironment has been shown to promote M2
polarization that is characterized by high expression of scavenger
receptors, such as CD206, and the release of factors that promote,
instead of suppress, tumor growth. These include vascular en-
dothelial growth factor, fibroblast growth factor, matrix metal-
loproteinases, and immunomodulatory cytokines, such as IL-10
and TGF-b, which in NK cells affect the expression of activating
receptors and modulate the chemokine receptor repertoire (33).
Importantly, the M2 status is not definitive, and TLR engagement
can promote M1 polarization of macrophages, which release high
amounts of proinflammatory/immunostimulatory cytokines, such
as IL-1b, IL-6, TNF-a, IL-12, and IL-18 and are capable of in-
ducing strong activation of NK cells (34, 35).
In this study, we examined the effect of two TKIs, imatinib and
nilotinib, routinely used in the clinical management of several neo-
plasms, on the survival and function of human NK cells, monocytes,
and macrophages, also considering their polarization properties and
ability to interact with autologous NK cells.
Materials and Methods
Cells and TKIs
Buffy coats were collected from healthy volunteer blood donors admitted
at the blood transfusion center of IRCCS S. Martino-IST after obtaining
informed consent, and the study was approved by the Ethics Commit-
tee of IRCCS San Martino-IST (39/2012). After standard Ficoll-Paque
density-gradient (Euroclone, Pero, Italy), monocytes and NK cells were
purified with human monocyte cell isolation kit II or a human NK cell
isolation kit, respectively (Miltenyi Biotec, Bergisch Gladbach, Germany).
Macrophages (M0) were obtained culturing monocytes for 7 d in 24
lumox multiwell TC-QUALITAET plates (Greiner Bio-One, Frick-
enhausen, Germany) at a density of 5 3 105/ml and in the presence of
100 ng/ml rM-CSF (PeproTech, London, U.K.). To obtain M2 macro-
phages (M2), M0 were cultured for an additional 18 h with 20 ng/ml rIL-4
(PeproTech). For coculture experiments, NK cells, simultaneously purified
with monocytes, were cultured for 7 d with recombinant human IL-2 (32
U /ml) (Proleukin; Chiron, Emeryville, CA), then harvested, washed, and
added to autologous macrophages. To obtain short-term activated NK
cells, purified NK cells were cultured overnight with rIL-12 (1 ng/ml)
(PeproTech) and rIL-18 (Medical and Biological Laboratories, Nagoya,
Japan) at 100 or 20 ng/ml for IFN-g production or a CD107A degranulation
assay, respectively. For TLR stimulation, macrophages were incubated
for 24 h with 100 ng/ml LPS from Escherichia coli (Sigma-Aldrich)
either in the absence or in the presence of imatinib or nilotinib. M2
macrophages were cocultured overnight with autologous NK cells in the
presence of LPS at the 1:1 NK cell/macrophage ratio either in the ab-
sence or in the presence of drugs. For macrophage differentiation ex-
periments, monocytes were cultured for 7 d with M-CSF in the absence
or in the presence of imatinib or nilotinib, which were added to the
cultures daily.
The NB cell line HTLA-230 was provided by Dr. E. Bogenmann
(Children’s Hospital Los Angeles, Los Angeles, CA) (36); the SH-SY5Y
cell line was purchased from Banca Biologica and Cell Factory (IRCCS
Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy).
NB cell lines were cultured in the presence of RPMI 1640 medium sup-
plemented with 10% heat-inactivated FCS (Biochrom, Berlin, Germany),
50 mg/ml streptomycin, 50 mg/ml penicillin (Sigma-Aldrich), and 2 mM
glutamine (EuroClone). NB cell lines were periodically checked forMYCN
amplification by fluorescence in situ hybridization analysis and for mor-
phology, proliferation rate, and mycoplasma contamination, after thawing
and within four passages in culture.
The K-562 (chronic myelogenous leukemia) cell line (American Type
Culture Collection, Rockville, MD) was maintained in RPMI 1640 medium
with 10% FBS (Biowest, Nuaille, France).
Clinical-grade imatinib mesylate (Glivec) and nilotinib (Tasigna) were
provided by Novartis Pharma (Basel, Switzerland) to M.V.C. (MTA
number 39985). The lyophilized powders were reconstituted in distilled
water (imatinib) or DMSO (nilotinib) at the concentration of 10 mg/ml
and further diluted in cell culture medium at the indicated work con-
centrations and times. Medium supplemented with the same percentage
of DMSO present at the various nilotinib concentrations was used as a
control.
NB and CML patients
The PB samples were collected after informal consent from seven patients
diagnosed with high-risk NB either at the disease onset or relapsing (ad-
mitted at the Oncology Units of the Istituto Giannina Gaslini, Genoa and
Ospedale Bambino Gesù, Rome), two pediatric CML patients (pCML1 and
pCML3) (admitted at Ospedale Bambino Gesù, Rome), and three adult
CML patients (aCML2, aCML3, and aCML4) (admitted the Hematology
Unit, University of Pavia, Pavia). The CML patients were taking imatinib
therapy daily.
After standard Ficoll-Paque density gradient separation, PBMCs were
treated or not with rIL-12 (1 ng/ml) and rIL-18 (100 ng/ml) in the pres-
ence or in the absence of imatinib (6 mg/ml) for 24 h. For the analysis of
NK cells and monocytes, PBMCs were stained with a mixture of anti–
CD56-PC5 and anti–CD3-FITC (NK cells) and anti-CD14 (monocytes)
(Beckman Coulter/Immunotec, Marseille, France). PBMCs derived from
healthy volunteer blood donors were used as control.
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Flow cytofluorimetric analysis and cytokine release assay
For cytofluorimetric analysis (FACSCalibur; Becton Dickinson, Mountain
View, CA), cells were stained with PE-, FITC-, or PC5-conjugated mAbs or
with unconjugated mAbs followed by PE-conjugated isotype-specific goat
anti-mouse second reagent (SouthernBiotech, Birmingham, AL). Isotype-
matched irrelevant mAbs were used as control. Monocytes and macro-
phages were preincubated for 30 min at 4˚C with FcR blocking reagent
(Miltenyi Biotec) before specific mAb staining. For apoptosis and ne-
crosis assays, before cytofluorimetric analysis, cells were incubated for
10 min at room temperature with annexin V and TO-PRO-3 iodide (Life
Technologies, Carlsbad, CA) to identify apoptotic (annexin V+), necrotic
(TO-PRO-3 iodide+), or viable (annexin V2, TO-PRO-3 iodide2) cells.
For phagocytosis assays, macrophages were incubated with unopsonized
pHrodo E. coli BioParticles or opsonized pHrodo E. coli BioParticles
(Life Technologies), at the 1:5 macrophage/BioParticle ratio, at the in-
dicated times and then harvested and analyzed by flow cytometry. On
every experimental session, the flow cytometer performances were mon-
itored and the reproducibility of the fluorescence intensity was aligned by
calibrated microsphere (Becton Dickinson).
Cytokine content in the supernatants of NK cells or macrophages was
quantified by ELISA kits: IFN-g, TNF-a, IL-12p40/p70 (Life Technolo-
gies), and IL-18 (Medical and Biological Laboratories).
CD107a degranulation assay
HTLA-230 or cytokine-activated NK cells were cultured for 24 h in medium
alone or supplemented with different concentrations of imatinib or nilotinib.
Then cells were cocultured for 3 h at the E:T ratio of 1:1 in the presence of
anti–CD107a-PE mAb. M2 macrophages were cocultured for 24 h with
autologous NK cells in the presence of LPS at the 1:1 NK/macrophage
ratio either in the absence or in the presence of drugs. NK cells were then
collected and incubated with the HTLA-230 cell line at the E:T ratio of
1:1 for 3 h in the presence of anti–CD107a-PE mAb. Before flow
cytometry, NK cells were stained with a mixture of anti–CD56-PC5 and
anti–CD3-FITC.
PBMCs derived from CML patients, treated or not with I6, or PBMCs
derived from healthy donors were cocultured with the K562 cell line for
3 h in the presence of anti–CD107a-PE mAb, taking in consideration the
percentage of NK cells and using a NK/target ratio of 1:1. Before flow
cytometry, NK cells were stained with a mixture of anti–CD56-PC5 and
anti–CD3-FITC.
Real-time PCR
Total RNA was extracted from NK cells, monocytes, and SH-SY5Y cells
using the miRCURY RNA isolation kit—cell and plant (Exiqon), according
to the manufacturer’s guidelines. RNA (300 ng) was reverse transcribed
using the SuperScript VILO cDNA synthesis kit (Invitrogen). Real-time
PCR was performed using specific TaqMan gene expression assays (Ap-
plied Biosystems). CXCR4 gene expression was normalized to HPRT1
gene expression. Experiments were performed in triplicate.
Antibodies
The following mAbs were produced in our laboratory: BAB281 (IgG1, anti-
NKp46), AZ20 (IgG1, anti-NKp30), Z231 (IgG1, anti-NKp44), BAT221
(IgG1, anti-NKG2D), KRA236 (IgG1, anti-DNAM-1), MA127 (IgG1, anti-
NTBA), PP35 (IgG1, anti-2B4), C227 (IgG1, anti-CD69), MAR93 (IgG1,
anti-CD25), M5A10 (IgG1, anti-PVR), L14 (IgG2a, anti–Nectin-2), 5B14
(IgM, anti–4IgB7-H3), BAM195 (IgG1, anti-MICA), A6136 (IgM) and
6A4 (IgG1) (anti–HLA class I), D1.12 (IgG2a anti–HLA-DR), and C127
(IgG1 anti-CD16). Anti–PD-L1.3.1 (IgG1, anti-PD-L1) and anti–PD-L2
(IgG1, anti–PD-L2) mAbs were produced in D. Olive’s laboratory. Anti-
CD14 (IgG2a) and a mixture of anti–CD56-PC5 and anti–CD3-FITC
(IgG1) and anti–CD20-FITC were purchased from Beckman Coulter/
Immunotec; anti-CD64 (IgG1), anti–CD80-PE, anti–CD107A-PE, and
anti–CD206-FITC were purchased from BD Biosciences (San Diego, CA);
anti–human IL-18 (IgG1) and anti–CX3CR1-PE (rat, IgG2b) were pur-
chased from Medical and Biological Laboratories; anti-CCR1 (IgG2b),
anti-CCR7 (IgG2a), anti-CXCR4 (IgG2b), anti-CXCR3 (IgG1), anti–
CD204-PE, and anti–M-CSFR (IgG1) were purchased from R&D Systems
(Minneapolis, MN); anti–CD31-PE, anti–CD33-PE, anti–CD36-PE, and
anti–CCR6-PE were purchased from Miltenyi Biotec; anti-CXCR1 (IgG1)
and anti-ULBP3 (166510, IgG2a) were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA); and anti–annexin V-FITC was purchased
from eBioscience (San Diego, CA). All Abs were of mouse origin, unless
otherwise specified. PE and FITC isotype-matched mouse (BD Biosci-
ences) (Miltenyi Biotec) or rat (Medical and Biological Laboratories)
mAbs were used as negative controls.
Statistical analysis
AWilcoxon–Mann–Whitney p value test (nonparametric significance test)
was employed. Graphic representation and statistical analysis were per-
formed using PASW Statistics version 20.0 software (formerly SPSS
Statistics) (IBM, Milan, Italy) and GraphPad Prism 6 (GraphPad Software,
La Jolla, CA).
Results
PB NK cells are more resistant than monocytes to the cytotoxic
effects of imatinib and nilotinib
The HTLA-230 human NB cell line was treated with concentra-
tions of either imatinib or nilotinib ranging from 120 to 0.3 mg/ml
(Fig. 1A, Supplemental Fig. 1A) and after 24 h assessed for ap-
optosis and/or necrosis by staining with annexin V and TO-PRO-3
iodide and flow cytometry analysis. Whereas the cells were un-
affected by nilotinib, with imatinib concentrations $15 mg/ml,
increasing numbers of necrotic cells were detected and all cells
died upon exposure to concentrations of 120 mg/ml.
We analyzed the influence of decreasing concentration of drugs
on the survival of circulating monocytes and NK cells. Monocytes
and NK cells were purified from PB of healthy donors and their
viability was assessed after 24 h of treatment with one or another
drug (Fig. 1B, 1C, Supplemental Fig. 1A). At high concentration
($15 mg/ml), monocytes were susceptible to treatment with both
drugs, whereas NK cells were killed by imatinib but virtually
resistant to treatment with nilotinib, even at the highest concen-
tration used. At drug concentration#6 mg/ml, a low percentage of
dead monocytes was detected after treatment with imatinib,
whereas with nilotinib high numbers of cells underwent apoptosis
and/or necrosis, particularly at 6 mg/ml. NK cells were poorly
susceptible to treatment with a low concentration of imatinib and
virtually resistant to nilotinib.
To confirm that NK cells were less susceptible than monocytes to
the cytotoxic effect of TKIs, cells were treated daily with a drug
concentration of #6 mg/ml and analyzed for apoptosis/necrosis
after 24, 48, and 72 h (Supplemental Fig. 1B). The NB cell line
was resistant to treatment with TKIs. The percentage of mono-
cytes undergoing apoptosis/necrosis increased at 48 h, and with
drug concentrations $3 mg/ml most cells died on day 3. On the
contrary, NK cells remained resistant to all nilotinib concentra-
tions even after 3 d of treatment. Two days of treatment with
imatinib minimally affected NK cell survival, and relevant num-
bers of dead cells were detected on day 3 only. This, however,
occurred in some donors, whereas in others NK cells were poorly
susceptible to imatinib cytotoxicity even after 3 d of treatment.
Imatinib and nilotinib modify the chemokine receptor
repertoire of monocytes and NK cells
We analyzed the phenotype of monocytes and NK cells that had
been treated with a concentration of #6 mg/ml, gating on annexin
Vand TO-PRO-3 iodide double-negative viable cells. Neither drug
altered the expression of a large panel of surface markers, typical
of one or another cell type (34, 35) (Supplemental Fig. 1C). On the
contrary, imatinib and nilotinib significantly modified the che-
mokine receptor repertoire of immune cells (Fig. 2A, Supplemental
Fig. 1C). In particular, both monocytes and NK cells showed
strong upregulation of the expression of CXCR4. Moreover, at
6 mg/ml, downregulation of CCR1 or CXCR3 was detected in
monocytes and NK cells, respectively. Neither drug modified the
expression of other chemokine receptors, including CX3CR1,
which is expressed by both monocytes and NK cells (Supplemental
Fig. 1C).
The drug-mediated upregulation of CXCR4 was observed not
only in monocytes and NK cells but also in PB T and B cells
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(Fig. 2B). Notably, neither drug induced significant modulation of
CXCR4 expression in NB cell lines that constitutively expressed
different levels of the chemokine receptor (Fig. 2B, Supplemental
Fig. 1D).
With regard to the mechanism responsible for TKI-mediated
upregulation of CXCR4 in immune cells, preliminary results
showed regulation at the transcriptional level. Indeed, according to
the surface phenotype, imatinib and nilotinib increased CXCR4
mRNA expression in NK cells and monocytes, but not in NB cell
lines (Fig. 2C).
Imatinib and nilotinib did not affect or marginally impair
cytokine-mediated activation of NK cells
Activated NK cells display cytolytic activity against NB cells, and
DNAM-1/PVR interactions play a predominant role in tumor recog-
nition (29). We analyzed whether drug concentrations of #6 mg/ml
could impair the capability of NK cells to degranulate in the
presence of NB. In NB, neither drug modified the expression of
ligands for the activating NK receptors DNAM-1 and NKG2D,
or induced upregulation of molecules that could limit the NK cell
function (Supplemental Fig. 1D). These include HLA class I, B7-H3
(37), and PD-L1 and PD-L2 (38), ligands of the PD-1 inhibitory
receptor (39).
Next we analyzed whether TKI conditioning could affect
cytokine-mediated activation of NK cells. As shown in Fig. 3, the
presence of imatinib and 0.3 mg/ml nilotinib did not significantly
impact the acquisition of the CD69 activation marker, and NK
cells in the presence of NB showed a degranulation capability
comparable to that observed in the absence of TKIs. The only
exception was represented by nilotinib used at 6 mg/ml, which
hampered degranulation capability, with this effect being paral-
leled by a reduced upregulation of CD69.
Interestingly, as observed in PBNK cells, all drug concentrations
also induced significant upregulation ofCXCR4 in cytokine-stimulated
NK cells (Fig. 3B).
M0 and M2 macrophages are more resistant to TKIs than
monocytes and maintain the capability of polarizing
toward M1
We investigated whether imatinib or nilotinib could affect the
survival and function of macrophages, in particular of those po-
larized toward M2 that might display a tumor-promoting role
(Fig. 4, Supplemental Fig. 2A–D). Purified PB monocytes were
cultured with M-CSF and on day 7 differentiated macrophages
(M0) were polarized toward M2 in the presence of IL-4. M0 and
M2 macrophages were treated with different concentrations of
imatinib or nilotinib and analyzed for apoptosis and/or necrosis by
flow cytometry. M0 and M2 were more resistant to TKI exposure
(Fig. 4, Supplemental Fig. 2A–D) as compared with monocytes
(see Fig. 1B, Supplemental Fig. 1A, 1B). Indeed, imatinib con-
centrations $30 mg/ml were necessary to induce apoptosis/necrosis
in a relevant number of macrophages, and cell viability was only
marginally affected by TKI concentration up to 15 mg/ml. More-
over, macrophages were highly resistant to all concentrations of
nilotinib (Fig. 4, Supplemental Fig. 2A).
The treatment with drug concentrations #6 mg/ml did not
damage the phagocytosis capability of macrophages, which showed
levels comparable to controls (Supplemental Fig. 2B), or their
ability to polarize toward M1 via TLR stimulation. Indeed, also in
the presence of drugs, LPS stimulation increased the expression of
CD80 and HLA class I and abolished that of the membrane-bound
form of IL-18 (mIL-18) (40) (Supplemental Fig. 2C). Moreover,
after TLR stimulation, M0 and M2 released proinflammatory/
immunostimulatory cytokines such as IL-12, TNF-a, and, accord-
ing to the loss of mIL-18, soluble IL-18 (Supplemental Fig. 2D).
In the presence of imatinib and nilotinib, TLR-stimulated M2
macrophages promote NK cell activation
We analyzed whether imatinib or nilotinib could influence the
capability of M1-polarizing macrophages to induce the activation
of PB NK cells. Purified PB NK cells were cocultured with au-
tologous M2 macrophages stimulated with LPS, either in the ab-
sence or in the presence of TKI concentration #6 mg/ml. After 24
h, NK cells were recovered and evaluated for the phenotypic and
functional characteristics (Fig. 5, Supplemental Fig. 2E).
In agreement with previously published data (34, 35), TLR-
stimulated M2 induced in NK cells upregulation of the expres-
sion of CD69, CD25, and CCR7, enhancement of degranulation
capability, and the release of high amounts of IFN-g. In the pres-
ence of imatinib, NK cells maintained the capability to upregulate
FIGURE 1. Imatinib and nilotinib have different effects on the via-
bility of NB, monocytes, and NK cells. The HTLA-230 NB cell line
(A), monocytes (Mo) (B), and NK cells (C) purified from unrelated healthy
donors were treated with decreasing concentration of imatinib or nilotinib
(micrograms per milliliter) and analyzed by flow cytometry (annexin Vand
TO-PRO-3 iodide) to identify the percentages of apoptotic, necrotic, or
viable cells. Data were normalized considering as 100% the percentage of
viable cells in the control (cells cultured in the absence of drugs). Data
were pooled from four independent experiments. Mean and 95% confi-
dence intervals are shown.
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the CD69 and CD25 expression, to degranulate in the presence of
the NB cell line, and released IFN-g at levels comparable to those
observed with the classical rIL-12 plus rIL-18 cytokine stimulation.
In the presence of nilotinib at 0.3 mg/ml, NK cells showed CD69
and CD25 upregulation, as well as increased degranulation and
IFN-g production. On the contrary, at a concentration of 6 mg/ml,
nilotinib significantly impaired the acquisition of CD69 and the
increase of degranulation capability.
In the presence of either TKI, CCR7 expression displayed
considerable variability among donors, and only in some cases an
increased percentage of CCR7+ cells was detected, particularly
when using imatinib.
Imatinib and nilotinib affect the survival of monocytes
differentiating toward macrophages in the presence of M-CSF
We also evaluated whether imatinib or nilotinib could affect the
capacity of monocytes to differentiate toward macrophages in the
presence of M-CSF.
Purified PB monocytes were differentiated toward M0 with
M-CSF in the presence of TKIs. Cells were analyzed by flow
cytometry for cell survival rate and, gating on viable cells, for the
expression of surface markers typical of macrophages (Fig. 6A,
Supplemental Fig. 3A, 3B). At drug concentration of 6 mg/ml
most cells underwent apoptosis/necrosis. At 0.3 mg/ml, high
percentages of viable cells were detected, which progressively
acquired a phenotype typical of macrophages. In particular, cells
reduced the expression of CD14 and HLA II, increased that of
CD16, and de novo expressed NTB-A, B7-H3, CD204, and mIL-18
(Supplemental Fig. 3B) (34, 40).
We evaluated whether the reduced numbers of surviving and
differentiating monocytes could correlate with a drug-mediated
reduction of the expression of the M-CSF receptor (CSF1R)
(Fig. 6B, Supplemental Fig. 3C). Purified PB monocytes were
treated with imatinib and nilotinib for 24 h and analyzed by flow
cytometry. Exposure to TKI concentrations of 6 mg/ml strongly
decreased both the percentage of monocytes expressing M-CSFR
FIGURE 2. Imatinib and nilotinib modify the chemokine receptor repertoire of monocytes and NK cells. (A) Purified monocytes (Mo) and NK cells were
treated with 6 or 0.3 mg/ml imatinib (I6, I0.3) or nilotinib (N6, N0.3) for 24 h and analyzed by flow cytometry for the expression of the indicated chemokine
receptors. (B) CXCR4 expression was analyzed by flow cytometry in PBMC T and B cells (gating on CD3+ CD562 and CD20+ cells, respectively) and in
two representative NB cell lines after treatment with I6, I0.3 or N6, N0.3. For (A) and (B), data were pooled from eight independent experiments. (C) NK
cells and monocytes (five or six unrelated donors) and the SH-SY5Y NB cell line (three independent experiments) were treated with I6 or N6 for 24 h and
analyzed by RT-PCR for CXCR4 mRNA expression. Each experiment was performed in triplicate. Fold increase or decrease refers to control represented by
untreated cells (arbitrarily normalized to 1). Mean, 95% confidence intervals, and significance (*p , 0.05, **p , 0.01, ***p , 0.001) are shown.
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and its surface density. On the contrary, treatment with 0.3 mg/ml
did not significantly affect M-CSFR expression.
Effect of imatinib on immune cells from high-risk NB and
CML patients
PBMCs were obtained from seven children with high-risk NB
either at the disease onset or relapsing and analyzed for CXCR4
expression. In these patients, NK cells and monocytes constitu-
tively expressed levels of the chemokine receptor comparable to
those of healthy donors. In vitro treatment with imatinib (6 mg/ml)
induced upregulation of CXCR4 expression in both cell types
(Fig. 7A, Supplemental Fig. 4A).
We extended the analysis to PBMCs from three adult and two
pediatric patients receiving imatinib for CML. CML NK cells
and monocytes displayed a higher CXCR4 surface expression as
compared with healthy donors (Fig. 7B, Supplemental Fig. 4B).
The chemokine receptor surface density further increased when
CML PBMCs were treated in vitro with imatinib at the concen-
tration of 6 mg/ml (Fig. 7B, Supplemental Fig. 4B). Moreover, the
treatment downregulated the expression of CCR1 and M-CSFR in
monocytes (Fig. 7C, Supplemental Fig. 4B). Unlike what was
observed in healthy donors (see Fig. 2A, Supplemental Fig. 1C),
in vitro imatinib exposure did not decrease the expression of
CXCR3 in CML NK cells (Supplemental Fig. 4B).
NK cells of CML patients were also analyzed for degranulation
in the presence of the prototypical K562 target cell line (Fig. 7D,
Supplemental Fig. 4C). The degranulation capability of resting
NK cells did not significantly differ from that of healthy donors.
Moreover, the in vitro treatment with imatinib did not affect the
degranulation capability of resting and cytokine-stimulated CML
NK cells. Notably, in some patients NK cells appeared to degra-
nulate better in the presence than in the absence of the drug.
Discussion
More than 20 TKIs are approved as cancer therapies for patients
with Ph+ hematological malignancies, melanoma, breast cancer,
non–small cell lung cancer, and colorectal cancer. Recently it
has been demonstrated that imatinib provides clinical benefits in
GISTs (18) and NB (15). In particular, in GISTs, benefits were
associated with drug-dependent off-target effects, such as modu-
lation of immune responses, and in NB a similar mechanism was
postulated to occur. This prompted us to analyze the effect of two
TKIs, namely imatinib and nilotinib, on NK cells, which represent
pivotal cytolytic effectors in antitumor responses. Moreover, owing
to the existence of a crosstalk between NK cells and macrophages
(34), the analysis was extended to monocytes and macrophages,
with particular attention to those characterized by tumor-promoting
M2 polarization. TKI concentrations $15 mg/ml are higher than
those achievable in adult patients in which plasma concentrations
between 1 and 3 mg/ml are presently recommended (1). In pediatric
patients, who showed higher tolerability than adults, plasma con-
centrations of imatinib ranged from 2 to 7 mg/ml, with lower values
associated with better responses (15). We thus selected drug con-
centrations#6 mg/ml that, under our experimental conditions, were
devoid of direct effects on NB cells and we analyzed their influence
on phenotype and function of immune cells.
PB (resting) NK cells were highly resistant to the cytotoxic effect
of the drugs, as ,10% of cells died when exposed to imatinib and
virtually all survived when exposed to nilotinib. Moreover, with
the exception of nilotinib used at 6 mg/ml, NK cells maintained
FIGURE 4. Macrophages are highly resistant to imatinib and nilotinib. M0 and M2 cells were treated with the indicated concentrations (micrograms per
milliliter) of imatinib or nilotinib and analyzed for flow cytometry (annexin V and TO-PRO-3 iodide) to identify the percentage of necrotic, apoptotic, and
viable cells. Data were normalized considering as 100% the percentage of viable cells in the control (untreated macrophages). Data were pooled from three
independent experiments. Mean and 95% confidence intervals are shown.
FIGURE 3. Imatinib and nilotinib marginally affect the cytokine-dependent activation of NK cells. (A) Purified PB NK cells were stimulated with rIL-12
and rIL-18 either in the absence (2) or in the presence of I6, I0.3 or N6, N0.3 and analyzed by flow cytometry for degranulation (CD107a assay) in the
presence of HTLA-230. The change in percentage (Δ%) refers to the percentage of CD107a+ NK cells with target minus the percentage of CD107a+ NK
cells without target. (B) NK cells treated as in (A) were analyzed for the expression of CD69 and CXCR4. Fold decrease or increase versus control
(cytokine-stimulated NK cells without drugs, arbitrarily normalized to 1) is shown. Data pooled from five independent experiments. Mean, 95% confidence
intervals, and significance (*p , 0.05, **p , 0.01) are shown.
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the ability to be activated by immunostimulatory cytokines,
increasing the expression of activation markers and acquiring a
degranulation capability in the presence of NB cells, comparable
to that detected in the absence of drugs. In this context, in NB cells
neither drug substantially modified the expression of ligands for
the activating NK receptors (14) or induced upregulation of HLA
class I and of other molecules involved in the immune checkpoints
(38, 41, 42). Importantly, the drugs did not substantially alter the
expression in NK cells of activating receptors, including DNAM-1
and NKp30, which are crucial for recognition and killing of both
leukemia (23) and NB cells (29). Of note, a certain degree of
variability in NKp30 surface expression upon TKI exposure was
detected among donors. This could be explained by changes in the
expression levels of the NKp30 receptor isoforms (a, b, and c)
FIGURE 6. Imatinib and nilotinib reduce the number of monocytes differentiating toward macrophages. (A) Purified PB monocytes were cultured in the
presence of M-CSF either in the absence or in the presence of I6, I0.3 or N6, N0.3 and analyzed (on days 3 and 7) by flow cytometry (annexin V and TO-
PRO-3 iodide) to identify the percentage of necrotic, apoptotic, and viable cells. Data were normalized considering as 100% the percentage of viable cells
in the control (monocytes with M-CSF, without drugs). (B) PB monocytes were treated with I6, I0.3 or N6, N0.3 for 24 h and, gating on viable cells,
analyzed by flow cytometry for M-CSFR expression. The percentage or mean fluorescence intensity (MFI) fold decrease versus control (untreated
monocytes, arbitrarily normalized to 1) is shown. Data were pooled from eight independent experiments. Mean, 95% confidence intervals, and significance
(*p , 0.05) are shown.
FIGURE 5. Imatinib and nilotinib do not significantly affect the capability of M1-polarizing macrophages to activate PB NK cells. Purified PB NK cells
were cultured alone (CTR) or with autologous M2 stimulated with LPS either in the absence (2) or in the presence of I6, I0.3 or N6, N0.3. NK cells were
recovered and analyzed by flow cytometry for (A) the surface expression of CD69, CD25, and CCR7 and (B) degranulation capability in the presence of
HTLA-230 cell line (CD107a assay). The change in percentage (Δ%) refers to the percentage of CD107a+ NK cells with target minus the percentage of
CD107a+ NK cells without target. (C) IFN-g release (culture supernatants, ELISA assay). IFN-g release by ΝΚ cells stimulated with rIL-12 plus rIL-18 is
shown as positive control. Data were pooled from six (A), four (B), and eight (C) independent experiments. Mean, 95% confidence intervals, and signi-
ficance (*p , 0.05, **p , 0.01, ***p , 0.001) are shown.
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(43). This interpretive hypothesis is under further investigation,
because it could correlate with differences in responses to drug treat-
ments. Indeed, recent data showed a reduced response to imatinib in
GIST patients with the NKp30 isoform c, which induces production
of IL-10 instead of IFN-g and TNF-a (18).
Importantly, both TKIs revealed a striking capacity to modulate
the chemokine receptor repertoire of NK cells. In particular, they
strongly increased CXCR4 expression in both resting and activated
NK cells, and imatinib at the highest concentration used decreased
that of CXCR3. Interestingly, increased CXCR4 expression upon
TKI exposure was detected also in PB T and B lymphocytes, but it
did not occur in NB cells. These data suggest that imatinib and
nilotinib through CXCR3 downregulation and CXCR4 upregula-
tion might disfavor the recruitment of NK cells toward peripheral
tissues, while supporting their homing into BM niches. This might
potentiate the NK immune surveillance against tumor cells that, as
occur in stage 4 NB patients, metastasize in BM. It is of note that,
different from what has been described for TGF-b (33), imatinib and
nilotinib did not modify the expression of CX3CR1, which partic-
ipates in the recruitment and extravasation of NK cells into BM.
Increased CXCR4 expression upon TKI exposure also occurred
in PB monocytes and was accompanied by downregulation of
CCR1, which participates in their extravasation in peripheral
tissues. Monocytes were more susceptible than NK cells to drug
exposure and, in particular, at 6 mg/ml, significant numbers of cells
underwent apoptosis/necrosis with imatinib and up to 60% died
with nilotinib. This effect was not prevented by stimulation with
M-CSF, the major factor involved in monocyte differentiation
toward macrophages (44). In keeping with the low survival rate
and the reduced number of cells undergoing differentiation, in the
presence of TKIs, monocytes strongly decreased the expression of
the M-CSFR. These results are in line with previous data showing
that M-CSF is fundamental for survival of monocytes (45, 46) and
that imatinib impairs the signal transduction pathway of the
M-CSFR (47). Our data suggest that imatinib and nilotinib could
decrease in vivo the half-life of circulating monocytes, as well as
their recruitment and macrophage differentiation in tissues, pos-
sibly reducing the generation of macrophages that in the tumor
microenvironment might acquire M2 tumor-promoting function.
Interestingly, it has been shown that imatinib inhibited the early
phase of the differentiation of myeloid-derived suppressor cells
and reduced their number in CML patients (48), whereas it did not
affect differentiation toward dendritic cells (49).
Macrophages, both unpolarized (M0) and M2, were highly re-
sistant to imatinib and nilotinib. A high number of cells survived to
TKI exposure and maintained their phenotypic and functional
characteristics, thus showing that drugs did not induce or modify
macrophage polarization. Importantly, in the presence of TKIs, M2
FIGURE 7. Imatinib effects in NK and monocytes from NB and CML patients. (A) PBMCs from seven NB patients were treated in vitro with I6 for 24 h
and analyzed by flow cytometry for CXCR4 expression, gating on NK cells (CD32CD56+) or monocytes (Mo; CD14+). Fold increase versus control
(untreated NB PBMCs, arbitrarily normalized to 1) is shown. (B) PBMCs from five CML patients either untreated (2) or treated in vitro with I6 for 24 h
were analyzed by flow cytometry for CXCR4 expression gating on NK cells or monocytes. Fold increase versus controls (NK cells or monocytes from three
untreated healthy donors, arbitrary normalized to 1) is shown. (C) CML PBMCs were treated in vitro with I6 for 24 h and analyzed by flow cytometry for
CCR1 and M-CSFR expression, gating on monocytes. Fold decrease versus control (untreated CML PBMCs, arbitrarily normalized to 1) is shown. (D)
PBMCs of five CML patients, untreated (2) or I6 treated, were analyzed for NK cell degranulation (CD107a assay) gating on NK cells, either in the
absence or in the presence of stimulatory cytokines (rIL-12 plus rIL-18). PBMCs of three healthy donors (HD) are shown as controls. The change in mean
fluorescence intensity (ΔMFI) refers to MFI of CD107a+ NK cells with target (K562) minus MFI of CD107a+ NK cells without target. Mean, 95%
confidence intervals, and significance (*p , 0.05, **p , 0.01) are shown.
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maintained the capability to revert their immunosuppressive func-
tional phenotype toward M1 after TLR engagement. Indeed, they
released high amounts of proinflammatory and immunostimulatory
cytokines. Moreover, with the exception of nilotinib used at 6 mg/ml,
M1-polarized M2 macrophages acquired the capability of fully
activating NK cells that increased the expression of the a-chain of
the IL-2 receptor, the degranulation capability in the presence of
NB, and released a high amount of IFN-g, a cytokine crucial for
amplification of both innate and adaptive Th1 antitumor immune
responses.
Collectively, our results shed light on the influence of imatinib
mesylate and nilotinib on NK cells and monocyte/macrophage
survival, function, and expression of chemokine receptors, con-
tributing both to better interpreting the efficacy of these agents in
tumors and to envisaging strategies aimed at facilitating an anti-
tumor immune response rather than to promoting a direct effect on
tumor cells.
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ABSTRACT
Angiogenesis represents a hallmark of tumor progression in Multiple Myeloma 
(MM), a still incurable malignancy. Here we analyzed the activity of cytokine-
stimulated NK cells against tumor-associated endothelial cells isolated from bone 
marrow aspirates of MM patients with active disease (MMECs). We show that NK cells 
activated with optimal doses of IL-15 killed MMECs thanks to the concerted action 
of multiple activating receptors. In particular, according to the high expression of 
PVR and Nectin-2 on MMECs, DNAM-1 actively participated in target recognition. 
Interestingly, in MMECs the surface density of PVR was significantly higher than 
that detected in endothelium from patients with MM in complete remission or with 
monoclonal gammopathy of undetermined significance (MGUS). Importantly, IL-
27, which unlike IL-15 does not display pro-angiogenic properties, maintained or 
increased the NK cell functions induced by suboptimal concentrations of IL-15. NK cell 
properties included killing of MMECs, IFN-γ production as well as a peculiar increase 
of NKp46 expression on NK cell surface. Finally, IL-27 showed a striking capability 
of up-regulating the expression of PD-L2 and HLA-I on tumor endothelium, whereas 
it did not modify that of PD-L1 and HLA-II. 
Our results suggest that cytokine-activated endogenous or adoptively transferred 
NK cells might support conventional therapies improving the outcome of MM patients.
INTRODUCTION
In the last decades important advancements in 
the treatment of different malignances have led to 
significant improvement in patients’ survival. A variety 
of therapies are currently available including those 
targeting specific pathways involved in the growth and 
survival of cancer cells or tumor-associated stromal cells 
such as endothelial cells. A pro-tumoral crosstalk between 
cancer and endothelial cells occurs and is essential for 
tumor growth. In multiple myeloma (MM), an incurable 
malignancy of monoclonal plasma cells [1], angiogenesis 
represents a hallmark of tumor progression and anti-
VEGF drugs, alone or in combination with other agents, 
are currently used. In some patients however, available 
therapeutic approaches resulted in limited benefits and in 
a short-lasting tumor regression. Thus, many efforts have 
been made to evaluate additional therapeutic protocols 
aimed at obtaining a more durable tumor control in 
different malignances including MM. New strategies 
consist of immunotherapeutic approaches including the 
strengthening of the function of endogenous Natural 
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Killer (NK) cells or the adoptive transfer of “armed” 
or activated NK cells [2–5]. These cells are cytotoxic 
members of the Innate Lymphoid Cell (ILCs) family [6, 7] 
and have been shown to play a crucial role in tumor 
surveillance also due to their capability of killing tumor 
cells including those with stem cell like properties [8–11]. 
The mechanisms allowing the NK-mediated recognition 
of tumor cells have been largely clarified and consist 
of the cooperation of different triggering receptors that 
are engaged by specific ligands upregulated or de novo 
expressed on transformed cells [3, 11, 12]. Activating 
NK receptors are represented by NKp46 (CD335), 
NKp30 (CD337) and NKp44 (CD336) (collectively 
termed natural cytotoxicity receptors, NCR), DNAM-1 
(CD226) and NKG2D (CD314) [3, 13]. Although viral 
glycoproteins have been identified as ligands for NCR, 
their cellular ligands are not fully defined [14].  Two 
molecules, the mixed-lineage leukemia (MLL5) [15] 
and B7-H6 [16] have been found to be expressed on a 
wide panel of tumors [17] and represent cellular surface 
ligands of NKp44 and NKp30, respectively. It is of note 
however, that different evidences suggest that NKp30 
would be able to recognize additional, still undefined, 
tumor-associated ligand(s). NKG2D recognizes MICA/B 
and ULBPs [12] stress inducible molecules de-novo 
expressed after tumor transformation and virus infection. 
DNAM-1 binds PVR (CD155) and Nectin-2 [18], two 
members of the Nectin family that are also recognized 
by Tactile [19] and TIGIT [20]. PVR and Nectin-2 are 
over-expressed in tumors of different histotype and 
their interaction with DNAM-1 is non-redundant and 
crucial to obtain an efficient tumor cell killing [21–24]. 
Accordingly, different studies highlighted the importance 
of DNAM-1/ligands interactions in the establishment of 
the activating immunological synapse that allows tumor 
recognition by both NK and T cells [25–28]. 
The possible effect of NK-cell based therapeutic 
approaches in killing of tumor-associated endothelial cells 
with the consequent reduction of the vascular network 
remains to be determined. 
In the present study we analyzed the NK cell 
activity against tumor-associated endothelial cells (EC) 
isolated from bone marrow aspirates of MM patients in 
active phase (MMECs). We evaluated the susceptibility of 
MMECs to killing mediated by IL-15-stimulated NK cells 
and dissected the molecular interactions occurring between 
effector and target cells. Moreover, we investigated the 
immunostimulatory effects of IL-27 [29] that, unlike 
IL-15, does not display pro-angiogenic properties [30, 31]. 
Finally, considering that NK cell activation might result 
in vivo in a cytokine storm responsible for the activation 
of immune checkpoints, [32, 33] we analyzed in MMECs 
the constitutive and cytokine-induced surface expression 
of Programmed Death Ligands (PD-Ls) and HLA 
class I and II [34–36]. 
RESULTS
DNAM-1 actively participates to the killing of 
MMECs mediated by rIL-15-activated NK cells 
Tumor-associated endothelial cells were isolated from 
bone marrow (BM) aspirates of nine Multiple Myeloma 
Patients in active phase (Table 1) [37]. MMECs were 
analyzed for the susceptibility to lysis mediated by peripheral 
blood mononuclear cells (PBMCs) of healthy donors 
activated with optimal doses of rIL-15 (20 ng/ml) (Figure 
1A). Overall, activated PBMCs killed the MMECs analyzed 
and HLA class I molecules had a poor protective role as 
demonstrated by the lack of significant differences observed 
in the presence of the anti-HLA-I mAb (Figure 1A). It is 
of note however that a certain degree of heterogeneity in 
the susceptibility of MMECs to activated PMBCs could 
be appreciated. Indeed, MMEC3 and MMEC4 showed a 
susceptibility to lysis comparable to that of EA, a prototypic 
tumor endothelial cell line used as control, whereas MMEC1 
and MMEC2 were more resistant (Figure  1A). 
Assuming a predominant role of NK lymphocytes in the 
killing of MMECs by rIL-15 activated PBMCs, we analyzed 
the susceptibility of MMECs to lysis mediated by highly 
purified activated NK cells (Figure 1B). Moreover, in order to 
analyze the possible contribution of the different activating NK 
receptors in the recognition of MMECs, cytolytic assays were 
performed in the presence of mAbs able to specifically disrupt 
the interactions between the receptors (on NK cells) and their 
ligands (on target cells). Similar to EA, MMECs were highly 
susceptible to killing mediated by rIL-15 activated NK cells, a 
process that depended on the cooperation of various activating 
receptors (Figure 1B). In particular, NKG2D and DNAM-1 
contributed to the killing of MMEC3 and a significant 
inhibition of lysis was observed only after the combined 
mAb-mediated masking of both molecules. NKG2D was 
not involved in MMEC5 recognition, whereas DNAM-1 
played a major role in the NK-mediated cytotoxicity, as its 
mAb-mediated masking resulted in a significant reduction 
of lysis. Moreover, mAb-mediated masking of NKp30 
and NKp46 significantly reduced the lysis demonstrating 
the involvement of these receptors in killing of MMEC5 
(Figure 1B). The NK-mediated recognition of EA cells 
involved the four different activating receptors thus 
recapitulating what observed in endothelial cells derived 
from MM patients. A similar scenario was observed 
using endothelial cells obtained from patients with 
monoclonal gammopathy of undetermined significance 
(MGECs). In these experiments we used the CD107a 
assay that was more suitable to preserve the viability of 
target cells. As shown in Supplementary Figure 1, rIL-15 
stimulated NK cells degranulated in the presence of MGECs 
(and in the presence of EA, used as control) and DNAM-1, 
NKG2D, NKp30 and NKp46 receptors clearly cooperated in 
the process. 
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MMECs and EA cell line express the ligands of 
DNAM-1 activating receptor
MMECs were analyzed for the surface expression 
of the ligands of activating receptors known to regulate 
NK cell functions including cytolytic activity. The 
gating strategy is shown in Supplementary Figure  2. For 
comparison, the analysis was performed on endothelial 
cells derived from BM of patients with MM in complete 
remission (cr-MMEC), monoclonal gammopathy of 
undetermined significance (MGEC 1-5) or anemia due to 
iron deficiency (IDAEC). 
In all cells analyzed NKG2D-ligands were either 
undetectable or expressed at very low levels (Table 2). 
In particular, according to the involvement of NKG2D 
in NK-mediated lysis (see Figure 1B) MMEC3 
expressed MICA, ULBP-2 and ULBP-3.  The latter two 
ligands were also detected in the EA cell line whereas 
MMEC5, which was killed in an NKG2D-independent 
manner, did not express any of the NKG2D ligands 
analyzed. All endothelial cells analyzed expressed 
good levels of PVR and Nectin-2 (Table 2), ligands of 
DNAM-1 receptor involved in the killing of MMECs 
and EA (see Figure 1B). Interestingly, in MMECs and 
EA the surface density of PVR was significantly higher 
than in cr-MMEC, MGECs and IDAEC (Figure 2A). 
Accordingly, MMECs and EA but not the other 
endothelial cells analyzed were stained by the DNAM-
1-Fc soluble receptor (Figure 2B). 
In spite of the clear involvement of NKp30 in the 
NK-mediated lysis of some MMECs and EA cells, none of 
the endothelial cells analyzed was stained by the NKp30-
Fc soluble receptor (Figure 2B), which efficiently bound 
the B7-H6 specific ligand on B7-H6+ cell transfectants and 
K562 cell line   (Supplementary Figure 3A). EA cell line 
was characterized by a very low level of B7-H6 transcript, 
comparable to that detected in immature Dendritic cells 
(iDC), whose interaction with NK cells is mostly NKp30-
dependent [38, 39] (Supplementary Figure 3B). Lack of 
staining of NKp30-Fc soluble receptor on MMECs might 
be due to the poor surface expression of B7-H6, not 
sufficient to bind NKp30-Fc soluble receptor, but capable 
of engaging the native NKp30 receptor. Alternatively, 
both MMECs and iDC may express an additional, not 
yet identified, NKp30 ligand that is not recognized by the 
NKp30-Fc soluble receptor. 
rIL-27 plus suboptimal doses of rIL-15 enhance 
NK cell cytotoxicity against tumor endothelial 
cells
NK cells stimulated with optimal doses of rIL-15 
displayed cytotoxicity against all MM-associated 
endothelial cells analyzed, an effect that was accompanied 
by the upregulated expression of CD69 activation marker 
(Figure 3B and 3C), NKG2D (Figure 3D) and NKp30 
(Figure 3E) and by a modest but significant production 
of IFN-γ (Figure 3H). However, IL-15 might exert 
Table 1: Endothelial cells analyzed in the study
Endothelial cells Disease Phase Age Gender
MMEC1 MM Active 55 Male
MMEC2 MM Active 63 Female
MMEC3 MM Active 70 Male
MMEC4 MM Active 67 Female
MMEC5 MM Active 73 Female
MMEC6 MM Active 55 Male
MMEC7 MM Active 65 Male 
MMEC8 MM Active 60 Female
MMEC9 MM Active 63 Female
cr-MMEC MM Complete remission 71 Male
MGEC1 MGUS 47 Male
MGEC2 MGUS 59 Male
MGEC3 MGUS 61 Female
MGEC4 MGUS 75 Female
MGEC5 MGUS 53 Male
MGEC6 MGUS 75 Male
MGEC7 MGUS 64 Male
IDAEC IDA 56 Female
The endothelial cells analyzed in this study were derived from bone marrow aspirates of patients with Multiple Myeloma 
in active phase (MMEC1-9) or complete remission (cr-MMEC), patients with monoclonal gammopathy of undetermined 
significance (MGEC1-7) and a patient with anemia due to iron deficiency (IDAEC).
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unwanted in vivo side effects due to its strong pro-
angiogenic activity. Thus, we analyzed the function of 
NK cells cultured in the presence of rIL-27 (100 ng/ml), 
which has been described to combine immunostimulatory 
and anti-angiogenic properties. As shown in Figure 3, 
the stimulatory capability of rIL-27 was lower than that 
of rIL-15. In particular, rIL-27 induced a slight increase 
in NK cell-mediated killing of EA cells (Figure 3A), a 
modest increase in the surface expression of CD69 and 
NKG2D, and did not stimulate the release of IFN-γ. It is of 
note, however, that rIL-27 caused a peculiar upregulation 
of the NKp46 receptor (Figure 3F). When used in 
combination with rIL-15, rIL-27 did not improve CD69 
and NKG2D upregulation but significantly increased the 
cytolytic activity, the surface expression of NKp30 and the 
IFN-γ production as compared to rIL-15 alone (Figure 3). 
DNAM-1 expression was not modified by rIL-27 or rIL-15 
used either alone or in combination (Figure 3G).
To determine the dose of cytokines suitable to induce 
NK cell activation minimizing pro-angiogenic side effects, 
NK cells were treated with rIL-27 in combination with 
decreasing concentration of rIL-15, ranging from 20 to 
1 ng/ml (Figure 4). NK cells stimulated with rIL-27 and 
the lowest rIL-15 concentration used (1 ng/ml) showed a 
significant increased expression of CD69 (in terms of both 
% of positive cells and MFI) and levels of degranulation 
in the presence of EA cells that reached those observed 
in the presence of optimal doses of rIL-15. Moreover, 
rIL-27 promoted an upregulation of DNAM-1 expression 
(Figure 4C) that progressively increased by reducing the 
concentration of rIL-15. The ability of rIL-27 to increase 
NK cell degranulation in the presence of suboptimal doses 
of rIL-15 (1 ng/ml) was confirmed using as targets both 
MMECs and MGECs (Figure 5).
rIL-27 up-regulates PD-L2 and HLA class I 
expression in tumor endothelial cells 
We analyzed whether the positive effects of the rIL-
151 ng-rIL-27100 ng combination on NK cell functions could 
be associated with side effects such as the up-regulation 
of ligands capable to inhibit the NK cell-mediated attack. 
The EA cell line was analyzed for the expression of 
the PD-Ls and HLA-II immune-checkpoints molecules, 
Figure 1: Susceptibility of MMECs to NK-mediated killing and activating receptors involved. (A) PBMCs from 3 healthy 
donors were stimulated with rIL-15 (20 ng/ml) and analyzed for their cytolytic activity (51Cr release assay) against MMECs derived from 
4 different patients (MMEC1-4), (E:T ratio 80:1) in the absence (white bars) or in the presence of anti-HLA-I mAbs (gray bars). Mean (3 
healthy donors in duplicate), 95% confidence intervals and significance are indicated. *p < 0.05. (B) IL-15 activated NK cell populations 
were analyzed for their cytolytic activity (51Cr release assay) against MMECs and EA cell line (E:T ratio 20:1) in the absence (white bars) 
or in the presence of mAbs (10 μg/ml) specific for the indicated activating NK receptors used alone or in combination. Mean (3 healthy 
donors in duplicate), 95% confidence intervals and significance are indicated. *p < 0.05.
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as well as of HLA-I. As shown in Figure 6, EA cells 
constitutively expressed PD-L1, PD-L2 and HLA-I. Similar 
to what has been demonstrated in tumor cells [34, 40], 
rIFN-γ up-regulated the PD-Ls and HLA-I expression 
and de novo induced that of HLA-II, whereas rTNFα  was 
effective only in the induction of HLA-I expression.
EA cells were treated with culture supernatants 
derived from NK cells stimulated with the rIL-151 ng-
rIL-27100 ng combination. EA cells did not modify the 
expression of PD-L1 and HLA-II, whereas they showed 
upregulation of PD-L2 and HLA-I (Figure 6) at levels 
comparable to those obtained using rIFN-γ. It is of note 
that a similar effect was obtained using supernatants from 
NK cells stimulated with rIL-27100 ng but not with rIL-151 ng 
(Figure 6). Moreover, negligible amounts of IFN-γ were 
detected in the supernatants of NK cells stimulated with 
rIL-151 ng and rIL-27100 ng, both used alone or in combination 
(Supplementary Table 1). Overall the data suggested that 
the increased expression of PD-L2 and HLA-I in EA 
cells treated with NK supernatants was mainly rIL-27 
dependent and IFN-γ/IL-15 independent. To confirm 
this hypothesis, EA cells were directly stimulated with 
the cytokines either alone or in combination (Figure 7 
and Supplementary Figure  4). rIL-27 alone did not modify 
the expression of PD-L1 and HLA-II, whereas increased 
that of PD-L2 and HLA-I that reached levels comparable 
to those obtained using the rIL-151ng-rIL-27100 ng 
combination. On the contrary, rIL-15 alone had no effect 
even at the highest (20 ng/ml) concentration used. 
 The rIL-27 capability of up-regulating HLA-I and PD-
L2 molecules in tumor endothelium was confirmed using 
three different MMECs that were treated with rIL-27100 ng 
(or IFN-γ, as control) (Figure 8). According to results 
obtained on EA, rIL-27 did not significantly modify the 
PD-L1 expression whereas it up-regulated HLA-I expression 
in all MMECs, although at different extent. Increased 
PD-L2 expression was detected in MMEC7 that derived 
from a patient with MM in progression and unresponsive 
to chemotherapy. In line with results on EA, IFN-γ induced 
PD-L1 and HLA-I expression on MMEC6 and MMEC7. 
Interestingly however, on MMEC8 derived from a 
patient in relapse IFN-γ increased PD-L1 but not HLA-I 
expression.  
DISCUSSION 
Multiple Myeloma remains an incurable disease 
and novel therapeutic strategies did not lead to a survival 
higher than 5 years in the adult [41]. Some benefits have 
been achieved using drugs such as lenalidomide that 
can exert several immunomodulatory effects, including 
the exacerbation of NK cell-mediated cytotoxicity 
against MM [42]. In vitro studies and clinical trials have 
also explored the possible efficacy of novel strategies 
combining standard treatments with emerging therapies 
aimed to interrupt receptors/ligands interactions such 
as PD1/PD-L1 [43] or KIRs/HLA-I [44], which are 
capable of limiting the anti-tumor function of immune 
effectors. NKp46, NKG2D and DNAM-1 activating 
receptors recognize specific ligands on MM cell surface 
and unchain the anti-MM activity of NK cells [45, 46]. 
In particular, as for other malignancies [21, 22], a pivotal 
role in the NK-mediated aggression of MM is played 
by DNAM-1/PVR interactions. These are required for 
optimal anti-MM efficacy of standard therapies based on 
the administration of cyclophosphamide and bortezomib. 
Moreover, it has been shown that different classes 
of therapeutic agents upregulate DNAM-1 as well as 
Table 2: NKG2D and DNAM-1 ligands expression in endothelial cells 
ULBP-1 ULBP-2 ULBP-3 ULBP-4 MICA PVR Nectin-2
MMEC1 (−) 10 11 (−) (−) 186 40
MMEC2 (−) ND ND ND ND 147 43
MMEC3 (−) 7 13 (−) 12 93 44
MMEC4 (−) (−) 10 (−) ND 93 24
MMEC5 (−) (−) (−) (−) (−) 65 23
cr-MMEC (−) (−) (−) (−) (−) 38 36
MGEC1 (−) 12 (−) (−) (−) 57 24
MGEC2 ND (−) 9 ND ND 35 21
MGEC3 (−) 10 10 13 (−) 49 19
MGEC4 (−) (−) (−) 6 (−) 61 40
MGEC5 (−) 6 (−) ND ND 57 13
IDAEC ND (−) (−) ND ND 10 14
EA (−) 12 24 (−) (−) 257 57
Endothelial cells used in this study were analyzed by flow cytometry for the expression of the indicated ligands. Values indicate 
the MFI. Undetectable = (–), ND = not determined. For EA cell line values represent the mean of 10 different experiments.
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NKG2D ligands [47, 48], thus strengthening the concept 
that NK cells might truly represent powerful adjuvant 
arms against MM. 
Our present study suggests that NK cell-based 
immunotherapy might also be effective in MM patients 
because of the capability of NK cells to kill tumor-
associated endothelial cells, which are involved in neo-
angiogenesis and represent a source of soluble factors 
involved in paracrine loops mediating plasma cell 
proliferation and spread [49, 50]. We showed that activated 
NK cells efficiently killed MMECs (and MGECs) thanks 
to the cooperation of multiple triggering receptors. These 
include NKp30 whose known ligand B7-H6, however, 
is virtually absent on tumor endothelium, suggesting the 
possible existence of novel unidentified NKp30 specific 
ligand/s. NKG2D ligands were weakly expressed on 
MMECs surface, whereas all MMECs analyzed expressed 
good levels of both PVR and Nectin-2, ligands of DNAM 
that clearly contributed to killing of MMECs. A striking 
exception was represented by MMEC1 and MMEC2 that 
resulted poorly susceptible to lysis despite the expression 
of high levels of PVR. DNAM-1/PVR interaction is crucial 
for recognition and killing of different tumors [3]. It is 
of note however that its action could be counteracted by 
the engagement of TIGIT [20, 51] an inhibitory receptor 
which recognizes nectin-3 as well as PVR and nectin-2, 
with higher affinity than DNAM-1 [51]. Thus the different 
susceptibility to killing of PVRhigh MMECs might be 
Figure 2: PVR and nectin-2 expression in MMECs and normal endothelial cells. (A) MMECs (black triangles), cr-MMEC, 
MGECs, IDAEC (gray triangles) and EA (white triangles) were analyzed by flow cytometry for the expression of PVR and Nectin-2. Mean 
and 95% confidence intervals are indicated. *p < 0.05, **p < 0.0001, ****p < 0.001, p = ns means not significant. (B) Representative 
cytofluorimetric analysis of PVR, Nectin-2, DNAM-1-Fc and NKp30-Fc staining in MMECs, cr-MMEC, IDAEC and EA. White profiles 
refer to cells incubated with isotype-matched mAbs. Value inside each histogram indicates the Median Fluorescence Intensity (MFI).
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linked to different combinations of PVR-specific paired 
receptors on NK cells [51]. Another possibility is that in 
some patients the function of TIGIT may dominate due to 
the expression of nectin-3 on MMECs. Both hypotheses 
are currently under investigation.
In line with data obtained from the 
immunohistochemical analysis of primary glioblastoma 
specimens [8], PVR showed a high expression in tumor-
associated endothelium from MM BM aspirates. In a 
physiological context, DNAM-1/PVR interactions have 
been shown to promote the transendothelial migration 
process of monocytes [52]. It would be of interest to 
understand whether the high expression of PVR in MMECs 
might improve migration of monocytes, which in the tumor 
microenvironment tend to differentiate into macrophages 
and acquire a M2 tumor-promoting functional polarization 
[53, 54]. Moreover, PVR expression might directly favor 
the function of MMECs thus contributing to the formation 
Figure 3: Comparison between rIL-27 and rIL-15-mediated stimulation of resting NK cells. NK cells purified from 
healthy donors were stimulated with rIL-15 (20 ng/ml) and rIL-27 (100 ng/ml) used alone or in combination. Cells were analyzed for (A) 
cytotoxicity against EA cells (51Cr release assay, E:T ratio 20:1),  (B–G) expression of the indicated surface molecules (flow cytometry). 
Culture supernatants were analyzed for the presence of IFN-γ (ELISA assay) (H). Mean and 95% confidence intervals are indicated. 
*p < 0.05, p = ns means not significant. Data shown are pooled from 6 independent experiments performed using NK cells from 6 unrelated 
healthy donors.
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Figure 4: rIL-27 plus suboptimal doses of rIL-15 induce NK cell activation. NK cells purified from healthy donors were 
stimulated with decreasing concentrations of rIL-15 alone (circle) or in combination with rIL-27 (100 ng/ml) (triangle). Cells were analyzed 
for (A–C) surface phenotype (flow cytometry), (D) release of cytotoxic granules in the presence of EA cells (CD107a assay).  Mean and 
95% confidence intervals are indicated. *p < 0.05, **p < 0.01. p = ns means not significant. Data shown are pooled from 6 independent 
experiments performed using NK cells from 6 unrelated healthy donors.  
Figure 5: NK cell degranulation in the presence of MMECs and MGECs is increased by rIL-27 and suboptimal 
concentrations of rIL-15. NK cell populations derived from 2 healthy donors (black and white circles) were stimulated with suboptimal 
concentrations (1 ng/ml) of rIL-15 alone or in combination with rIL-27 (100 ng/ml). Cells were analyzed for degranulation (CD107a assay) 
in the presence of the indicated MMECs and MGECs.  Controls (CTR) represent NK cell degranulation of NK cells stimulated with rIL-15 
and rIL-27 in the absence of target. Data shown are pooled from 2 independent experiments. Mean are indicated.
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of the complex architecture of tumor vasculature. In this 
context, different studies showed that PVR improve tumor 
cell invasion, being localized at the migrating cellular front 
together with actin and alphav-integrin, known mediators 
of motility and adhesion [55–57]. Thus, it should be 
taken into consideration that therapies upregulating PVR 
expression could on one side potentiate the NK cell-
mediated killing by improving the formation of effective 
immune synapses, on the other they may favor functional 
capabilities of MM and MMECs. 
DNAM-1/PVR interactions also occur during the 
crosstalk between NK cells and Dendritic cells (DC) 
[58, 59] or Macrophages [60, 61]. During their activation 
these antigen presenting cells (APC) release different 
cytokines capable of amplifying NK (and T) cell-mediated 
responses. These include IL-27 that is of interest in tumor 
immunology because it combines immunostimulatory and 
anti-angiogenic properties [30, 31]. We have analyzed the 
effects of IL-27 on NK cell functions, using the cytokine 
alone or in combination with IL-15. IL-15 represents a 
promising immunostimulatory adjuvant for therapies 
[62, 63], and a clinical grade formulation is currently 
available. However, different data suggested that IL-15 is 
also endowed with strong pro-angiogenic effects [64, 65]. 
According to previous data, we showed that optimal 
doses of IL-15 efficiently stimulate NK cells and increase 
their killing of MMECs. Interestingly, a similar cytolytic 
potential was observed in NK cells stimulated with IL-27 
and suboptimal doses of IL-15 (IL-151 ng and IL-27100 ng). 
This effect was paralleled by a trend toward the increased 
expression of DNAM-1, NKp30, NKG2D and NKp46 
activating receptors. In this context, and according with 
previous published data [66], the upregulation of NKp46 
in NK cells was mainly IL-27-dependent. 
In some instances, IL-27 did not ameliorate the 
effect of optimal doses of IL-15. For example, a significant 
increase of DNAM-1 expression could be appreciated only 
when IL-27 was used in combination with suboptimal 
doses of IL-15 (see Figures  3 and 4). This observation 
could be partially due to the fact that, in NK cells, IL-15- 
and IL-27-mediated signals share some transducing 
molecules such as JAK1 and STAT5 [67, 68]. Moreover, 
IL-15 might play a role in regulating IL-27R expression 
and/or function (under investigation).
NK cells stimulated with IL-27 and suboptimal 
doses of IL-15, release negligible amounts of IFN-γ, 
which is considered the best inducer of HLA-I molecules 
as well as of the PD-Ls immune-checkpoints ligands [34]. 
Figure 6: Constitutive or inducible expression of PD-Ls, HLA-II and HLA-I in EA cell line. The EA cell line untreated 
(CTR), treated with IFN-γ, TNF-α or culture supernatants from NK cells unstimulated (none) or stimulated with the indicated cytokines, 
was analyzed by flow cytometry for the expression of PD-Ls, HLA-II and HLA-I. Panel A and B show two independent experiments 
performed using NK cells purified from two unrelated healthy donors. White profiles refer to cells incubated with isotype-matched mAbs. 
Values inside each histogram indicate the MFI.
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In EA and MMECs, IL-27 (either alone or in combination 
with IL-151ng) did not upregulate the expression of PD-L1 
or induce that of HLA-II. On the other hand, it upregulated 
the expression of HLA-I, as previously demonstrated in 
normal endothelium (HUVEC cells) [69]. Moreover our 
study highlighted a peculiar function of this cytokine, i.e. 
the capability of upregulating the expression of PD-L2 on 
tumor endothelium. It is of note that previous published 
data suggest that IL-27 function might vary depending 
on target cell type and cytokine milieu. Indeed, IL-27 has 
been shown to drive upregulation of HLA-I also in chronic 
eczema keratinocytes that produced IL-27, but it promoted 
PD-L1 expression in different cell types including CD4+ 
and CD8+ T cells, monocytes, DC and tumor cells [29, 30, 
70]. Thus, similar to IFN-γ (and TNF-α), IL-27 might exert 
possible side effects modulating the expression in MMECs 
of HLA-I, which downregulates the NK cell function, 
and PD-L2 that controls the duration and amplitude of 
both CD8+ T and NK cell functions. In this context, it 
has been shown that in MM patients more than 50% of 
peripheral blood NK cells express PD-1 [43], the PD-Ls 
receptor, although at levels lower than PD1+ NK cells 
detected in normal individuals or in different pathological 
conditions [72]. Thus, standard or emerging therapeutic 
approaches should not disregard the possible induction 
of a cytokine storm that might shape immune responses 
against tumor cells and/or tumor-associated endothelium. 
As for IFN-γ [71] the IL-27 capability of upregulating 
immune checkpoint ligands on tumor endothelium, may 
greatly vary among patients. Notably, during anti-tumor 
immune responses IL-27 may act earlier than IFN-γ, being 




Bone marrow (BM) aspirates were obtained from 
nine MM patients fulfilling the International Myeloma 
Working Group diagnostic criteria for multiple myeloma 
(MM). MM patients, enrolled at diagnosis (MM1-6, 
MM9), in progression because unresponsive to therapy 
(MM7), in relapse (MM8), were characterized by active, 
symptomatic disease (D&S stage II-III). Additional BM 
aspirates were obtained from a MM patient in complete/
objective remission (cr-MM), seven patients with 
monoclonal gammopathy of undetermined significance 
(MGUS), and a patient with anemia due to iron deficiency 
(IDA). Approval from the Ethics Board was obtained 
(N°4220/2013), and patients were asked to provide 
their written informed consent in accordance with the 
Declaration of Helsinki. 
Cells used in the study
Primary endothelial cells (ECs) were obtained 
from BM of patients as described [37]. Briefly, ECs 
were purified from BM-derived mononuclear cells by 
immunoselection, using magnetic microbeads (Dynal, 
Oslo, Norway) coated with Ulex europaeus agglutinin-1 
lectin (UEA-1, Sigma Chemical), whose receptor is 
selectively and highly expressed by endothelial cells. 
ECs bound to microbeads were cultured in complete 
DMEM medium supplemented with 20% of heat-
inactivated fetal bovine serum (FBS) to allow cells to 
adhere, spread and grow. Endothelial cells were growth 
Figure 7: rIL-27 upregulates PD-L2 and HLA-I in EA cell line. The EA cell line untreated (white bar) or treated with rIL-15 
and rIL-27 alone or in combination (gray bars) was analyzed by flow cytometry for the expression of PD-Ls, HLA-II and HLA-I. MFI fold 
increase is shown. Mean and 95% confidence intervals are indicated. *p < 0.05. Data shown are pooled from 4 independent experiments.
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for at least one passage and their purity was confirmed 
by flow cytometry (FACScalibur, Becton Dickinson and 
Co, Mountain View, CA) analyzing the presence of the 
ECs markers factor VIII–related antigen (anti-human 
Von Willebrand factor mAb, Beckman Coulter, Marseille, 
France) and CD105 (anti-human CD105 mAb, Beckman 
Coulter), and the absence of CD14 (anti-human CD14 
mAb, Becton Dickinson) and CD38 (anti-human CD38 
mAb, Becton Dickinson) molecules. ECs viability was 
assessed by trypan blue exclusion staining (> 97% viable 
cells). The human endothelial (EA.hy926, henceforth 
named EA) and erythroleukemia (K562) cell lines were 
purchased from American Type Culture Collection (ATCC).
After approval by the Ethics Board (N°39/2012) and 
informed consent, buffy coats were obtained from healthy 
volunteer blood donors admitted at the transfusion center of 
IRCCS AOU San Martino-IST (Genova, Italy). Peripheral 
blood mononuclear cells (PBMC) were isolated on Ficoll-
Hypaque gradients and frozen at –80°C. Upon arrival of 
MMECs in the laboratory by express courier, PBMC were 
thawed and either stimulated with cytokines or used to 
purify NK cells (Human NK Cell Isolation kit, Miltenyi 
Biotec, GmbH, Bergisch Gladbach, Germany) as previously 
described [53]. The degree of purity of the isolated NK cells 
(CD3-, CD56+, NKp46+) was superior to 98%.
Monoclonal antibodies and cytokines
The following mAbs were produced in our laboratory: 
A6136 (IgM) and 6A4 (IgG1) (anti-HLA class I-A, -B, -C 
and HLA-E), FST24 (IgG2b, anti-HLA-II), A6/220 (IgM, 
anti-CD56), BAB281 (IgG1) and KL247 (IgM) (anti-
NKp46), AZ20 (IgG1) and F252 (IgM) (anti-NKp30), 
BAT221 (IgG1, anti-NKG2D), KRA236 (IgG1) and F5 
(IgM) (anti-DNAM-1), BAM195 (IgG1, anti-MICA), 
M5A10 (IgG1, anti-PVR), U191 (IgM, anti-Nectin-2), 
c227 (IgG1, anti-CD69). MAB1380 (IgG2a, anti-ULBP1), 
MAB163903 (IgG2A, anti-ULBP2), MAB1517 (IgG2A, 
Figure 8: Effect of rIL-27 on PD-Ls and HLA-I expression in MMECs. Three MMECs either untreated (open triangle) or 
treated for 5 days with IFN-γ  (black triangle) or IL-27 (open circle) were analyzed by flow cytometry for the expression of PD-Ls and 
HLA-I. Percentage of positive cells or MFI is indicated. 
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anti-ULBP3) and M475 (IgG2B, anti-ULBP4) mAbs were 
purchased from R&D System Inc., (Minneapolis, MN, 
USA); anti-CD107a-PE and anti-CD56-PC5 mAbs were 
purchased from Becton Dickinson. Anti-PD-L1.3.1 (IgG1, 
anti-PD-L1) and anti-PD-L2 (IgG1, anti-PD-L2) were 
generated in D. Olive’s lab. 
Human recombinant cytokines were purchased 
from PeproTech (rIL-15, rIFN-γ  and rTNFα) MBL 
International (rIL-18) and R&D Systems (rIL-27). 
Flow cytometry, cytolytic and ELISA assays 
For one-color immunofluorescence and 
cytofluorimetric analysis (FACSCalibur Becton Dickinson) 
cells were stained with the appropriate mAbs or isotype 
matched controls followed by PE-isotype-specific goat anti-
mouse second reagent (Southern Biotechnology Associated, 
Birmingham, AL). On every experimental session, the 
flow cytometer performances were monitored and the 
reproducibility of the fluorescence intensity was aligned by 
calibrated microsphere (Becton Dickinson). ECs were gated 
on the basis of physical parameters (SSC = Side Scatter; 
FSC = Forward scatter) to detect viable cells. To verify the 
appropriateness of the gating strategy cells were stained (10 
minutes at the room temperature) with Annexin V and To-
Pro-3 Iodide (Life Technologies, CA, USA).
Purified NK cells were cultured for 2 days in the 
presence of recombinant cytokines to obtain polyclonal 
activated NK cell populations, which were analyzed for 
their cytolytic activity against target cells using a 4 h 51Cr-
release assay [21]. For CD107a (LAMP-1) degranulation 
assay NK cells were incubated for three hours with target 
cells in the presence of a PE-conjugated anti-human 
CD107a (IgG1; BD Biosciences).
The IFN-γ enzyme-linked immunosorbent 
human assay (ELISA) was performed according to the 
manufacturer’s instruction (Life Technologies). 
Cell transfectants and chimeric receptors 
The BW5147/B7-H6+ stable cell transfectant 
was prepared by retrovirus gene transfer using a B7-H6 
ORF cDNA obtained by RT-PCR from the MM6 human 
myelomonocytic cell line and subcloned in pMXs-IG 
(IRES-GFP) retrovirus vector (kindly provided by Dr. 
Kitamura, Tokyo, Japan). The empty vector pMXs-IG 
was used to generate the negative control (mock cell 
transfectant). DNAM1-Fc and  NKp30-Fc were obtained 
in our lab fusing the extracellular region of the receptor 
with a mutated human IgG1 Fc portion that lack the ability 
to bind FcRs [52, 73].
Real-time PCR
Total RNA was extracted from K562 and EA cell 
lines and from immature dendritic cells (iDC) using 
RNAeasy Mini Kit (Qiagen, Hilden, Germany) according 
to manufacturer’s instructions. Starting from 1 μg RNA, 
oligodT-primed cDNA was prepared using Transcriptor 
First Strand Synthesis Kit (Roche diagnostic, Mannheim, 
Germany). The expression of B7-H6 and HPRT1 
(hypoxanthine phosphoribosyltransferase 1) transcripts 
was assessed by real-time PCR with the Taqman Gene 
expression assays (Hs02340611_m1 and Hs99999909_
m1, respectively) and Express qPCR SuperMix (Thermo 
Fisher Scientific, Waltham, MA, USA). Samples were 
run on a ViiA 7 Real-Time PCR System (Thermo Fisher 
Scientific). Each reaction was performed in triplicate 
and each sample was analysed in three independent 
experiments. Relative expression of B7-H6 transcript 
was determined in each sample by normalization with 
respect to the HPRT1 gene, according to the standard 
∆CT method.
Statistical analysis
Statistical analysis with level of significance (p) and 
graphic representation were performed using Wilcoxon-
Mann-Whiteny p-value test (non-parametric significance 
test) and GraphPad Prism 6 (GraphPad Software La 
Jolla, CA). 
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Activity of human natural killer (NK) cells against cancer cells is deeply suppressed by 
TGF-β1, an immunomodulatory cytokine that is released and activated in the tumor 
microenvironment. Moreover, our previous data showed that TGF-β1 modifies the 
chemokine receptor repertoire of NK  cells. In particular, it decreases the expression 
of CX3CR1 that drives these effectors toward peripheral tissues, including tumor sites. 
To identify possible mechanisms mediating chemokine receptors modulation, we ana-
lyzed the microRNA profile of TGF-β1-treated primary NK cells. The analysis pointed 
out miR-27a-5p as a possible modulator of CX3CR1. We demonstrated the functional 
interaction of miR-27a-5p with the 3′ untranslated region (3′UTR) of CX3CR1 mRNA 
by two different experimental approaches: by the use of a luciferase assay based on a 
reporter construct containing the CX3CR1 3′UTR and by transfection of primary NK cells 
with a miR-27a-5p inhibitor. We also showed that the TGF-β1-mediated increase of 
miR-27a-5p expression is a consequence of miR-23a-27a-24-2 cluster induction. 
Moreover, we demonstrated that miR-27a-5p downregulates the surface expression 
of CX3CR1. Finally, we showed that neuroblastoma cells induced in resting NK cells a 
downregulation of the CX3CR1 expression that was paralleled by a significant increase of 
miR-27a-5p expression. Therefore, the present study highlights miR-27a-5p as a pivotal 
TGF-β1-induced regulator of CX3CR1 expression.
Keywords: TgF-β1, chemokine receptors, micrornas, nK cells, tumor microenvironment
inTrODUcTiOn
Human natural killer (NK) cells mainly consist of CD56bright CD16low/neg KIRneg perforinlow and 
CD56dim CD16pos KIRpos perforinhigh cells, which represent sequential stages of maturation and NK 
subsets with different function and tissue distribution (1, 2). CD56bright NKs, which release large 
amount of soluble factors (IFN-γ, GM-CSF, and TNF-α) in response to proinflammatory cytokines, 
are poorly represented in peripheral blood, while populating most tissues, and, in particular, second-
ary lymphoid organs (SLOs) (3, 4). Conversely, CD56dim cells, which are highly cytotoxic effectors, 
2
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represent the largest percentage of circulating NKs, while being 
detectable only in selected peripheral tissues such as lung and 
breast (1). Notably, upon appropriate stimulation, CD56dim cells 
increase the cytolytic potential, become cytokines producers, and 
also acquire the capability to migrate to SLO (5, 6).
The NK  cells distribution in physiological and pathological 
conditions is dictated by the expression of chemokine recep-
tors that retain or drive the migration toward tissues of one or 
another NK cell subset. Peripheral blood (resting) CD56dim and 
CD56bright NK  cells share the expression of CXCR4 (CXCL12 
receptor) (7) and CXCR3 (CXCL4, 9, 10, 11 receptor). CD56bright 
NKs selectively express CCR5 (CCL3-5 receptor) and CCR7 that 
guides their migration toward tissues with high levels of CCL19 
and CCL21, such as SLO. Conversely, the expression of CXCR1 
(CXCL8 receptor), CXCR2 (CXCL1, 2, 3, 5, 8 receptor), and 
CX3CR1 (CX3CL1 receptor) is restricted to CD56dim NKs (4), 
which are also characterized by the peculiar expression of the 
ChemR23 specific for chemerin (8).
CX3CL1, also termed fractalkine, is the only known member 
of the CX3C chemokine family. It is synthesized as a membrane 
anchored molecule expressed by cells such as endothelial cells, 
epithelial cells, osteoblasts, and mesenchymal stromal cells. 
CX3CL1 can be shed by A Disintegrin And Metalloproteinases 
(ADAM) 10 or 17 in non-inflammatory and inflammatory condi-
tions, respectively (9). Once released, it interacts with the specific 
receptor (CX3CR1), a molecule belonging to the 7-transmem-
brane G protein-coupled receptor family, which is expressed by 
different immune cell types, including monocytes, dendritic cells 
(DCs), T, and NK lymphocytes.
Tumor tissues set up different strategies to escape immune 
recognition and in particular to affect chemokine/chemokine 
receptor axes such as CX3CL1/CX3CR1, which are crucial for 
the recruitment of cells such as CD56dim NK cells exerting tumor 
suppressive properties. A possible strategy is to unbalance in 
the tumor microenvironment the equilibrium between CD56dim 
and CD56bright attracting chemokines. Immature, poor cytolytic 
CD56bright cells represent the major NK subset present in most 
tumor tissues (4, 10), and breast carcinomas have been shown to 
decrease the expression of CXCL2 and CX3CL1 while increasing 
that of CCL5 and CCL19 (1). Accordingly, CX3CL1 expression in 
breast carcinoma specimens was shown to correlate with a good 
prognosis (11).
Another possible mechanism exerted by tumors for limiting 
immune surveillance is represented by their capability of modify-
ing the chemokine receptor repertoire of crucial effector cells, thus 
affecting their responsiveness to given chemoattractant gradients. 
Among the soluble mediators involved, TGF-β1 shows a pivotal 
role in chemokine receptors modulation (12). TGF-β1 is pleio-
tropic cytokine whose major physiologic role is to limit the dura-
tion of immune responses and promote tissue repair (13, 14). In 
the tumor microenvironment, its release and activation by cancer 
cells and immune cells, including tumor-associated macrophages 
(TAM), is exacerbated (9, 15). This results in tumor-promoting 
side effects including angiogenesis and suppression of anticancer 
immunity. In NK cells, tumor-derived and recombinant TGF-β1 
has been shown to downregulate the expression of NKp30 and 
NKG2D activating receptors involved in tumor recognition and 
DC editing (16, 17) and to modulate the chemokine receptor 
repertoire. In particular, TGF-β1 increases the expression of 
CXCR3 and CXCR4 (12, 18), involved in peripheral tissues and 
bone marrow (BM) recruitment, respectively, and decreases that 
of CX3CR1, which drives effector cells toward peripheral tissues, 
including central nervous system (CNS) (19–21). Interestingly, 
in glioma cells TGF-β1 has also been shown to downregulate 
CX3CL1 (22). The presence of CD56dim NK cells, characterized by 
low expression of CX3CR1, has been detected in ascitic fluids of 
ovarian carcinoma patients (10). Moreover, a possible systemic 
effect has been demonstrated in patients with high-risk (stage 4 
or M) neuroblastoma (NB), who were characterized by the 
presence of unconventional CD56dim CX3CR1low NKs, both in 
metastatic sites, such as BM and peripheral blood (12).
Understanding how TGF-β1 impairs the expression of 
CX3CR1 in CD56dim NK has potential clinical implications, since 
it could improve the current knowledge of the mechanisms that 
regulate the immune responses and, in cancer, participate in the 
escape from immune surveillance. MicroRNAs (miRNAs), small 
non-coding RNA molecules, are key players in the regulation 
of gene expression and modulate several biological processes, 
including immune responses. In this study, we performed a 
profile of NKs to identify miRNA that could play roles in TGF-
β1-mediated modulation of chemokine receptors expression. 




NK  cells were purified from peripheral blood mononuclear 
cells of healthy donors using the Human NK Cell Isolation kit 
(Miltenyi Biotec) (12). A total of 13 unrelated healthy donors 
were used for all the experiments described. Donors provided 
an informed consent according to the procedures approved 
by the Ethics Committee of Ospedale Policlinico San Martino 
(39/2012).
nK cell Treatments for mirna and mrna 
expression analysis
To obtain miRNA profiling, NK  cells were incubated for 24  h 
in the presence of complete medium (RPMI 1640 with 10% of 
fetal bovine serum, 2 mM glutamine, 50 mg/mL penicillin and 
50 mg/mL streptomycin) supplemented with TGF-β1 at the final 
concentration of 40 or 5 ng/mL. Control cells were represented by 
NK cells cultured in the presence of complete medium alone (12). 
For miRNA validation and mRNA expression analysis, NK cells 
were incubated in the presence of 40 or 5 ng/mL of TGF-β1 or 
complete medium for 12 or 24 h.
rna isolation
RNA containing the small RNA fraction was extracted using the 
miRCURY RNA Isolation Kit—Cell and Plant (Exiqon) accord-
ing to the manufacturer guidelines. RNA amount was determined 
using the Quant-iT RiboGreen RNA Assay Kit (Invitrogen) 
following to the manufacturer instructions.
3
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mirna Profiling
miRNA profiling was performed according to the TaqMan 
MicroRNA Array Workflow (Applied Biosystems). Briefly, 
100 ng of RNA comprehensive of the small RNA fraction were 
reverse transcribed using the TaqMan MicroRNA Reverse 
Transcription kit with the Megaplex RT Primers Human Pool 
A + B set v3.0 (Applied Biosystems). A preamplification step 
was performed using the TaqMan PreAmp Master Mix with 
the Megaplex PreAmp Primers Human Pool A  +  B set v.3.0 
(Applied Biosystems). Preamplified cDNAs were loaded in 
TaqMan Array Human MicroRNA Cards A and B set v3.0 
(Applied Biosystems). Amplification reactions were performed 
using an Applied Biosystems ViiA 7 Real-Time PCR System. 
Data were analyzed using the miScript miRNA PCR Array Data 
Analysis Tool.1 miRNAs expression was normalized to the U6 
snRNA expression. Data from this miRNA profiling have been 
submitted to the NCBI Gene Expression Omnibus2 under acces-
sion no. GSE98769. miRNAs that showed a fold change >2 or 
<0.5 between TGF-β1-treated and -untreated NK cells in three 
different donors were considered to be differentially expressed. 
Using the computational prediction on-line tools TargetScan3 
(23), miRanda4 (24), and miRmap5 (25), selected miRNAs were 
investigated as possible regulators of CXCR4, CXCR3, and 
CX3CR1 expression.
expression of mirnas
Expression of selected miRNAs was evaluated using TaqMan 
MicroRNA Assays as described by the manufacturer (Applied 
Biosystems). Briefly, 10 ng of RNA were reverse transcribed using 
the TaqMan MicroRNA Reverse Transcription kit primed with 
the specific RT primers. Real-time PCR was performed in quad-
ruplicate using the specific primers. Expression of each miRNA 
was normalized to the RNU44 expression.
expression of cX3cr1 mrna
To evaluate the expression of CX3CR1 mRNAs, 100 ng of RNA 
were reverse transcribed using the SuperScript VILO cDNA 
Synthesis Kit (Invitrogen). The cDNA was used for real-time 
PCR using the specific primers contained in the TaqMan Gene 
Expression Assay (Applied Biosystems). CX3CR1 expression 
was normalized to the GAPDH expression. Experiments were 
performed in quadruplicate.
cX3cr1 3′ Untranslated region construct
A 700 bp fragment of the CX3CR1 3′ untraslated region (3′UTR) 
containing the putative target site for miR-27a-5p was amplified 
by PCR using primers CX3UTR2F and CX3UTR2R, containing 






product was purified using the MinElute PCR Purification Kit 
(Qiagen), NheI-XhoI digested and ligated to the NheI-XhoI 
digested pmirGLO vector (Promega) using the Rapid DNA 
Ligation kit (Roche, Basel, Switzerland). Ligation product was 
used for transformation of TOP10 Escherichia coli competent 
cells (Invitrogen). Colonies containing the recombinant plasmid 
were selected by PCR using primers CX3UTR2F/CX3UTR2R. 
Plasmid DNA was purified using the Illustra PlasmidPrep 
Mini Spin Kit (GE Healthcare). The inserted fragment and 
flanking sequences were sequenced using primers CX3UTR2F, 
CX3UTR2R, CX3UTR22R2, and CX3UTR22F2. Sequencing was 
performed using the BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems) in a 3100 Genetic Analyzer (Applied 
Biosystems). The selected plasmid is reported as pmirCX-
3UTRWT. Primers, when not otherwise indicated, were designed 
by primerBLAST.6 Primer sequences are reported in Figure S1 in 
Supplementary Material.
site-Directed Mutagenesis
A mutated version of pmirCX3UTRWT (pmirCX3UTRMT), 
containing a C>G mutation in the putative target site for miR-
27a-5p, was prepared by site-directed mutagenesis using the 
Geneart Site-Directed Mutagenesis System (Invitrogen) accord-
ing to the manufacturer guidelines. Oligonucleotides (CX3MUTF 
and CX3MUTR) were designed using the QuickChange Primer 
Design on-line tool (Agilent Technologies7). Presence of the 
mutation was confirmed by restriction analysis and by sequenc-
ing the mutagenized region using primers CX3UTR2FS and 
CX3UTR22R2.
luciferase reporter assay
Wild-type (pmirCX3UTRWT) and mutant (pmirCX3UTRMT) 
plasmids containing the 3′UTR of the CX3CR1 mRNA, as well as 
the parental pmirGLO vector (Promega), were used in cotransfec-
tion experiments with the mirVana miRNA Mimic miR-27a-5p 
and the mirVana miRNA Mimic Negative Control #1 (Ambion). 
HEK293T cells were used for cotransfection experiments. The day 
before transfection 8 × 104 cells per well were plated in 24-well 
plates in 500 µL of DMEM supplemented with 10% FCS. Cells 
were transfected with 100 ng of plasmid and 20 pmol of mimic 
miRNA using lipofectamine 2000 (Invitrogen) according to the 
manufacturer protocol. Twenty-four hours post transfection 
cells were harvested. Firefly and Renilla Luciferase activities were 
determined on cell lysates using the Dual Luciferase Reporter 
Assay System (Promega) according to the manufacturer guide-
lines. A single-tube DLReady validated luminometer TD-20/20 
Turner Biosystems was used. Firefly luciferase activity was 
normalized to renilla luciferase activity. Normalized values were 
expressed as changes relative to the value of the negative control, 
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mir-23a-27a-24-2 cluster Primary 
Transcript expression
The 1 × 106 NK cells from healthy donors were cultured in the 
presence or in the absence of 5  ng/mL of TGF-β1. Real-time 
PCR was performed using the hsa-mir-23a TaqMan Pri-miRNA 
Assay (Applied Biosystems). Hsa-mir-23a pri-miRNA expression 
was normalized to the GAPDH expression. Experiments were 
performed in triplicate.
Transient Transfection of nK cells
The 1  ×  106 NK  cells from healthy donors were cultured in 
24-well plates in 500 µL RPMI + 10% serum in the presence of 
TGF-β1 (5 ng/mL). Cells were transfected with 20 pmol of miR-
27a-5p inhibitor (Applied Biosystems) or with a negative control 
(mirVana™ miRNA Inhibitor, Negative Control #1; Ambion) 
using Lipofectamine 3000 according to manufacturer instruc-
tions. Efficiency of transfection, determined with a fluorescently 
labeled miRNA (Cy3™ Dye-Labeled Pre-miR Negative Control 
#1; Ambion) was about 30% (data not shown). Cells were har-
vested after 72 h, RNA was extracted, and CX3CR1 mRNA levels 
were determined as described previously.
cX3cr1-lentiviral Vector generation
Primer CX3ATGKZF, designed to contain a Kozak consensus 
sequence, and primer CX3UTR2R (Figure S1 in Supplementary 
Material) were used for the amplification of a genomic fragment 
(2,494  bp in length) containing the whole CX3CR1 gene open 
reading frame (ORF) and a portion of the 3′UTR in which the 
two putative target sites for miR-27a-5p are included. The product 
was cloned in a pcDNA 3.1/V5-His-TOPO vector (Invitrogen), 
excised by XbaI-BamHI digestion, and ligated to an XbaI-BamHI 
digested pCDH-CMV-MCS-EF1-GFP lentiviral vector (System 
Biosciences).
Ligation product was transformed in Stbl3 E. coli cells 
(Invitrogen), a positive colony was selected by PCR, endotoxin-
free plasmid DNA was extracted using the QIAfilter Plasmid 
Midi Kit with the EndoFree Plasmid Buffer Set (Qiagen), the 
whole insert and the flanking vector regions were sequenced 
using 16 primers (whose sequences are reported in Figure S1 in 
Supplementary Material).
Virus Packaging
The lentiviral vector containing the CX3CR1 gene was assembled 
in lentiviral particles using the pPACKH1 HIV Lentivector 
Packaging Kit (System Biosciences). Briefly, 3 ×  106 293T  cells 
plated in a 10 cm plate were tranfected with the packaging plas-
mids and the CX3CR1 lentiviral vector with lipofectamine 2000 
(Invitrogen). Medium was changed every 24 h and collected at 
48 and 72  h. Virus containing supernatants were pooled and 
concentrated by the use of a PEG precipitation solution. Titration 
was performed by flow cytometric detection of GFP fluorescence 
emitted by infected cells.
heK293T cells Transduction
HEK293T cells (2 × 105) were plated in six-well plates and infected 
with viral preparation at a multiplicity of infection of 2 in 500 µL 
complete medium without antibiotics in the presence of 8 µg/mL 
of polybrene (Santa Cruz Biotechnology, Dallas, TX, USA). 
Infected cells were centrifuged for 1  h at room temperature at 
2,000 rpm, then incubated at 37°C. 24 h after infection, medium 
was removed and replaced with 4 mL of fresh medium without 
polybrene. One week after infection, CX3CR1 positive cells were 
selected using the anti-CX3CR1 Microbead Kit (Miltenyi Biotec). 
Clones generated by limited dilution of the selected cells were 
analyzed for CX3CR1 surface expression by flow cytometry. 
Clones showing a good and stable expression of CX3CR1 were 
expanded and used for transfection with miR-27a-5p and with 
miR-Neg.
Transfection of cX3cr1-expressing 
heK293T cells
An HEK293T clone stably expressing CX3CR1 was transfected 
with miR-27a-5p and with miR-Neg to evaluate the modulation 
of CX3CR1 expression. The 105 cells were plated in six-well plates 
in 2  mL complete medium, transfection was performed using 
100 pmol of miRNA mimics and 3 μL of Lipofectamine RNAiMAX 
(Invitrogen) according to the manufacturer guidelines. Cells were 
harvested 48 and 72 h after transfection. CX3CR1 expression was 
analyzed by flow cytometry.
coculture of nK cells and sh-sY5Y nB 
cell line in Transwell condition
For coculture experiments in transwell condition, 2 × 105 rest-
ing NK cells were cultured for 48 h with 3 × 105 SH-SY5Y cells. 
NK  cells and SH-SY5Y cells were placed in 24-well transwell 
(0.3-µm pore size; Corning Costar), upper and bottom chamber, 
respectively (12).
statistical analysis
The statistical level of significance (p) is indicated using Student’s 
t-test, a parametric significance test. Graphic representation 
and statistical analysis were performed using GraphPad Prism 
6 (GraphPad Software, La Jolla, CA, USA). Pearson’s correlation 
coefficient (two-tailed test) was used to evaluate the correlation 
between CX3CR1 mRNA and miR-27a-5p expression.
resUlTs
mirna Profiling of TgF-β1-Treated  
nK cells
To identify miRNAs possibly involved in the TGF-β1-mediated 
modulation of chemokine receptors expression, we investigated 
the miRNA expression profile variation in TGF-β1-treated 
NK cells purified from the peripheral blood of three unrelated 
healthy donors. The analysis, allowing the simultaneous profiling 
of 754 miRNAs (Figure 1), showed that miRNAs up- or down-
regulated by the treatment ranged from 127 in donor 2 to 234 
in donor 3 (Figure S2 in Supplementary Material). A total of 14 
miRNAs were modulated in NK cells from all donors analyzed 
upon treatment with either 5 or 40 ng/mL of TGF-β1. Among 
these 14 miRNAs, 11 were excluded from further analysis being 
expressed at low levels (threshold cycle <33), while 1 (miR-1201) 
FigUre 1 | Scatter plot showing microRNAs (miRNAs) up- or downregulated 
in TGF-β1-treated natural killer (NK) cells. Results are referred to NK cells 
from a representative healthy donor of three analyzed (donors 1, 2, and 3) 
treated with TGF-β1 (5 ng/mL). Plot is referred to TaqMan Array Human 
MicroRNA Cards B (Applied Biosystems). Results are expressed as arbitrary 
units on a log scale. U6 snRNA has been used as reference control. 
miR-27a-5p is indicated by the arrow. Diagonal lines represent the 2, 1, and 
0.5 values for fold induction.
FigUre 2 | Expression profile of miR-27a-5p in TGF-β1-treated natural killer (NK) cells. NK cells untreated or treated for 24 h with the indicated concentration of 
TGF-β1 were analyzed for miR-27a-5p expression. RNU44 was used as reference control. Experiments were performed in quadruplicate on NK cells derived from 
three healthy donors (donors 1, 2, and 3). Expression relative fold changes are referred to the expression of untreated cells, whose miR-27a-5p expression has been 
arbitrarily assigned the value 1. **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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was forsaken due to its sequence overlapping to an annotated 
small nucleolar RNAs (snoRNA, SNORD126), as reported in 
miRBase.8 The remaining two miRNAs (miR-302a and miR-
27a-5p) were further investigated as putative regulators of 
CXCR4, CXCR3, or CX3CR1 expression (Figure 1 and Figure S2 
in Supplementary Material).
8 www.mirbase.org.
mir-27a-5p as Putative regulator  
of cX3cr1 expression
The differential expression of miR-302a and miR-27a-5p in 
untreated and TGF-β1-treated NK cells was checked for valida-
tion by using specific miRNA assays. The analysis revealed that 
miR-302a was virtually absent in both untreated and TGF-β1-
treated NK cells (data not shown). On the contrary, in agreement 
with data obtained by miRNA profiling, TGF-β1-treated NK cells 
showed a significant increase of miR-27a-5p expression, which 
was higher at low TGF-β1 concentration (Figure  2). Thus, 
miR-27a-5p was further investigated as putative regulator of 
CXCR4, CXCR3, or CX3CR1 expression using the computa-
tional prediction on-line tools TargetScan (see text footnote 3) 
(23), miRanda (see text footnote 4) (24), and miRmap (see text 
footnote 5) (25). The analysis indicated miR-27a-5p as a putative 
regulator of CX3CR1 expression with relatively high scores. The 
three softwares predicted the same principal site of interaction 
in the CX3CR1 3′UTR with the miR-27a-5p seed region (Figure 
S3A in Supplementary Material). An additional site in the 
CX3CR1 3′UTR, with a weaker interaction with miR-27a-5p, was 
predicted by miRanda and miRmap tools only (Figure S3B in 
Supplementary Material).
inverse correlation of mir-27a-5p and 
cX3cr1 mrna expression in TgF-β1-
Treated nK cells
Since miRNAs properties include the capability of inducing deg-
radation of targeted mRNAs, expression profiles of miR-27a-5p 
and CX3CR1 mRNAs were simultaneously analyzed over time. As 
shown in Figure 3A, at both concentrations used, TGF-β1 caused 
a significant increment of miR-27a-5p and decrease of CX3CR1 
mRNA expression. Importantly, expression of miR-27a-5p and 
CX3CR1 mRNA was inversely correlated (Pearson’s correlation 
coefficient r = 0.766, p < 0.05; Figure 3B). While preliminary data 
showed that 1 ng/mL of TGF-β1 may be sufficient for induction 
of miR-27a-5p, concentrations of 5 and 40 ng/mL were chosen for 
a more systematic investigation. Next, to deepen the molecular 
FigUre 3 | Expression profile of miR-27a-5p and CX3CR1 mRNA in TGF-β1-treated natural killer (NK) cells. (a) NK cells treated for 12 or 24 h with the indicated 
amounts of TGF-β1 were simultaneously analyzed for the expression of miR-27a-5p and CX3CR1. RNU44 and GAPDH were used as reference controls, 
respectively. Data in quadruplicate from one representative donor (donor 1), of two analyzed (donors 1 and 4), are shown. Expression relative fold changes are 
referred to the expression of miR-27a-5p and CX3CR1 mRNA in untreated NK cells (medium alone, 24 h) whose expression has been arbitrarily assigned the value 
1. **p < 0.01, ***p < 0.001, ****p < 0.0001. (B) Correlation between miR-27a-5p and CX3CR1 mRNA expression in TGF-β1-treated NK cells. Scatter plot showing 
miR-27a-5p and CX3CR1 mRNA expression in TGF-β1-treated NK cells from the same donor (donor 1) of (a). Each point represents the miR-27a-5p and CX3CR1 
expression detected in one of the seven reported conditions, with different TGF-β1 concentrations (0, 5, and 40 ng/mL) and time of treatment (0, 12, and 24 h).  
The trendline, its equation and the R2 value is reported. Significance of correlation was determined using the Pearson’s coefficient (r = −0.765948064, p < 0.05). 
Data are referred to a representative donor (donor 1), of two analyzed (donors 1 and 4). (c) miR-23a-27a-24-2 cluster primary transcript expression in TGF-β1-
treated NK cells. NK cells cultured for 24 h in the presence or absence of 5 ng/mL of TGF-β1 were analyzed by real-time PCR for the expression of miR-
23a~27a~24-2 cluster primary transcript. GAPDH was used as reference control. Data in triplicate from one representative donor of three analyzed  
(donors 5, 6, and 7) are shown. Expression relative fold changes are referred to the expression of untreated NK cells (medium alone) whose expression  
has been arbitrarily assigned the value 1. *p < 0.05.
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mechanism responsible for the TGF-β1-induced increase of 
miR-27a-5p, we analyzed the expression of the miR-23a-27a-24-2 
cluster, precursor of miRNAs, including miR-27a-5p. As shown 
in Figure  3C, TGF-β1 caused a significant increment of the 
primary miR-23a-27a-24-2 transcript, thus demonstrating that 
the increased amount of miR-27a-5p might be due, at least in 
part, to induction of its gene expression other than, for example, 
to miR-27a-5p egress from intracellular stores.
mir-27a-5p interacts with the cX3cr1 
mrna
To unequivocally demonstrate that miR-27a-5p could interact 
with the 3′UTR of the CX3CR1 mRNA, modulating its expres-
sion, we performed a luciferase reporter assay (Figure  4). We 
cloned a 700 bp fragment of the CX3CR1 gene 3′UTR, containing 
all the putative sites of interaction with the seed region of miR-
27a-5p, into a luciferase reporter vector, downstream of the firefly 
luciferase gene. Moreover, we also produced a mutated version of 
the construct, containing a C>G substitution in the main site of 
the CX3CR1 3′UTR (Figure S3A in Supplementary Material). The 
two plasmids were separately cotransfected in HEK293T  cells 
with a miR-27a-5p mimic or with a random sequence miRNA 
negative control. As shown in Figure 4A, a significant reduction 
of the normalized luciferase activity was detected in the presence 
of miR-27a-5p mimic compared to the miRNA negative control. 
Importantly, this effect was lost when the miR-27a-5p mimic was 
cotransfected with the construct having the mutated sequence 
of the CX3CR1 3′UTR, thus confirming the interaction of miR-
27a-5p with the CX3CR1 3′UTR.
Next, to further confirm miR-27a-5p and CX3CR1 mRNA 
interaction, before TGF-β1 treatment NK cells were transiently 
transfected with a specific miR-27a-5p inhibitor or with a scram-
bled miRNA as negative control (Figure  4B). As expected, we 
observed a significantly higher CX3CR1 mRNA expression in 
TGF-β1-treated NK  cells previously transfected with the miR-
27a-5p inhibitor when compared with cells transfected with a 
scrambled miRNA.
mir-27a-5p Downregulates the surface 
expression of cX3cr1
To determine whether miR-27a-5p is able to downregulate 
the surface expression of CX3CR1, we prepared a lentiviral 
FigUre 4 | Functional interaction between miR-27a-5p and CX3CR1 mRNA. (a) Luciferase activity in HEK293T cells cotransfected with luciferase reporter 
construct containing the 3′ untranslated region (3′UTR) CX3CR1 and miR-27a-5p mimics. Firefly luciferase activity was normalized to the renilla luciferase activity, 
expressed by the same vector. Data in quadruplicate are from one experiment of three performed. Luciferase activities are referred to the activity of cells transfected 
with the miRNA negative control whose expression has been arbitrarily assigned the value 1. pmirGLO, parental vector; pmirCX3CR1UTRWT, pmirGLO vector 
containing 700 bp of the CX3CR1 3′UTR downstream of the firefly luciferase gene; pmirCX3CR1UTRMT, mutated version of pmirCX3CR1UTRWT containing the 
C>G mutation in the CX3CR1 3′UTR target site; miR-Neg, miRNA mimic negative control. **p < 0.01; ns, not significant. (B) CX3CR1 mRNA expression in NK cells 
transfected with miR-27a-5p inhibitor (Inh) or with a negative control miRNA Inh. Cells were cultured for 72 h in the presence of 5 ng/mL of TGF-β1. Data in triplicate 
are from one representative healthy donor of three analyzed (donors 8, 9, and 10). GAPDH has been used as reference control. Expression relative fold changes are 
referred to CX3CR1 mRNA expression in NK cells transfected with the negative control miRNA inhibitor, whom expression has been arbitrarily assigned the  
value 1. *p < 0.05.
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vector containing the whole ORF of the CX3CR1 gene and 
the portion of the 3′UTR region containing the two putative 
binding sites for miR-27a-5p. HEK293T cells where transduced 
with the vector and cultured under limiting dilution to obtain 
CX3CR1 positive clones. A clone (#124) was selected that stably 
expressed at the cell surface optimal levels of the chemokine 
receptor. Clone #124 was transfected with a miR-27a-5p 
mimic or with a miRNA negative control and analyzed by flow 
cytometry for the chemokine receptor expression. As shown in 
Figure 5, miR-27a-5p mimic induced a significant downregula-
tion of the percentage of CX3CR1 positive cells. On the contrary, 
the expression of other molecules such as PVR (CD155) was 
unaffected (Figure S4 in Supplementary Material). These data 
further support the role of miR-27a-5p as modulator of the 
chemokine receptor.
mir-27a-5p induction in the context of 
nB-nK cocultures
To analyze the relevance of miR-27a-5p induction in a patho-
logical context, we cocultured under transwell condition resting 
NK  cells and the prototypic SH-SY5Y NB  cell line, which we 
described to induce a TGF-β1-mediated downregulation of 
CX3CR1 surface expression (12). Accordingly with our previous 
published data (12), NB conditioning resulted in a significant 
downregulation of CX3CR1 expression at both protein and 
mRNA level. Importantly, this modulatory effect matched with a 
significant increase of miR-27a-5p as compared to unconditioned 
NK cells (Figure 6).
DiscUssiOn
A previous study by our group reported that TGF-β1 released by 
NB cells is able to modify the chemokine receptor repertoire of 
NK cells (12). In particular, it downregulates CX3CR1 expression 
in resting NK  cells. In the present article, we show that TGF-
β1-induced miR-27a-5p directly modulates the expression of 
CX3CR1 mRNA at the post-transcriptional level. Increment of 
miR-27a-5p expression is due to upregulation of the miR-23a-
27a-24-2 cluster, which contains, among others, miR-27a-5p. 
Importantly, we observed that this regulatory mechanism also 
occurs in NK cells during NB-conditioning.
All our results were obtained using unfractioned blood 
NK  cells from healthy donors, mostly represented (more than 
90%) by the CD56dim population (7, 26). Since CD56bright NK cells 
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virtually do not express CX3CR1, further experiments should 
clarify whether miR-27a-5p might contribute to their costitutive 
CX3CR1low/neg phenotype.
The downregulation of CX3CR1 has important consequences 
on NK cells function, as CX3CR1, with other chemokine recep-
tors, drives, at steady state, NK  cell localization in peripheral 
tissues as well as their migration under inflammatory conditions 
(27). In particular, it has been shown that the relative expression 
of CX3CR1 and CXCR4 regulates NK cell migration within the 
BM and their egress from it (28, 29). Moreover, in a model of 
experimental autoimmune encephalomyelitis (EAE), CX3CR1/
fractalkine axis specifically recruits NK cells into the brain (30). 
Indeed in CX3CR1-deficient mice with EAE the amount of NK cells 
in the inflamed CNS cells was markedly reduced, as compared 
to wild-type mice, whereas that of other cell types, including T, 
NKT cells, and monocyte/macrophages, did not show significant 
variation (30). Importantly, recruitment of CX3CR1+  NK  cells 
toward the inflamed CNS ameliorated the EAE disease severity, 
since mature NK cells showed a higher cytolytic activity against 
autoreactive CD4+ T cells (21).
Interestingly, CX3CR1/CX3CL1 axis, other than regulate 
NK  cell migration, increases NK  cell responsiveness to CCL4 
(MIP1β) and CXCL8 (IL-8) (31) and promotes IFN-γ production 
and cytotoxicity by NK cells (32).
The functional relevance of CX3CR1 in NK cells tropism and 
activity is further underlined by the identification of viruses 
producing viral chemokines able to bind CX3CR1: vMIP-II, 
encoded by the Kaposi’s sarcoma-associated herpesvirus, 
which inhibits naive migration of CD56dim NK  cells blocking 
the binding of CX3CL1 (33), and vCXCL1, encoded by human 
cytomegalovirus, which induces NK and neutrophils migration, 
presumably to facilitate a neutrophil-mediated viral dissemina-
tion (34).
CX3CR1 expression also has a pivotal role in tumors, con-
ditioning migration and adhesion of tumor cells, and tumor 
invasiveness and metastasis (35). In particular, CX3CR1 expres-
sion in pancreatic and prostate cancer cells increases invasiveness 
and metastasis to neuronal tissues (36). Interestingly, however, 
while CX3CR1 expression in cancer is generally associated with 
invasiveness and metastasis, the coexpression of CX3CR1 and 
CX3CL1 by the same cell type, as occurs in human colorectal 
cancer cells, acts as a retention factor, limiting tumor spreading 
to metastatic sites (37).
Due to the wide properties of CX3CR1, we can argue that 
the receptor downregulation caused by TGF-β1 in mature 
cytolytic NK  cells might severely hamper their recruitment 
and functions at tumor sites. This might occur thanks the 
TGF-β1-induced upregulation of the miR-23a-27a-24-2 cluster 
in NK  cells, which in turn causes miR-27a-5p upregulation 
and the consequent CX3CR1 downregulation. It is likely that 
a tight control of the miR-23a-27a-24-2 cluster expression is 
necessary, given that its deregulation has been reported in 
several tumors and other diseases (38). Interestingly, TGF-β1 
has been shown to be responsible for upregulation of the miR-
23a-27a-24-2 cluster in hepatocellular carcinoma cells (39), in 
lung adenocarcinoma cells (40) as well as in CD8 T cells (41). 
In these lymphocytes, additionally, upregulation of the cluster 
has been associated with inhibition of IFN-γ expression and 
reduced cytotoxicity (41). miR-27a-5p has been also reported 
to downregulate perforine 1 (Prf1) and granzyme B (GzmB) 
expression in resting and IL-15-activated NK  cells (42), thus 
hampering NK cells cytotoxicity. NK92 and primary NK cells 
overexpressing miR-27a-5p showed a reduced cytotoxicity but 
unmodified levels of the activating receptors NKG2D, NKp30, 
NKp44, and NKp46. Moreover, knockdown of miR-27a-5p in 
NK  cells increased in  vitro cytotoxicity and decreased tumor 
growth in a human tumor xenograft model (42). Overall, 
these data suggest that miR-23a-27a-24-2 cluster could be an 
important target of TGF-β1, possibly acting as an intermediate 
inducer of its effects. miR-27a-5p, a product of this cluster, is 
able to regulate the expression of multiple targets crucial for 
NK cells function. Thus, it appears as a key node for NK activity 
control, being able to dampen NK cell recruitment, cytotoxicity, 
and IFN-γ production, potentially representing, in perspective, 
an interesting cancer therapeutic target.
FigUre 5 | miR-27a-5p-induced downregulation of CX3CR1 surface 
expression. (a) CX3CR1+ HEK293T cells (clone #124) untrasfected (white 
bar), transfected with miR-27a-5p mimic (black bar), or miRNA negative 
control (stripped bar) were analyzed by flow cytometry for the expression of 
CX3CR1 at the indicated time intervals. Average of four independent 
experiments. 95% confidence intervals and significance (*p < 0.05) are 
shown. ns, non-significant. (B) Representative cytofluorimetric analysis of 
CX3CR1 surface expression. Values inside each histogram indicate the 
percentage (%) of positive cells. NEG: miRNA negative control.
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